WO2022182731A1 - Sn-labeling and radiolabeling of epichaperome inhibitors - Google Patents
Sn-labeling and radiolabeling of epichaperome inhibitors Download PDFInfo
- Publication number
- WO2022182731A1 WO2022182731A1 PCT/US2022/017482 US2022017482W WO2022182731A1 WO 2022182731 A1 WO2022182731 A1 WO 2022182731A1 US 2022017482 W US2022017482 W US 2022017482W WO 2022182731 A1 WO2022182731 A1 WO 2022182731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nitrogen
- membered
- sulfur
- oxygen
- partially unsaturated
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 27
- 238000002372 labelling Methods 0.000 title description 6
- 238000000163 radioactive labelling Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 136
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 397
- 229910052757 nitrogen Inorganic materials 0.000 claims description 222
- 125000005842 heteroatom Chemical group 0.000 claims description 204
- 150000001875 compounds Chemical class 0.000 claims description 200
- 229910052760 oxygen Inorganic materials 0.000 claims description 189
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 188
- 239000001301 oxygen Substances 0.000 claims description 188
- 229910052717 sulfur Inorganic materials 0.000 claims description 186
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 185
- 239000011593 sulfur Substances 0.000 claims description 185
- 150000003839 salts Chemical class 0.000 claims description 156
- 229920006395 saturated elastomer Polymers 0.000 claims description 142
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 98
- 238000006243 chemical reaction Methods 0.000 claims description 73
- 125000001931 aliphatic group Chemical group 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 63
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical class [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 61
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 57
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 claims description 50
- 229960001479 tosylchloramide sodium Drugs 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 46
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 45
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 41
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 40
- 229910052736 halogen Chemical group 0.000 claims description 37
- 150000002367 halogens Chemical group 0.000 claims description 37
- 125000004429 atom Chemical group 0.000 claims description 35
- 125000006239 protecting group Chemical group 0.000 claims description 31
- 239000011541 reaction mixture Substances 0.000 claims description 31
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 claims description 30
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 14
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 claims description 8
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 abstract description 76
- 239000002243 precursor Substances 0.000 abstract description 8
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 115
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- 229940125782 compound 2 Drugs 0.000 description 68
- 239000000047 product Substances 0.000 description 52
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 47
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 45
- -1 radioiodine sodium salt Chemical class 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000003054 catalyst Substances 0.000 description 27
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 23
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 23
- 239000003814 drug Substances 0.000 description 23
- 125000001424 substituent group Chemical group 0.000 description 22
- 229910001868 water Inorganic materials 0.000 description 22
- 229940124597 therapeutic agent Drugs 0.000 description 21
- 238000011194 good manufacturing practice Methods 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 239000012458 free base Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 125000000623 heterocyclic group Chemical group 0.000 description 17
- 208000015122 neurodegenerative disease Diseases 0.000 description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 150000003335 secondary amines Chemical class 0.000 description 12
- 229940125904 compound 1 Drugs 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000004968 inflammatory condition Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000004821 distillation Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 9
- 229940001584 sodium metabisulfite Drugs 0.000 description 9
- 235000010262 sodium metabisulphite Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000002699 waste material Substances 0.000 description 9
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 208000027747 Kennedy disease Diseases 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 206010002022 amyloidosis Diseases 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- 102100039328 Endoplasmin Human genes 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 4
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 108010017007 glucose-regulated proteins Proteins 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000017004 dementia pugilistica Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- QJLFNDIEDQOREP-UHFFFAOYSA-N 2-[4-[1-[3,4-bis(difluoromethoxy)phenyl]-2-(3-methyl-1-oxidopyridin-1-ium-4-yl)ethyl]phenyl]-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound CC1=C[N+]([O-])=CC=C1CC(C=1C=C(OC(F)F)C(OC(F)F)=CC=1)C1=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C1 QJLFNDIEDQOREP-UHFFFAOYSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical class NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 2
- 229960001694 anagrelide Drugs 0.000 description 2
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 2
- 229950009746 arofylline Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000004988 autoimmune vasculitis Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 229950001653 cilomilast Drugs 0.000 description 2
- 208000012482 complete androgen insensitivity syndrome Diseases 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000002031 ethanolic fraction Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 2
- 229960003574 milrinone Drugs 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229950002896 tetomilast Drugs 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- FTVXFBJENACRRL-UHFFFAOYSA-N (1-hydroxypiperidin-2-yl) carbamate Chemical compound NC(=O)OC1CCCCN1O FTVXFBJENACRRL-UHFFFAOYSA-N 0.000 description 1
- LEDMDNAHWYVAPC-UHFFFAOYSA-N (2-carbamoylphenyl)methyl benzoate Chemical compound NC(=O)C1=CC=CC=C1COC(=O)C1=CC=CC=C1 LEDMDNAHWYVAPC-UHFFFAOYSA-N 0.000 description 1
- SWHAGWLVMRLFKO-UHFFFAOYSA-N (2-nitrophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1[N+]([O-])=O SWHAGWLVMRLFKO-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BPNUQXPIQBZCMR-IBGZPJMESA-N (2s)-1-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}-3-phenylpropan-2-amine Chemical compound C([C@H](N)COC=1C=NC=C(C=1)C1=CC=C2NN=C(C2=C1)C)C1=CC=CC=C1 BPNUQXPIQBZCMR-IBGZPJMESA-N 0.000 description 1
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- HIPYHINICCKLGX-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=CC(OC)=C1 HIPYHINICCKLGX-UHFFFAOYSA-N 0.000 description 1
- YVOBGLMMNWZYCL-UHFFFAOYSA-N (3-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=CC([N+]([O-])=O)=C1 YVOBGLMMNWZYCL-UHFFFAOYSA-N 0.000 description 1
- HIIOEWGKFCWTJU-UHFFFAOYSA-N (4-chlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1 HIIOEWGKFCWTJU-UHFFFAOYSA-N 0.000 description 1
- NULWVEYYQSYAHP-UHFFFAOYSA-N (4-cyanophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(C#N)C=C1 NULWVEYYQSYAHP-UHFFFAOYSA-N 0.000 description 1
- IERCGNSLWQVTPC-UHFFFAOYSA-N (4-decoxyphenyl)methyl carbamate Chemical compound CCCCCCCCCCOC1=CC=C(COC(N)=O)C=C1 IERCGNSLWQVTPC-UHFFFAOYSA-N 0.000 description 1
- OKLFHGKWEQKSDZ-UHFFFAOYSA-N (4-methoxyphenyl)methanimine Chemical compound COC1=CC=C(C=N)C=C1 OKLFHGKWEQKSDZ-UHFFFAOYSA-N 0.000 description 1
- LRJOVUGHUMSKFA-UHFFFAOYSA-N (4-nitrophenyl)methanimine Chemical compound [O-][N+](=O)C1=CC=C(C=N)C=C1 LRJOVUGHUMSKFA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RASLWNGTMHFPIQ-AATRIKPKSA-N (e)-3-(2-nitrophenyl)prop-2-enamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1[N+]([O-])=O RASLWNGTMHFPIQ-AATRIKPKSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical class OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical class NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- PXVUDLXXKGSXHH-UHFFFAOYSA-N 2,4,6-trimethoxybenzenesulfonamide Chemical compound COC1=CC(OC)=C(S(N)(=O)=O)C(OC)=C1 PXVUDLXXKGSXHH-UHFFFAOYSA-N 0.000 description 1
- YECJUZIGFPJWGQ-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonamide Chemical compound CC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 YECJUZIGFPJWGQ-UHFFFAOYSA-N 0.000 description 1
- DVCVYHFEWYAJCP-UHFFFAOYSA-N 2-(2-nitrophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC=C1[N+]([O-])=O DVCVYHFEWYAJCP-UHFFFAOYSA-N 0.000 description 1
- JTQUNAJHSFYGSN-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonylethyl carbamate Chemical compound CC1=CC=C(S(=O)(=O)CCOC(N)=O)C=C1 JTQUNAJHSFYGSN-UHFFFAOYSA-N 0.000 description 1
- KXKIBGGGFMXVBJ-UHFFFAOYSA-N 2-(4-phenylphenyl)propan-2-yl carbamate Chemical compound C1=CC(C(C)(OC(N)=O)C)=CC=C1C1=CC=CC=C1 KXKIBGGGFMXVBJ-UHFFFAOYSA-N 0.000 description 1
- FGJAPOYTPXTLPY-UHFFFAOYSA-N 2-(benzylideneamino)-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1N=CC1=CC=CC=C1 FGJAPOYTPXTLPY-UHFFFAOYSA-N 0.000 description 1
- NUQZXROIVGBRGR-UHFFFAOYSA-N 2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=CN=C(C=CC(Cl)=C2)C2=N1 NUQZXROIVGBRGR-UHFFFAOYSA-N 0.000 description 1
- ZVAGBRFUYHSUHA-UHFFFAOYSA-N 2-[5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=CC(=C2N=C3C=CC=CC3=C2)NC1=CC=1NC(C)=CC=1C ZVAGBRFUYHSUHA-UHFFFAOYSA-N 0.000 description 1
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- AUQKXXDHDKEBEY-UHFFFAOYSA-N 2-methylbutan-2-yl carbamate Chemical compound CCC(C)(C)OC(N)=O AUQKXXDHDKEBEY-UHFFFAOYSA-N 0.000 description 1
- BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical class CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 1
- IXTODZAWAAKENF-UHFFFAOYSA-N 2-methylsulfonylethyl carbamate Chemical compound CS(=O)(=O)CCOC(N)=O IXTODZAWAAKENF-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- UCZSGRLQZLKLCQ-UHFFFAOYSA-N 2-phenylpropan-2-yl carbamate Chemical class NC(=O)OC(C)(C)C1=CC=CC=C1 UCZSGRLQZLKLCQ-UHFFFAOYSA-N 0.000 description 1
- WYECGUSLBPACPT-UHFFFAOYSA-N 2-pyridin-4-ylpropan-2-yl carbamate Chemical class NC(=O)OC(C)(C)C1=CC=NC=C1 WYECGUSLBPACPT-UHFFFAOYSA-N 0.000 description 1
- XSXPJNJLDYOPTF-UHFFFAOYSA-N 2-trimethylsilylethoxymethanamine Chemical compound C[Si](C)(C)CCOCN XSXPJNJLDYOPTF-UHFFFAOYSA-N 0.000 description 1
- QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
- OLYFGLXPXPABOP-XXIQNXCHSA-N 220997-99-9 Chemical compound Cl.C([C@]1(O)CC)C(=O)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC(Cl)=C(C)C=C1C=4CN1CCC(C)CC1 OLYFGLXPXPABOP-XXIQNXCHSA-N 0.000 description 1
- NRZLJLXOGSCRAO-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enyl carbamate Chemical compound NC(=O)OCC=CC1=CC=C([N+]([O-])=O)C=C1 NRZLJLXOGSCRAO-UHFFFAOYSA-N 0.000 description 1
- MTZNODTZOSBYJW-UHFFFAOYSA-N 3-amino-5,5-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CC(N)=CC(=O)C1 MTZNODTZOSBYJW-UHFFFAOYSA-N 0.000 description 1
- SCLGGNBFBLJQFU-UHFFFAOYSA-N 3-aminopropyl acetate Chemical compound CC(=O)OCCCN SCLGGNBFBLJQFU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- UVODFYVXDPJZFJ-UHFFFAOYSA-N 3-methyl-3-nitrobutanamide Chemical compound [O-][N+](=O)C(C)(C)CC(N)=O UVODFYVXDPJZFJ-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical class NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RZIDZIGAXXNODG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CCC1(N)CC1=CC=C(Cl)C=C1 RZIDZIGAXXNODG-UHFFFAOYSA-N 0.000 description 1
- FPEIJQLXFHKLJV-UHFFFAOYSA-N 4-[6-(1h-indol-5-yl)-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-4-yl]morpholine Chemical compound C=1C=CN=CC=1CN(CC1)CCC1N(C1=NC(=N2)C=3C=C4C=CNC4=CC=3)N=CC1=C2N1CCOCC1 FPEIJQLXFHKLJV-UHFFFAOYSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- IBPVXAOOVUAOKJ-UHFFFAOYSA-N 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine Chemical compound FC1=CC(C=2C3=NC(=CN=C3C=CC=2)C2=CN(N=C2)C2CCNCC2)=CC(F)=C1CN1CCOCC1 IBPVXAOOVUAOKJ-UHFFFAOYSA-N 0.000 description 1
- XYOXIERJKILWCG-UHFFFAOYSA-N 4-chlorobutanamide Chemical compound NC(=O)CCCCl XYOXIERJKILWCG-UHFFFAOYSA-N 0.000 description 1
- BYWWNRBKPCPJMG-UHFFFAOYSA-N 4-dodecyl-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(CCCCCCCCCCCC)=CC=C1S(=O)(=O)NC1=NN=CS1 BYWWNRBKPCPJMG-UHFFFAOYSA-N 0.000 description 1
- UHAAUDAFKLCPEA-UHFFFAOYSA-N 4-methoxy-2,3,5,6-tetramethylbenzenesulfonamide Chemical compound COC1=C(C)C(C)=C(S(N)(=O)=O)C(C)=C1C UHAAUDAFKLCPEA-UHFFFAOYSA-N 0.000 description 1
- ZJJLGMUSGUYZQP-UHFFFAOYSA-N 4-methoxy-2,6-dimethylbenzenesulfonamide Chemical compound COC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 ZJJLGMUSGUYZQP-UHFFFAOYSA-N 0.000 description 1
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 1
- ZCCPLJOKGAACRT-UHFFFAOYSA-N 4-methyl-3-[[1-methyl-6-(3-pyridinyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CC1=CC=C(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)C=C1NC(C=1C=NN(C)C=1N=1)=NC=1C1=CC=CN=C1 ZCCPLJOKGAACRT-UHFFFAOYSA-N 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HWUHTJIKQZZBRA-UHFFFAOYSA-N 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2h-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride Chemical compound Cl.Cl.C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 HWUHTJIKQZZBRA-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 108010032947 Ataxin-3 Proteins 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- PCFQGFFLUBXRAV-UHFFFAOYSA-N CC(C)(C)CNCCN1C(SC2=CC3=C(OCO3)C=C2[Sn](C)(C)C)=NC2=C(N)N=CN=C12 Chemical compound CC(C)(C)CNCCN1C(SC2=CC3=C(OCO3)C=C2[Sn](C)(C)C)=NC2=C(N)N=CN=C12 PCFQGFFLUBXRAV-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101710130649 Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- RFSMUFRPPYDYRD-CALCHBBNSA-N Ku-0063794 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3C[C@@H](C)O[C@@H](C)C3)N3CCOCC3)C2=N1 RFSMUFRPPYDYRD-CALCHBBNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000019090 Machado-Joseph disease type 3 Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028561 Myeloid metaplasia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108010075501 N-(succinyl-beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CLPYVPMXLNNKLB-UHFFFAOYSA-N [(2-nitrophenyl)-phenylmethyl] carbamate Chemical compound C=1C=CC=C([N+]([O-])=O)C=1C(OC(=O)N)C1=CC=CC=C1 CLPYVPMXLNNKLB-UHFFFAOYSA-N 0.000 description 1
- RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
- MQLDYIKXBMSDCL-UHFFFAOYSA-N [2,4-bis(methylsulfanyl)phenyl] carbamate Chemical compound CSC1=CC=C(OC(N)=O)C(SC)=C1 MQLDYIKXBMSDCL-UHFFFAOYSA-N 0.000 description 1
- OJUHIDQVEFLXSE-UHFFFAOYSA-N [2-(4-methoxyphenyl)-2-oxoethyl] carbamate Chemical compound COC1=CC=C(C(=O)COC(N)=O)C=C1 OJUHIDQVEFLXSE-UHFFFAOYSA-N 0.000 description 1
- XSXGGUVGOHDUPF-UHFFFAOYSA-N [4-(carbamoyloxymethyl)phenyl]boronic acid Chemical compound NC(=O)OCC1=CC=C(B(O)O)C=C1 XSXGGUVGOHDUPF-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N allylamine Natural products NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229950008356 becatecarin Drugs 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- DUXANUSOCMOJSI-UHFFFAOYSA-N benzhydryl carbamate Chemical compound C=1C=CC=CC=1C(OC(=O)N)C1=CC=CC=C1 DUXANUSOCMOJSI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- XQVVPGYIWAGRNI-JOCHJYFZSA-N bi-2536 Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CC=3)C(=O)NC3CCN(C)CC3)OC)N=C21)=O)CC)C1CCCC1 XQVVPGYIWAGRNI-JOCHJYFZSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- JSKFWUPVIZYJMR-UDOAKELVSA-N bmy-27557 Chemical compound O=C1N(CCN(CC)CC)C(=O)C(C2=C3[CH]C=CC(Cl)=C3NC2=C23)=C1C2=C1C=CC=C(Cl)[C]1N3[C@@H]1O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]1O JSKFWUPVIZYJMR-UDOAKELVSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 1
- JROFGZPOBKIAEW-HAQNSBGRSA-N chembl3120215 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1[C@H]1CC[C@H](C(O)=O)CC1 JROFGZPOBKIAEW-HAQNSBGRSA-N 0.000 description 1
- ROWSTIYZUWEOMM-UHFFFAOYSA-N chembl488755 Chemical compound C12=CC=CC=C2C(=O)C2=C1C1=CC=C(O)C=C1N=C2NCCN(C)C ROWSTIYZUWEOMM-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- NNGAQKAUYDTUQR-UHFFFAOYSA-N cyclohexanimine Chemical compound N=C1CCCCC1 NNGAQKAUYDTUQR-UHFFFAOYSA-N 0.000 description 1
- AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- DCYUBZJZSBAWEZ-UHFFFAOYSA-N dimethyl 2-(carbamoyloxymethylidene)propanedioate Chemical compound COC(=O)C(C(=O)OC)=COC(N)=O DCYUBZJZSBAWEZ-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- HSYBQXDGYCYSGA-UHFFFAOYSA-L disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate Chemical compound [Na+].[Na+].COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP([O-])([O-])=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 HSYBQXDGYCYSGA-UHFFFAOYSA-L 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- RGEAONPOJJBMHO-UHFFFAOYSA-N furan-2-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=CO1 RGEAONPOJJBMHO-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229950008908 gandotinib Drugs 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- HSNUXDIQZKIQRR-UHFFFAOYSA-N hydroxy-imino-bis(phenylmethoxy)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1COP(=O)(N)OCC1=CC=CC=C1 HSNUXDIQZKIQRR-UHFFFAOYSA-N 0.000 description 1
- QWMUDOFWQWBHFI-UHFFFAOYSA-N hydroxy-imino-diphenoxy-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1OP(=O)(N)OC1=CC=CC=C1 QWMUDOFWQWBHFI-UHFFFAOYSA-N 0.000 description 1
- RIGIWEGXTTUCIQ-UHFFFAOYSA-N hydroxy-imino-diphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=O)(N)C1=CC=CC=C1 RIGIWEGXTTUCIQ-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000013256 infectious meningitis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000027125 intermittent hydrarthrosis Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- VEJCBCPEURAYAS-MEAXDALNSA-N methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate Chemical compound CO\C=C(\C(=O)OC)C1=CC=CC=C1\C=C\C1=CC=CC=C1 VEJCBCPEURAYAS-MEAXDALNSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- VMOWKUTXPNPTEN-UHFFFAOYSA-N n,n-dimethylpropan-2-amine Chemical class CC(C)N(C)C VMOWKUTXPNPTEN-UHFFFAOYSA-N 0.000 description 1
- WPOXAFXHRJYEIC-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CN=2)=C1 WPOXAFXHRJYEIC-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical class NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229960004403 pixantrone Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- YBKWIGSMABMNJZ-UHFFFAOYSA-N s-(2,3,4,5,6-pentachlorophenyl)thiohydroxylamine Chemical compound NSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl YBKWIGSMABMNJZ-UHFFFAOYSA-N 0.000 description 1
- RTKRAORYZUBVGQ-UHFFFAOYSA-N s-(2,4-dinitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O RTKRAORYZUBVGQ-UHFFFAOYSA-N 0.000 description 1
- LOVVSIULYJABJF-UHFFFAOYSA-N s-(2-nitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=CC=C1[N+]([O-])=O LOVVSIULYJABJF-UHFFFAOYSA-N 0.000 description 1
- DAXSYWBYJZACTA-UHFFFAOYSA-N s-(4-methoxy-2-nitrophenyl)thiohydroxylamine Chemical compound COC1=CC=C(SN)C([N+]([O-])=O)=C1 DAXSYWBYJZACTA-UHFFFAOYSA-N 0.000 description 1
- MAGSSGQAJNNDLU-UHFFFAOYSA-N s-phenylthiohydroxylamine Chemical compound NSC1=CC=CC=C1 MAGSSGQAJNNDLU-UHFFFAOYSA-N 0.000 description 1
- PIDYQAYNSQSDQY-UHFFFAOYSA-N s-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 238000005797 stannylation reaction Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229950003999 tafluposide Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 1
- 229960004247 tofacitinib citrate Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- MFAQYJIYDMLAIM-UHFFFAOYSA-N torkinib Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC2=CC(O)=CC=C2N1 MFAQYJIYDMLAIM-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- Hsp90 family of proteins has four recognized members in mammalian cells: Hsp90-alpha (a) and -beta (b), GRP94 and TRAP-1.
- Hsp90-alpha and -beta exist in the cytosol and the nucleus in association with many other proteins.
- the Hsp90 family collectively represents the most abundant cellular chaperones, and it has been proposed to function in several beneficial ways including for example as part of the cellular defense against stress such as exposure to heat or other environmental stress. However, it has also been postulated to facilitate the stability and function of mutated proteins such as for example mutated p53.
- Hsp90 Under extreme or chronic stress Hsp90 has also been found to form tight complexes, called epichaperomes, with other chaperones and regulatory proteins. Many diseased cells are dependent on epichaperome function thus epichaperomes have been identified as putative targets of therapeutic agents.
- Radiolabeled inhibitors of Hsp90, Hsp90 isoforms and Hsp90 homologs.
- These radiolabeled inhibitors are referred to herein as radiolabeled Hsp90 inhibitors or radiolabeled epichaperome inhibitors. They are able to bind selectively to Hsp90 including Hsp90 isoforms and homologs when these proteins are complexed in an epichaperome.
- Radiolabeled Hsp90 inhibitors have numerous clinical applications including in situ visualization of on-target and off-target inhibitor localization and Hsp90 inhibitor metabolism and pharmacokinetics. Such applications may be used to diagnose disease in addition to informing personalized treatment regimens for patients.
- this disclosure is premised, in part, on the unexpected finding that peracetic acid and a particular ratio of chloramine-T to Hsp90 inhibitor substrate can be used to produce radiolabeled Hsp90 inhibitors at a high purity and yield.
- This disclosure is also premised, in part, on the unexpected finding that use of tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as a catalyst to produce tin (Sn)-labeled precursors results in a more robust production method.
- the use of this particular compound as a catalyst reduces reaction stalling and/or improves catalyst turnover.
- aspects of the present disclosure provide methods of producing a compound of Formula II: (Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting: a compound of Formula I: (Formula I) or a pharmaceutically acceptable salt thereof with a radioiodine salt in the presence of peracetic acid in a solution at a pH between 2-5, thereby forming a reaction mixture, wherein:
- W is a radioiodine
- X is — CH 2 — — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R) SO 2— , — SO 2 N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO 2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- R 3a is R 3 or hydrogen;
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
- the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of
- the compound of Formula I or the pharmaceutically acceptable salt thereof is Compound 1 or a pharmaceutically acceptable salt thereof or Compound 2 or a pharmaceutically acceptable salt thereof: (Compound 2) or a pharmaceutically acceptable salt thereof; or
- the compound of Formula I is provided as a free base. In some embodiments, the compound of Formula I is provided as a hydrogen iodide salt (HI).
- HI hydrogen iodide salt
- the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
- the radioiodine or salt thereof is selected from I 123 , I 124 , or I 131 or a salt thereof.
- the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
- GMP good manufacturing practices
- the solution comprises about 0.1 to about 1 M (e.g., 0.1-1 M) phosphoric acid (H 3 PO 4 ) or sulfuric acid and water and the reaction occurs between about 15 to about 30 °C (e.g., 15-30 °C) for about 0.5 to about 1.5 minutes (e.g., 0.5- 1.5 minutes).
- the solution comprises about 0.8 M phosphoric acid (H 3 PO 4 ) and water.
- the reaction occurs between about 20 °C to about 30 °C for about 0.5 to about 1.5 minutes, including about 1 minute.
- the method further comprises adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO 3 ) following the reaction.
- the peracetic acid is about 3% to about 10% peracetic acid. In some embodiments, the peracetic acid is about 6% to about 7% peracetic acid, including about 6.3%, about 6.4% and about 6.5% peracetic acid.
- the method further comprises purifying the compound of Formula II or a pharmaceutically acceptable salt thereof from the reaction mixture.
- the compound of Formula II or a pharmaceutically acceptable salt thereof is recovered at about 80%, about 85%, about 90%, or about 95% yield.
- the specific activity of the compound of Formula II or a pharmaceutically acceptable salt thereof is at least 10 mCi/mg, at least 20 mCi/mg, at least 30 mCi/mg, or at least 40 mCi/mg.
- Formula II (Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting:
- W is a radioiodine
- X is — CH 2 — , — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
- each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
- the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of (Formula III) or a pharmaceutically acceptable salt thereof; or a compound of (Formula IV) or a pharmaceutically acceptable salt thereof.
- the compound of Formula I or the pharmaceutically acceptable salt thereof comprises: (Compound 2) or a pharmaceutically acceptable salt thereof; or (Compound 1) or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is provided as a free base.
- the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
- the reaction further comprises phosphate buffer at about pH 7.
- the radioiodine or salt thereof is I 123 , I 124 , or I 131 or a salt thereof.
- the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof and is a good manufacturing practices (GMP) grade compound.
- the yield of the compound of Formula II or the pharmaceutically acceptable salt thereof is at least 80%.
- the compound of Formula I or the pharmaceutically acceptable salt thereof is provided in ethanol.
- the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a pre-mixed solution in acetic acid.
- the method further comprises passing the reaction mixture through a Sep-Pak and eluting the compound of Formula II with less than 3 mL of pure ethanol.
- the radioiodine salt is provided in about 0.01M NaOH. In some embodiments, the amount of radioiodine salt is between about 3 and about
- a reaction mixture a compound of Formula V: (Formula V) or a pharmaceutically acceptable salt thereof with hexamethylditin (Sn 2 Me 6 ) and tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) in a solution, thereby producing a compound of Formula I or a pharmaceutically acceptable salt thereof.
- the reaction occurs between about 60 °C to about 80 °C.
- the method further comprises purifying the compound of Formula I.
- purifying the compound of Formula I comprises mixing the compound of Formula I with dichloromethane (DCM) and stirring the mixture to form a substantially clear solution.
- DCM dichloromethane
- the method further comprises adding purified water to the substantially clear solution, stirring the solution for at least 5 minutes, and allowing the solution to separate into an organic layer and an aqueous layer.
- the method further comprises adding purified water, mixing the layers for at least 15 minutes, and allowing the layers to separate. In some embodiments, the method further comprises further adding purified water, mixing the layers for at least 15 minutes, and allowing the layers to separate.
- the method further comprises filtering the organic layer, washing the reaction vessel with DCM, and concentrating the filtrate and the wash.
- the concentrating occurs at no more than 50 °C to distill the compound of Formula I.
- the compound of Formula I is further dried under vacuum at no more than 70 °C.
- the compound of Formula V or the pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
- GMP good manufacturing practices
- the method further comprises adding ethanol (EtOH)-Heptane to the compound of Formula I.
- the compound of Formula I or the pharmaceutically acceptable salt thereof comprises:
- the compound of Formula V or the pharmaceutically acceptable salt thereof comprises:
- Compound 7 or a pharmaceutically acceptable salt thereof.
- kits comprising: (i) a compound of Formula I: (Formula I) or a pharmaceutically acceptable salt thereof;
- X is — CH 2 — — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO 2— , — SO 2 N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO 2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
- the compound in (i) comprises: (Compound 2) or a pharmaceutically acceptable salt thereof; or
- the kit further comprises a radioiodine salt.
- the radioiodine salt is sodium radioiodine.
- the kit further comprises (iv) about 0.1 to about 1 M phosphoric acid (H 3 PO 4 ).
- the kit further comprises (iv) about 0.8 M phosphoric acid (H 3 PO 4 ). In some embodiments, the kit further comprises sodium metabisulfite in saturated sodium bicarbonate (NaHCO,).
- the peracetic acid is about 3% to about 10% peracetic acid.
- the peracetic acid is about 6% to about 7% peracetic acid, including about 6.3%, about 6.4% and about 6.5% peracetic acid.
- the kit further comprises a syringe, Sep-Pak, and/or ethanol.
- the radioiodine salt is a salt of I 123 , I 124 , or I 131 .
- kits comprising:
- X is — CH 2 — — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO 2— , — SO 2 N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO 2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
- the kit further comprises phosphate buffer at about pH 7.
- the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a single container.
- the container comprising the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T further comprises acetic acid.
- the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in separate containers.
- the compound of Formula I or pharmaceutically acceptable salt thereof is provided in ethanol.
- the kit further comprises: i) ethanol; ii) water; iii) a reaction container; iv) a waste container; v) a product container; vi) a Sep-Pak; vii) one or more syringes; and/or viii) one or more stopcocks.
- the kit further comprises a radioiodine salt.
- the radioiodine salt is sodium radioiodine.
- the radioiodine salt is a salt of I 123 , I 124 , or I 131 .
- FIG. 1 is a schematic showing a non-limiting example of Compound 2 production using Pd 2 (dba) 3 .
- DCM dichloromethane
- MTBE methyl tert-butyl ether
- NET not less than
- NMT not more than
- PCT process control test
- MeOH methanol
- Et3N triethylamine
- FIGs. 2A-2C are schematics showing a non-limiting example of synthesis of Compound 2 using Pd 2 (dba) 3 .
- FIGs. 2A-2C show steps 1-3, respectively.
- FIG. 3 shows a non-limiting example of a device configured for synthesis of a compound of a radiolabeled Hsp90 inhibitor (e.g., a compound of Formula II, such as a compound of Formula III, or of Formula IV, or a pharmaceutically acceptable salt thereof, as defined herein).
- the device comprises the following components: R: reaction container (e.g., vial); W: waste container (e.g., vial); P: product container (e.g., vial); SP: Sep-Pak, SI, S2, and S3: Syringes; and SCI, SC2, SC3: stopcocks.
- This disclosure provides new and suprisingly improved methods for tin (Sn)-labeling and radiolabeling of compounds such as certain agents bind selectively to Hsp90 (i.e.., Hsp90 and/or Hsp90 isoforms and/or Hsp90 homologs such as but not limited to GRP94 and TRAP1) as it is complexed in an epichaperome, and are thus able to interfere with the structure and ultimately function of the epichaperome.
- Hsp90 i.e.., Hsp90 and/or Hsp90 isoforms and/or Hsp90 homologs such as but not limited to GRP94 and TRAP1
- Hsp90 inhibitors including those that make use of Pd(PPh3)4 as a catalyst, have resulted in reaction stalling and have required additional charges of the catalyst, rendering such methods inefficient and cumbersome.
- Radiolabeled Hsp90 inhibitors are useful in numerous clinical applications, including treatment of cancers, assessing the bioavailability of the inhibitor, disease diagnosis, and monitoring the efficacy of a treatment regimen.
- the radiolabeled Hsp90 inhibitors disclosed herein may be used to determine the therapeutically effective amount of a non-radiolabeled Hsp90 inhibitor.
- Hsp90 will be used herein to collectively refer to Hsp90, its isoforms and its homologs such as but not limited to GRP94 and TRAP1.
- the Hsp90 inhibitors of this disclosure refer to a class of inhibitors that inhibit Hsp90 and/or Hsp90 isoforms and/or Hsp90 homologs including but not limited to GRP94 and TRAP1.
- Hsp90 inhibitors interfere with the structure and ultimately function of an epichaperome.
- Hsp90 inhibitors includes iodinated Hsp90 inhibitors, radiolabeled Hsp90 inhibitors and Sn-labeled Hsp90 inhibitors having a parent compound of Formula I, Formula II, or Formula V.
- the Hsp90 inhibitor produced herein may interfere with the formation or stability of the epichaperome, thereby rendering target cells (such as cancer cells) more susceptible to cell death.
- target cells such as cancer cells
- the ability to target the epichaperome can also result in reduced general toxicity in subjects being treated. Accordingly, the inhibitors of this disclosure may also be referred to as epichaperome inhibitors.
- the disclosure also provides methods of producing certain Hsp90 inhibitors comprising a radiolabel or producing precursor compounds (e.g., Sn-labeled Hsp90 inhibitor compounds) to be used in the production of a radiolabeled Hsp90 inhibitor.
- a radiolabel or producing precursor compounds e.g., Sn-labeled Hsp90 inhibitor compounds
- Any of the compounds described herein, including those that are substrates and those that are products, may be a good manufacturing practices (GMP) grade compound.
- GMP good manufacturing practices
- X is a number or percentage
- X refers to a number or percentage that is between 99.5% and 100.5%, between 99% and 101%, between 98% and 102%, between 97% and 103%, between 96% and 104%, between 95% and 105%, between 92% and 108%, or between 90% and 110% of X, inclusive, of X.
- aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
- aliphatic groups contain 1-6 aliphatic carbon atoms.
- aliphatic groups contain 1-5 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
- cycloaliphatic (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
- Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl) alkenyl .
- heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quatemized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR (as in N- substituted pyrrolidinyl)).
- unsaturated means that a moiety has one or more units of unsaturation.
- alkylene refers to a bivalent alkyl group.
- An "alkylene chain” is a polymethylene group, i.e., — (CH 2 ) n — , wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
- a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- halogen means F, Cl, Br, or I.
- aryl refers to a radical of a monocyclic or polycyclic (e.g ., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 p electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("C 6-14 aryl”).
- an aryl group has 6 ring carbon atoms ("C 6 aryl”; e.g., phenyl).
- an aryl group has 10 ring carbon atoms ("C 10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl).
- an aryl group has 14 ring carbon atoms ("C 14 aryl”; e.g., anthracyl).
- each instance of an aryl group is independently unsubstituted (an “unsubstituted aryl") or substituted (a "substituted aryl”) with one or more substituents.
- the aryl group is an unsubstituted C 6-14 aryl.
- the aryl group is a substituted C 6-14 aryl.
- heteroaryl refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 p electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-14 membered heteroaryl").
- the point of attachment can be a carbon or nitrogen atom, as valency permits.
- Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings.
- Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system.
- Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system.
- Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
- the point of attachment can be on either ring, e.g., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
- the heteroaryl is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.
- the heteroaryl is substituted or unsubstituted, 9- or 10-membered, bicyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.
- a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl").
- a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl").
- a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl").
- the 5- 6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
- each instance of a heteroaryl group is independently unsubstituted (an "unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with one or more substituents.
- the heteroaryl group is an unsubstituted 5-14 membered heteroaryl.
- the heteroaryl group is a substituted 5-14 membered heteroaryl.
- Exemplary 5-membered heteroaryl groups containing 1 heteroatom include pyrrolyl, furanyl, and thiophenyl.
- Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
- Exemplary 5- membered heteroaryl groups containing 3 heteroatoms include triazolyl, oxadiazolyl, and thiadiazolyl.
- Exemplary 5-membered heteroaryl groups containing 4 hetero atoms include tetrazolyl.
- Exemplary 6-membered heteroaryl groups containing 1 heteroatom include pyridinyl.
- Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include pyridazinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include triazinyl and tetrazinyl, respectively.
- Exemplary 7- membered heteroaryl groups containing 1 heteroatom include azepinyl, oxepinyl, and thiepinyl.
- Exemplary 5,6-bicyclic heteroaryl groups include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
- Exemplary 6,6-bicyclic heteroaryl groups include naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
- Exemplary tricyclic heteroaryl groups include phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, and phenazinyl.
- heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or + NR (as in N- substituted pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
- heterocycle refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
- partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- compounds of the disclosure may, when specified, contain “optionally substituted” moieties.
- substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
- an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
- Suitable monovalent substituents on R° are independently halogen, — (CH 2 )O-2R ⁇ , -(haloR ⁇ ), — (CH 2 ) 0-2 OH, — (CH 2 ) 0-2 OR, — (CH 2 ) 0-2 CH(OR ⁇ ) 2 ; — O(haloR ⁇ ), — CN, — N 3 , — (CH 2 ) 0-2 C(O)R, — (CH 2 ) 0-2 C(O)OH, — (CH 2 ) 0-2 C(O)OR ⁇ , — (CH 2 ) 0-2 SR ⁇ , — (CH 2 ) 0-2 SH, — (CH 2 ) 0-2 NH 2 , — (CH 2 ) 0-2 NHR ⁇ , — (CH 2 ) 0-2 NR ⁇ 2 , — N
- Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: — O(CR* 2 ) 2-3 O — , wherein each independent occurrence of R* is selected from hydrogen, C 1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on the aliphatic group of R* include halogen, — R*, -(haloR*), —OH, —OR ⁇ , —O(haloR ⁇ ), — CN, — C(O)OH, — C(O)OR ⁇ , — NH 2 , — NHR ⁇ , —NR ⁇ 2 , or — NO 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C 1-4 aliphatic, — CH 2 Ph, — O(CH 2 ) 0-1 Ph, or a 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include — R ⁇ , — NR ⁇ 2 , — C(O)R ⁇ , — C(O)OR ⁇ , — C(O)C(O)R ⁇ , — C(O)CH 2 C(O)R ⁇ , — S(O) 2 R ⁇ , — S(O) 2 NR ⁇ 2 , — C(S)NR ⁇ 2 , — C(NH)NR ⁇ 2 , or — N(R ⁇ )S(O) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C 1-6 aliphatic which may be substituted as defined below, unsubstituted — OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the
- Suitable substituents on the aliphatic group of R ⁇ are independently halogen, — R*, - (haloR*), —OH, —OR*, —O(haloR*), — CN, — C(O)OH, — C(O)OR*, — NH 2 , —NHR*, — NR* 2 , or — N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci-4 aliphatic, — CH 2 Ph, — O(CH 2 ) 0- 1 Ph, or a 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1- 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- pharmaceutically acceptable salt refers to those salts which retain the biological effectiveness and properties of the "free” compounds provided herein.
- Any of the Hsp90 inhibitors or precursor compounds disclosed herein may be provided as pharmaceutically acceptable salts.
- a pharmaceutically acceptable salt can be obtained from the reaction of the free base of an active compound provided herein with an inorganic acid, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or an organic acid, for example, sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, citric acid, fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic acid, lactic acid, tartaric acid (e.g., (+) -tartaric acid or (-)-tartaric acid or mixtures thereof), and the like.
- inorganic acid for example,
- suitable acids include acetic acid, acetylsalicylic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, bisulfic acid, boric acid, butyric acid, camphoric acid, camphorsulfonic acid, carbonic acid, citric acid, cyclopentanepropionic acid, digluconic acid, dodecylsulfic acid, formic acid, glyceric acid, glycerophosphoric acid, glycine, glucoheptanoic acid, gluconic acid, glutamic acid, glutaric acid, glycolic acid, hemisulfic acid, heptanoic acid, hexanoic acid, hippuric acid, hydroiodic acid, hydroxyethanesulfonic acid, malic acid, malonic acid, mandelic acid, mucic acid, naphthylanesulfonic acid, naphthylic acid, nic
- Certain active compounds provided herein have acidic substituents and can exist as pharmaceutically acceptable salts with pharmaceutically acceptable bases.
- the present disclosure includes such salts.
- examples of such salts include metal counterion salts, such as sodium, potassium, lithium, magnesium, calcium, iron, copper, zinc, silver, or aluminum salts, and organic amine salts, such as methylamine, dimethylamine, trimethylamine, diethylamine, triethylamine, n-propylamine, 2 -propylamine, or dimethylisopropylamine salts, and the like.
- pharmaceutically acceptable salt includes mono-salts and compounds in which a plurality of salts is present, e.g. , di-salts and/or tri-salts.
- Pharmaceutically acceptable salts can be prepared by methods known to those in the art.
- the neutral forms of the compounds are regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure.
- structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this disclosure.
- Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.
- oxo means an oxygen that is double bonded to a carbon atom, thereby forming a carbonyl.
- protecting group it is meant that a particular functional moiety, e.g., O, S, or N, is masked or blocked, permitting, if desired, a reaction to be carried out selectively at another reactive site in a multifunctional compound.
- Suitable protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference.
- a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group is preferably selectively removable by readily available, preferably non-toxic reagents that do not attack the other functional groups; the protecting group forms a separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group will preferably have a minimum of additional functionality to avoid further sites of reaction.
- oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized.
- Amino-protecting groups include methyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9- (2,7-dibromo)fluoroenylmethyl carbamate, 4-methoxyphenacyl carbamate (Phenoc), 2,2,2- trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 1 -methyl- 1 -(4- biphenylyl)ethyl carbamate (Bpoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N- dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), allyl carbamate (Alloc), 4-nitrocinnamyl carbamate (Noc), N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl
- protecting groups are detailed herein, however, it will be appreciated that the present disclosure is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the method of the present disclosure. Additionally, a variety of protecting groups are described by Greene and Wuts ( Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999). In some embodiments, a compound described herein does not contain a protecting group. In some embodiments, a compound described herein does not contain a Boc protecting group.
- radiolabel refers to a moiety comprising a radioactive isotope of at least one element.
- exemplary suitable radiolabels include but are not limited to those described herein.
- a radiolabel is one used in positron emission tomography (PET).
- a radiolabel is one used in single-photon emission computed tomography (SPECT).
- SPECT single-photon emission computed tomography
- the radiolabel is radioiodine.
- the radioiodine is selected from I 123 , I 124 , or I 131 .
- good manufacturing practices (GMP) grade compound refers to a compound produced according to practices that conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture of the compound for the intended use.
- a good manufacturing practices (GMP) grade compound is suitable for use based on U.S. Food and Drug Administration guidelines.
- aspects of the present disclosure provide methods of producing Sn-labeled Hsp90 inhibitors.
- the method comprises one or more steps depicted in FIGs. 2A-2C.
- the method comprises all of the steps depicted in FIGs. 2A- 2C.
- Step 1 shown in FIG. 2A allows for a one-step synthesis of a Sn-labeled Hsp90 inhibitor.
- Step 2 shown in FIG. 2B allows for purification of the synthesized Sn-labeled Hsp90 inhibitor.
- Purification of an Sn-labeled Hsp90 inhibitor may comprise silica gel chromatography and/or use of solvents for separation of target compound from impurities (e.g ., dichloromethane and/or toluene). Purification of an Sn-labeled Hsp90 inhibitor may further comprise crystallization (e.g., with dichloromethane and methyl tert- butyl ether (MTBE)). Step 3 shown in FIG. 2B allows for further purification of a synthesized Sn-labeled Hsp90 inhibitor. For example, a synthesized Sn-labeled Hsp90 inhibitor purified via crystallization (e.g., with ethanol and/or heptane). As one of ordinary skill in the art would appreciate one or more purification steps shown in FIGs. 2A-2C may be omitted.
- the present disclosure provides a method of producing a compound of Formula I: comprising reacting in a reaction mixture: a compound of Formula V: (Formula V) with hexamethylditin (Sn 2 MOe 6 ) and tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) in a solution, wherein each of R 1 , R 2 , R 3 , R 4 , L, X, Y 1 , Y 2 , Z 1 , Z 2 , and Z 3 is as defined above and described in classes and subclasses herein.
- Any substrates and/or products may be good manufacturing practices (GMP) grade compounds.
- GMP good manufacturing practices
- X is — CH 2 — . In some embodiments, X is — S — . In other embodiments, X is — O — .
- Y 1 is — CR 3a — . In certain embodiments, Y 1 is — N — .
- Y 2 is — CR 3a — . In certain embodiments, Y 2 is — N — .
- R 3a is hydrogen
- Z 1 is — CH — . In certain embodiments, Z 1 is — N — . In certain embodiments, Z 2 is — CH — . In certain embodiments, Z 2 is — N — .
- Z 3 is — CH — . In certain embodiments, Z 3 is — N — .
- R 1 is hydrogen. In some embodiments, R 1 is halogen. In some embodiments, R 1 is fluro.
- -L-R 2 comprises a methylene that is replaced with — NH — to form a secondary amine.
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L.
- -L-R 2 does not contain a Boc-protected secondary amine.
- -L-R 2 does not contain a secondary amine that is protected with an acid-labile protecting group.
- -L-R 2 does not contain a protected secondary amine.
- L is a straight or branched, optionally substituted C 2- 14 aliphatic group wherein one, two, or three carbons are optionally and independently replaced by -Cy-, —NR—, — N(R)C(O)— , — C(O)N(R)— , — C(O)N(O)— , — N(R)SO 2— , — SO 2 N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S— , —SO—, or — SO 2— ,
- L is a straight or branched, C 2-14 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C 2-12 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C 2-10 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments,
- L is a straight or branched, C 2-8 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine.
- L is a straight or branched, C 2-6 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine.
- L is a straight or branched, C 2- 4 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine.
- L is a straight or branched, C 6-14 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C 6-12 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine.
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy- or — C(O) — . In some embodiments, L is a straight or branched, C 2-8 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy- or — C(O) — . In certain embodiments, L is a straight or branched, C 2-8 aliphatic group wherein one carbon of L is replaced by -Cy- and wherein -Cy- is a 6-membered saturated ring having one heteroatom selected from nitrogen.
- -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, -Cy- is an optionally substituted 3-8 membered bivalent, saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, -Cy- is an optionally substituted 5-6 membered bivalent, saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, -Cy- is bivalent piperidinyl.
- R 2 is hydrogen. In other embodiments, R 2 is optionally substituted C 1-6 aliphatic. In some embodiments, R 2 is optionally substituted C 1-4 aliphatic. In some embodiments, R 2 is C1-4 alkyl. In some embodiments, R 2 is 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. In some embodiments, R 2 is 5- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. In some embodiments, R 2 is piperidinyl. In some embodiments, R 2 is aziridinyl.
- R 2 is 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R 2 is cyclopropyl.
- -L-R 2 forms a primary amino-alkyl group. In some embodiments, -L-R 2 forms a secondary alkyl-amino-alkyl group. In some embodiments, -L-R 2 is selected from the following:
- -L-R 2 is selected from the following:
- each R 3 is independently halogen, — CN, — OR, — SR, — NCR) ! , or optionally substituted C 1-6 aliphatic.
- each R 3 is — OR.
- both Y 1 and Y 2 N — , as valency permits and there are two occurrences of R 3 .
- both Y 1 and Y 2 N — , as valency permits and there is one occurrence of R 3 .
- a compound of Formula V comprises Compound 6:
- a compound of Formula V comprises Compound 7:
- R 3 is — OR
- R is C 1-6 aliphatic.
- R 3 is — OR
- R is methyl.
- Ring A is an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl.
- Ring A is a 5-membered partially unsaturated monocyclic heterocyclyl having 2 heteroatoms selected from oxygen.
- Ring A is a 5-membered partially unsaturated monocyclic heterocyclyl having 1 heteroatom selected from oxygen.
- Ring A is a 6-membered partially unsaturated monocyclic heterocyclyl having 2 heteroatoms selected from oxygen.
- Ring A is phenyl.
- Ring A is taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl. In some embodiments, Ring A is an optionally substituted 5- to 6- membered partially unsaturated carbocyclyl.
- R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is butyl.
- a compound of the present disclosure is other than: wherein each of Ring A, R 1 , R 2 , R 4 , L, Y 1 , Y 2 , Z 1 , Z 2 , Z 3 , and X is as defined above and described in classes and subclasses herein, both singly and in combination.
- a compound provided herein is of Formula I-a:
- a compound is a compound of Formula I-a and:
- X is — CH 2 — or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L.
- a compound provided herein is a compound of Formula I-b, I- c, I-d, I-e, I-f, I-g, I-h, or I-j:
- R 1 , R 2 , R 4 , L, X, Y 1 , Y 2 , Z 1 , Z 2 , Z 3 , and R is as defined above and described in classes and subclasses herein, both singly and in combination.
- a compound provided herein is a compound of Formula I-i: I-i wherein each of R 1 , R 2 , R 4 , L, and X is as defined above and described in classes and subclasses herein, both singly and in combination.
- a compound of Formula I is selected from those depicted in
- the method comprises reacting a compound of Formula V: (Formula V) with hexamethylditin (Sn 2 Me 6 ) and tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) in a solution between about 60 °C to about 80 °C ( e.g between about 60°C to about 65°C, between about 65°C to about 70°C, between about 70°C to about 75°C, or between about 75°C to about 80°C, between about 65°C to about 75°C, between about 60°C to about 70°C, or between about 70°C to about 80°C).
- the temperature is about 65°C and about 75°C, or about 70°C.
- use of tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as a catalyst reduces reaction stalling by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% as compared to a control.
- use of tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as a catalyst reduces reaction stalling by at most 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% as compared to a control.
- use of tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as a catalyst reduces reaction stalling by about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% as compared to a control.
- use of tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as a catalyst reduces reaction stalling about 1% to about 10%, about 1% to about 50%, about 50% to about 100%, about 10% to about 20%, about 20% to about 30%, 30% to about 40%, 40% to about 50%, 50% to about 60%, 70% to about 80%, 80% to about 90%, 90% to about 100% as compared to a control.
- a control is performed using the same reaction but with a different catalyst, e.g., Pd(PPh 3 ) 4 in place of Pd 2 (dba) 3 .
- reaction stalling is measured by the time it takes to produce a certain amount (mass) of product (i.e., the product yield), and the reduction in reaction stalling may be measured by comparison with the reaction time when another catalyst is used, including for example Pd(PPh3)4.
- reaction stalling time is measured from when the substrates are initially combined.
- the amount of substrate and the amount of product are measured for a reaction, and reaction stalling occurs when the conversion of the substrate to the product does not change for a particular amount of time (e.g., for about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10, minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 50 minutes, or an hour).
- additional catalyst is added to the reaction following the stalling of a reaction.
- a reaction is stopped when the product (e.g., the Sn-labeled form of the Hsp90 inhibitor) represents greater than 70% of the combined amount of the product and substrate (e.g., the Sn-labeled form and the iodine-labeled form of the Hsp90 inhibitor) present in the reaction mixture (e.g ., between 70% to 80%, between 80% to 90%, or between 90% to 100% (e.g., about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%).
- use of tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as a catalyst improves the product yield.
- Improved product yield may be measured by the increased amount (mass) of product produced when Pd 2 (dba) 3 is used as a catalyst compared to when another catalyst (e.g., Pd(PPh3)4) is used.
- the yield may be improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% when using tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as compared to a control that uses another catalyst.
- the yield may be improved by at most 1%, 5%, 10%, 15%,
- the yield may be improved by 1% to 50%, 50 to 100%, 100% to 200%, 200% to 300%, 300% to 400%, 400% to 500%, 500% to 600%, 600% to 700%, 700% to 800%, 800% to 900%, 900% to 1000% when using tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) as compared to a control that uses another catalyst.
- Pd 2 (dba) 3 tris(dibenzylideneacetone)dipalladium(0)
- control uses Pd(PPh3)4 as the catalyst.
- the method further comprises purifying an Sn-labeled Hsp90 inhibitor by mixing the Sn-labeled Hsp90 inhibitor with dichloromethane (DCM) and stirring the mixture to form a substantially clear solution.
- DCM dichloromethane
- a substantially clear solution may be determined by eye.
- the method comprises adding water to the substantially clear solution, stirring the solution for at least 5 minutes (e.g., at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 10 minutes, at least 15 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, or at least 60 minutes, but typically no longer than 90 minutes (e.g., about 5 to about 90 minutes, about 6 to about 90 minutes, about 7 to about 90 minutes, about 8 to about 90 minutes, about 9 to about 90 minutes, about 10 to about 90 minutes, about 15 to about 90 minutes, about 20 to about 90 minutes, about 25 to about 90 minutes, about 30 to about 90 minutes, about 35 to about 90 minutes, about 40 to about 90 minutes, about 45 to about 90 minutes, about 50 to about 90 minutes, about 55 to about 90 minutes, about 60 to about 90 minutes), and allowing or causing the solution to separate into an organic layer and an aqueous layer.
- 90 minutes e.g., about 5 to about 90 minutes
- the water is purified water.
- the method comprises performing these steps one or more times. For example, a cycle comprising the steps of adding water to the solution, stirring the solution for at least 5 minutes, and allowing or causing the solution to separate into an organic layer and an aqueous layer, may be performed at least 1 time, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times, but typically no more than 12 times.
- the water is purified water.
- the solution is stirred for the same length of time in all of the cycles performed. In some embodiments, the solution is stirred for different lengths of time when the cycle is repeated.
- a method comprises filtering the organic layer, washing the reaction vessel with DCM, and concentrating the filtrate and the wash.
- the concentrating occurs at no more than 50 °C (e.g., no more than 45 °C, 40 °C, 35 °C, 30 °C, 25 °C, 20 °C, 15 °C, or 10 °C) to distill the product.
- the concentrating occurs at no less than 25 °C (e.g., no less than 45 °C, 40 °C, 35 °C, 30 °C, or 25 °C)) to distill the product.
- the product is dried under vacuum at no more than 70 °C (e.g., no more than 65 °C, 60 °C, 55 °C, 50 °C, 45 °C, 40 °C, 35 °C, 30 °C, 25 °C, 20 °C, 15 °C, or 10 °C). In some embodiments, the product is dried under vacuum at no less than 10 °C (e.g., no less than 65 °C, 60 °C, 55 °C, 50 °C, 45 °C, 40 °C, 35 °C, 30 °C, 25 °C, 20 °C, or 15 °C).
- a method comprises adding ethanol (EtOH)-Heptane to the product, which may be useful to precipitate the product.
- the product comprises a compound of Formula I.
- the methods of producing a radiolabeled Hsp90 inhibitor disclosed herein comprise producing a compound of Formula II: (Formula II), reacting, as substrates, a radioiodine and a compound of Formula I: (Formula I), wherein:
- W is radioiodine
- X is — CH 2 — , — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
- each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, , aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
- the compound of Formula II comprises: (Formula III); or
- the compound of Formula I comprises:
- the compound of Formula I is provided as a free base. In some embodiments, the compound of Formula I is provided as a hydrogen iodide salt (HI). In some embodiments, the compound of Formula I is reacted with a radioiodine sodium salt. In some embodiments, the radioiodine in Formula I is selected from I 123 , I 124 , or I 131 . In some embodiments, the radioiodine salt is selected from a I 123 , I 124 , or I 131 salt. In some embodiments, a radioiodine or a pharmaceutically acceptable salt thereof is not I 127 or a pharmaceutically acceptable salt thereof.
- the amount of radioiodine salt is at least 0.1 mCi (e.g ., at least 0.5 mCi, at least 1 mCi, at least 1.5 mCi, at least 2 mCi, at least 2.5 mCi, at least 3 mCi, at least 3.5 mCi, at least 4 mCi, at least 4.5 mCi, at least 5 mCi, at least 6 m mCi, at least 7 mCi, at least 8 mCi, at least 9 mCi, at least 10 mCi, at least 11 mCi, at least 12 mCi, at least 13 mCi, at least 14 mCi, or at least 15 mCi).
- the amount of radioiodine salt is at most 15 mCi (e.g., at most 0.5 mCi, at most 1 mCi, at most 1.5 mCi, at most 2 mCi, at most 2.5 mCi, at most 3 mCi, at most 3.5 mCi, at most 4 mCi, at most 4.5 mCi, at most 5 mCi, at most 6 m mCi, at most 7 mCi, at most 8 mCi, at most 9 mCi, at most 10 mCi, at most 11 mCi, at most 12 mCi, at most 13 mCi, at most 14 mCi, or at most 15 mCi).
- mCi e.g., at most 0.5 mCi, at most 1 mCi, at most 1.5 mCi, at most 2 mCi, at most 2.5 mCi, at most 3 mCi, at most 3.5
- the amount of radioiodine salt is between 1 mCi and 5 mCi, between 5 mCi and 10 mCi, or between 10 mCi and 15 mCi. In some embodiments, the amount of radioiodine salt is about 10 mCi, about 11 mCi, about 12 mCi, about 13 mCi, about 14 mCi, or about 15 mCi. In some embodiments, the amount of radioiodine salt is between 3 and 3.5 mCi (e.g., about 3 mCi, about 3.1 mCi, about 3.2 mCi, about 3.3 mCi, about 3.4 mCi, about 3.5 mCi).
- aspects of the present disclosure provide methods of producing a radiolabeled Hsp90 inhibitor comprising reacting substrates in the presence of peracetic acid.
- the method of producing a compound of Formula II comprises reacting a compound of Formula (Formula
- a radioiodine salt in the presence of peracetic acid, in a solution at a pH between 2-5 (e.g., at a pH between 2-3, between 3-4, between 4-5, or between 3-5).
- the solution is at a pH of about 2, about 3, about 4, or about 5.
- the peracetic acid is about 3% to about 10% (e.g., 4-10%, 5- 10%, 6-10%, 7-10%, 8-10%, 9-10%, 3-4%, 3-5%, 3-6%, 3-7%, 3-8%, 3-9%, 4-5%, 4-6%, 4- 7%, 4-8%, 4-9%, 5-6%, 5-7%, 5-8%, 5-9%, 6-7%, 6-8%, 6-9%, 7-8%, 7-9%, or 8-9%) peracetic acid.
- the peracetic acid is about 6%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, or 7% peracetic acid.
- the peracetic acid is 6-6.5% peracetic acid.
- the peracetic acid is about 6.4% peracetic acid.
- the solution comprises phosphoric acid (H 3 PO 4 ) or sulfuric acid.
- the solution comprises about 0.1- about 1 M (e.g., about 0.1 to about 0.2 M, about 0.1 to about 0.3 M, about 0.1 to about 0.4 M, about 0.1 to about 0.5 M, about 0.1 to about 0.6 M, about 0.1 to about 0.7 M, about 0.1 to about 0.8 M, about 0.1 to about 0.9 M, about 0.2 to about 0.3 M, about 0.2 to about 0.4 M, about 0.2 to about 0.5 M, about 0.2 to about 0.6 M, about 0.2 to about 0.7 M, about 0.2 to about 0.8 M, about 0.2 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3 to about 0.5 M, about 0.3 to about 0.6 M, about 0.3 to about 0.7 M, about 0.3 to about 0.8 M, about 0.3 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3
- the solution comprises 0.1-lM (e.g., 0.1-0.2 M, 0.1-0.3 M, 0.1-0.4 M, 0.1-0.5 M, 0.1-0.6 M, 0.1-0.7 M, 0.1-0.8 M, 0.1-0.9 M, 0.2-0.3 M, 0.2-0.4 M, 0.2-0.5 M, 0.2-0.6 M, 0.2-0.7 M, 0.2-0.8 M, 0.2- 0.9 M, 0.2-1 M, 0.3-0.4 M, 0.3-0.5 M, 0.3-0.6 M, 0.3-0.7 M, 0.3-0.8 M, 0.3-0.9 M, or 0.3-1 M, 0.4-0.5 M, 0.4-0.6 M, 0.4-0.7 M, 0.4-0.8 M, 0.4-0.9 M, 0.4-1 M, 0.5-0.6 M, 0.5-0.7 M, 0.5-0.8 M, 0.5-0.9 M, 0.5-1 M, 0.6-0.7 M, 0.6-0.8 M, 0.6-0.9 M, 0.6- 1 M, 0.7-0.8 M, 0.7-0.9 M, 0.7-
- the solution comprises 0.8 M H 3 PO 4 .
- the solution comprises about 0.1 to about 1 M (e.g ., (e.g., about 0.1 to about 0.2 M, about 0.1 to about 0.3 M, about 0.1 to about 0.4 M, about 0.1 to about 0.5 M, about 0.1 to about 0.6 M, about 0.1 to about 0.7 M, about 0.1 to about 0.8 M, about 0.1 to about 0.9 M, about 0.2 to about 0.3 M, about 0.2 to about 0.4 M, about 0.2 to about 0.5 M, about 0.2 to about 0.6 M, about 0.2 to about 0.7 M, about 0.2 to about 0.8 M, about 0.2 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3 to about 0.5 M, about 0.3 to about 0.6 M, about 0.3 to about 0.7 M, about 0.3 to about 0.8 M, about 0.3 to about 0.9 M, about or 0.3 to about 1 M, about 0.4 M, about 0.3 to about
- the solution comprises 0.8 M H 3 PO 4 .
- the solution comprises 0.1-1 M (e.g., 0.1-0.2 M, 0.1-0.3 M, 0.1-0.4 M, 0.1-0.5 M, 0.1-0.6 M, 0.1-0.7 M, 0.1-0.8 M, 0.1-0.9 M, 0.2-0.3 M, 0.2-0.4 M, 0.2-0.5 M, 0.2-0.6 M, 0.2-0.7 M, 0.2-0.8 M, 0.2-0.9 M, 0.2-1 M, 0.3-0.4 M, 0.3-0.5 M, 0.3-0.6 M, 0.3-0.7 M, 0.3- 0.8 M, 0.3-0.9 M, or 0.3-1 M, 0.4-0.5 M, 0.4-0.6 M, 0.4-0.7 M, 0.4-0.8 M, 0.4-0.9 M, 0.4-1 M, 0.5-0.6 M, 0.5-0.7 M, 0.5-0.8 M, 0.5-0.9 M, 0.5-1 M, 0.6-0.7 M, 0.6-0.8 M, 0.6-0.9 M, 0.6-0.9 M, 0.6
- the solution comprises water.
- the reaction in the presence of peracetic acid occurs at a temperature between about 15 to about 30 °C (e.g., between about 15 to about 20 °C, between about 20 °C to about 30 °C, between about 20 °C to about 25 °C, between about 25 °C to about 30 °C, between about 21 °C to about 30 °C, between about 22 °C to about 30 °C, between about 23 °C to about 30 °C, between about 24 °C to about 30 °C, between about 26 °C to about 30 °C, between about 27 °C to about 30 °C, between about 28 °C to about 30 °C, or between about 29 °C to about 30 °C).
- a temperature between about 15 to about 30 °C (e.g., between about 15 to about 20 °C, between about 20 °C to about 30 °C, between about 20 °C to about 25 °C, between about 25 °C to about 30 °C, between
- the reaction in the presence of peracetic acid occurs at a temperature between 15°C and 30 °C (e.g., between 15°C and 20 °C, between 20°C and 30 °C, between 20°C and 25 °C, between 25°C and 30 °C, between 21°C and 30 °C, between 22°C and 30 °C, between 23°C and 30 °C, between 24°C and 30 °C, between 26°C and 30 °C, between 27°C and 30 °C, between 28°C and 30 °C, or between 29°C and 30 °C).
- 15°C and 30 °C e.g., between 15°C and 20 °C, between 20°C and 30 °C, between 20°C and 25 °C, between 25°C and 30 °C, between 21°C and 30 °C, between 22°C and 30 °C, between 23°C and 30 °C, between 24°C and 30 °C, between 26°C and 30
- about the reaction occurs for about 0.5 to about 1.5 minutes (e.g., about 0.6 to about 1.5 minutes, about 0.7 to about 1.5 minutes, about 0.8 to about 1.5 minutes, about 0.9 to about 1.5 minutes, about 1 to about 1.5 minutes, about 1.1 to about 1.5 minutes, about 1.2 to about 1.5 minutes, about 1.3 to about 1.5 minutes, about 1.4 to about
- the reaction occurs for 0.5-1.5 minutes (e.g., 0.6-1.5 minutes, 0.7-1.5 minutes, 0.8-1.5 minutes, 0.9-1.5 minutes, 1-1.5 minutes, 1.1-1.5 minutes, 1.2-1.5 minutes, 1.3-1.5 minutes, 1.4-1.5 minutes, 0.5-1 minute, or 1-1.5 minutes).
- 0.5-1.5 minutes e.g., 0.6-1.5 minutes, 0.7-1.5 minutes, 0.8-1.5 minutes, 0.9-1.5 minutes, 1-1.5 minutes, 1.1-1.5 minutes, 1.2-1.5 minutes, 1.3-1.5 minutes, 1.4-1.5 minutes, 0.5-1 minute, or 1-1.5 minutes).
- the method further adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO,) following the reaction (e.g., following about 0.5 to about 1.5 minutes (e.g., about 0.6 to about 1.5 minutes, about 0.7 to about 1.5 minutes, about 0.8 to about 1.5 minutes, about 0.9 to about 1.5 minutes, about 1 to about 1.5 minutes, about 1.1 to about 1.5 minutes, about 1.2 to about 1.5 minutes, about 1.3 to about 1.5 minutes, about 1.4 to about 1.5 minutes, about 0.5 to about 1 minute, about or 1 to about 1.5 minutes) of incubating the substrates).
- the method further comprises adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO 1 ,) following the reaction (e.g., following 0.5 to 1.5 minutes (e.g., 0.6 to
- any of the methods of producing a radiolabeled Hsp90 inhibitor disclosed herein may further comprise purifying the compound of Formula II from the reaction mixture.
- the compound of Formula II is recovered at about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% yield.
- the compound of Formula II is recovered at a particular percentage (e.g., least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% yield).
- the percentage yield is determined by measuring the mass of a product (e.g ., a radiolabeled Hsp90 inhibitor) relative to the mass of the starting materials (e.g., a tin- labeled Hsp90 inhibitor).
- a product e.g ., a radiolabeled Hsp90 inhibitor
- the starting materials e.g., a tin- labeled Hsp90 inhibitor
- the specific activity of the compound of Formula II is at least 10 mCi/mg (e.g., at least 15 mCi/mg, at least 20 mCi/mg, at least 25 mCi/mg, at least 30 mCi/mg, at least 35 mCi/mg, or at least 40 mCi/mg).
- the specific activity of the compound of Formula II is at most 50 mCi/mg (e.g., at most 15 mCi/mg, at most 20 mCi/mg, at most 25 mCi/mg, at most 30 mCi/mg, at most 35 mCi/mg, or at most 40 mCi/mg).
- the method of producing a compound of: (Formula II), comprises reacting:
- a radioiodine salt wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I in the reaction is about 3 to about 5, thereby forming a reaction mixture.
- 25 ⁇ g of a compound of Formula I may be used with 15 pg chloramine-T.
- the reaction further comprises a phosphate buffer, optionally at a pH of about 7.
- the compound of Formula II is recovered at about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% yield. In some embodiments, the compound of Formula II is recovered at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% yield.
- the compound of Formula II is recovered at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, or at most 95% yield.
- the percentage yield is determined by measuring the mass of a product (e.g ., a radiolabeled Hsp90 inhibitor) relative to the mass of the starting materials (e.g., a tin- labeled Hsp90 inhibitor).
- the yield of Formula II using a method described herein is increased by at least 5% (e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 80%, at least 90%, at least 95%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1,000%) as compared to a control.
- a control is performed using the same reaction but with a different ratio of the mass of chloramine-T to the mass of Formula I in the reaction (e.g., a ratio that is not 3:5).
- the compound of Formula I is provided in ethanol.
- the compound of Formula I and chloramine-T are provided in a pre-mixed solution.
- the pre-mixed solution further comprises acetic acid.
- the compound of Formula I and chloramine-T are not provided in a pre-mixed solution.
- the method further comprises passing the reaction mixture through a column (e.g., a Sep-Pak) and eluting the product with less than 3 mL (e.g., less than 2.9 m., less than 2.8 ml, less than 2.7 ml, less than 2.6 ml, less than 2.7 ml, less than 2.6 ml, less than 2.5 ml, less than 2.4 ml, less than 2.3 ml, less than 2.2 ml, less than 2.1 ml, less than 2 ml, less than 1.5 ml, less than 1 ml, or less than 0.5 ml) of pure ethanol.
- the product comprises a compound of Formula II.
- the radioiodine salt is provided in about 0.01 M NaOH. In some embodiments, the radioiodine salt is provided in about 0.005 to about 0.05 M NaOH.
- Hsp90 inhibitors that may be used for Sn- labeling and/or radiolabeling are provided in US published application US 2009/0298857 Al, International Application Publication No. WO 2018/200534 Al, and in US Patent No. 7834181, the entire disclosures of which as they relate to such Hsp90 inhibitors and classes thereof are incorporated by reference herein.
- any of the methods described herein may comprise purifying a compound of interest.
- purifying a compound comprises distillation, chromatography, crystallization, filtration, or any combination thereof.
- Chromatography may comprise a normal phase, reverse phase, or ion-exchange elution over a cartridge comprising suitable sorbent media.
- chromatography comprises high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- a chromatography method may use one or more solvents, e.g., one or more known solvents or one or more solvents determined by routine experimentation.
- Non-limiting examples of solvents that are suitable for use with HPLC include acetonitrile (MeCN), ethanol (EtOH), methanol (MeOH), and trifluoroacetic acid (TFA). Any of the solvents may be prepared in a solution, e.g., TFA in deionized, Milli-Q or HPLC grade water.
- HPLC comprises two mobile phases (see, e.g., Example 1 below).
- Any of the methods described herein may result in a product purity of at least 1%, at least 15%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%.
- Product purity may be measured using known methods including HPLC.
- Product purity may be measured as the mass of the compound of interest relative to the entire mass of the product produced. See, e.g., the methods described in Example 1 below.
- kits e.g., pharmaceutical packs.
- the kits provided may comprise a pharmaceutical composition (i.e., pharmaceutical formulation) or compound described herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
- a container e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
- provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of a pharmaceutical composition or compound described herein.
- the pharmaceutical composition or compound described herein provided in the first container and the second container are combined to form one unit dosage form.
- kits are useful for producing a Sn-labeled Hsp90 inhibitor and/or a radiolabeled Hsp90 inhibitor.
- a kit further comprises instructions for producing a Sn-labeled Hsp90 inhibitor and/or radiolabeled Hsp90 inhibitor using a method described herein.
- a kit further comprises instructions for use of a compound disclosed herein (e.g., a radiolabeled Hsp90 inhibitor disclosed herein).
- a kit comprises a compound of Formula V: (Formula V) and hexamethylditin (Sn 2 Me 6 ) and tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ).
- a kit comprises a compound of Formula I as defined herein, phosphoric acid (H 3 PO 4 ), and peracetic acid.
- the kit further comprises a radioiodine salt.
- the kit does not comprise a radioiodine salt.
- the radioiodine salt is sodium radioiodine.
- the kit comprises about 0.1 to about 1 M (e.g ., (e.g., about 0.1 to about 0.2 M, about 0.1 to about 0.3 M, about 0.1 to about 0.4 M, about 0.1 to about 0.5 M, about 0.1 to about 0.6 M, about 0.1 to about 0.7 M, about 0.1 to about 0.8 M, about 0.1 to about 0.9 M, about 0.2 to about 0.3 M, about 0.2 to about 0.4 M, about 0.2 to about 0.5 M, about 0.2 to about 0.6 M, about 0.2 to about 0.7 M, about 0.2 to about 0.8 M, about 0.2 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3 to about 0.5 M, about 0.3 to about 0.6 M, about 0.3 to about 0.7 M, about 0.3 to about 0.8 M, about 0.3 to about 0.9 M, about or 0.3 to about 1 M, about 0.4 to about 0.5 M, about 0.4 to about 0.6 M, about 0.3 to about 0.7
- the solution comprises 0.8 M H 3 PO 4 .
- the solution comprises 0.1-1 M (e.g ., 0.1-0.2 M, 0.1-0.3 M, 0.1-0.4 M, 0.1-0.5 M, 0.1-0.6 M, 0.1-0.7 M, 0.1-0.8 M, 0.1-0.9 M, 0.2-0.3 M, 0.2-0.4 M, 0.2-0.5 M, 0.2-0.6 M, 0.2-0.7 M, 0.2-0.8 M, 0.2-0.9 M, 0.2-1 M, 0.3-0.4 M, 0.3-0.5 M, 0.3-0.6 M, 0.3-0.7 M, 0.3- 0.8 M, 0.3-0.9 M, or 0.3-1 M, 0.4-0.5 M, 0.4-0.6 M, 0.4-0.7 M, 0.4-0.8 M, 0.4-0.9 M, 0.4-1 M, 0.5-0.6 M, 0.5-0.7 M, 0.5-0.8 M, 0.5-0.9 M, 0.5-1 M, 0.6-0.7 M, 0.6-0.8 M, 0.6-0.9 M, 0.6-0.9 M,
- the kit comprises 0.8 M phosphoric acid (H 3 PO 4 ). In some embodiments, the kit further comprises sodium metabisulfite. In some embodiments, the sodium metabisulfite is in saturated sodium bicarbonate (NaHCO 3 ).
- the peracetic acid is about 3% to about 10% (e.g., 4-10%, 5- 10%, 6-10%, 7-10%, 8-10%, 9-10%, 3-4%, 3-5%, 3-6%, 3-7%, 3-8%, 3-9%, 4-5%, 4-6%, 4- 7%, 4-8%, 4-9%, 5-6%, 5-7%, 5-8%, 5-9%, 6-7%, 6-8%, 6-9%, 7-8%, 7-9%, or 8-9%) peracetic acid.
- the peracetic acid is about 6%, about 6.1%, about 6.2%, about 6.3%, about 6.4%, about 6.5%, about 6.6%, about 6.7%, about 6.8%, about 6.9%, or about 7% peracetic acid.
- the peracetic acid is 6-6.5% peracetic acid.
- the peracetic acid is about 6.4% peracetic acid.
- the kit further comprises a syringe, Sep-Pak, and/or ethanol.
- the radioiodine salt is a salt of I 123 , I 124 , or I 131 .
- a kit comprises a compound of Formula I as defined herein and chloramine-T, in which the ratio of the mass of chloramine-T to the mass of Formula I in the reaction is about 3 to about 5.
- the kit further comprises phosphate buffer at about pH 7.
- the compound of Formula I and chloramine-T may be provided in the same container or in separate containers.
- the compound of Formula I and chloramine-T are provided in the same container that also comprises acetic acid.
- the compound of Formula I is provided in ethanol in a container that is different from the container comprising chloramine-T.
- the kit further comprises: i) ethanol; ii) water; iii) a reaction container; iv) a waste container; v) a product container; vi) a Sep-Pak; vii) one or more syringes; and/or viii) one or more stopcocks.
- the kit further comprises a radioiodine salt.
- the radioiodine salt is sodium radioiodine.
- the radioiodine salt is a salt of I 123 , I 124 , or I 131 .
- kits are useful for treating a disease (e.g ., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof.
- the kits are useful for preventing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof.
- the kits are useful for reducing the risk of developing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof.
- the kits are useful for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a Hsp90 protein in a subject or cell.
- kits described herein further includes instructions for using the kit.
- a kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA).
- the information included in the kits is prescribing information.
- the kits and instructions provide for treating a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof.
- the kits and instructions provide for preventing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof.
- kits and instructions provide for reducing the risk of developing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof.
- the kits and instructions provide for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a Hsp90 protein in a subject or cell.
- the kits and instructions provide for assessment of epichaperome levels and/or to identify subjects that may be sensitive (and thus responsive) to treatment with an epichaperone inhibitor.
- kits and instructions may provide for determination of epichaperome levels and identification patients that would respond to treatment with epichaperome inhibitors (e.g., Hsp90 inhibitors) and can be used to follow and evaluate treatment effects by PET scans to assess the epichaperome level, or size of a tumor, or extent of neurodegenerative diseases.
- a kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
- the subjects to be administered a radiolabeled Hsp90 produced by a method provided herein include mammals such as humans and animals such as non-human primates, agricultural animals (e.g., cow, pig, sheep, goat, horse, rabbit, etc.), companion animals (e.g., dog, cat, etc.), and rodents (e.g., rat, mouse, etc.).
- mammals such as humans and animals such as non-human primates, agricultural animals (e.g., cow, pig, sheep, goat, horse, rabbit, etc.), companion animals (e.g., dog, cat, etc.), and rodents (e.g., rat, mouse, etc.).
- Preferred subjects are human subjects.
- Subjects may be referred to herein as patients in some instances.
- the active compounds and formulations provided herein are intended for use in subjects in need of Hsp90 inhibition.
- Such subjects may have or may be at risk of developing a condition characterized by the presence of epichaperomes or the elevated (compared to normal cells) presence of Hsp90 or which may benefit from inhibition of Hsp90 activity.
- Such conditions may be characterized by the presence of misfolded proteins.
- Such conditions include without limitation cancer, neurodegenerative disorder, inflammation (or inflammatory conditions) such as but not limited to cardiovascular diseases (e.g., atherosclerosis), autoimmune diseases, and the like.
- the compounds and formulations provided herein may be administered via any standard route of administration including but not limited to intraveous administration.
- a radiolabeled Hsp90 inhibitor may be used to treat cancer.
- the radiolabeled Hsp90 inhibitor is administered locally to treat glioblastoma.
- the radiolabeled Hsp90 inhibitor is 131 I.
- a therapeutically effective amount of one or more active compounds disclosed herein may be provided in a formulation.
- the term "therapeutically effective amount” refers to an amount of an active compound or a combination of two or more compounds that inhibits, totally or partially, the progression of the condition being treated or alleviates, at least partially, one or more symptoms of the condition.
- the compounds may be an Hsp90 inhibitor and a second therapeutic agent, and in some embodiments the therapeutically effective amount is the amount of these two classes of agents when used together (including for example the amount of each class of agent).
- a therapeutically effective amount can also be an amount which is prophylactically effective when given, for example, to a subject at risk of developing the condition or a subject who has been successfully treated but may be at risk of a recurrence. The amount which is therapeutically effective depends on the patient's gender and size, the condition to be treated, the condition's severity, and the result sought.
- Dosage strength refers to the amount of active compound in a single dose formulation (e.g., a single capsule, intravenous dose, or a single tablet, etc.). Dosages may range from about 0.001 to about 1000 mg, including about 0.01 mg to about 1000 mg, including 0.01 mg to about 1000 mg, including about 1 mg to about 1000 mg of Hsp90 inhibitor.
- Exemplary dosage strengths include at least 0.001, at least 0.005, at least 0.01, at least 0.05, at least 0.1, at least 0.5, at least 1 mg, at least 2 mg, at least 3 mg, at least 4 mg, at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 175 mg, at least 200 mg, at least 300 mg, at least 400 mg, at least 500 mg or more of Hsp90 inhibitor.
- Exemplary dosage strengths include 0.001 mg, 0.005 mg, 0.01 mg, 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 300 mg, 400 mg, 500 mg, or more, of Hsp90 inhibitor, including all doses therebetween as is explicitly recited herein. In some instances, when a large dose is required, several of a smaller dosage form may be administered or a single larger dosage form may be administered.
- the formulations may be administered daily, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every week, every 2 weeks, every 3 weeks, every 4 weeks, every month, every 2 months, every 3 months, every 4 months, every 6 months, or every year.
- the formulations provided herein may be administered for a period of time (referred to as a treatment period) followed by a period of time in which the formulations are not administered to the subjects (referred to herein as a non-treatment period).
- the treatment period may be 1, 2, 3, 4, 5, 6 or 7 days and the non-treatment period may be 1, 2, 3, 4, 5, 6, or 7 or more days.
- the treatment period may be 1, 2, 3 or 4 weeks and the nontreatment period may be 1, 2, 3, 4 or more weeks.
- the non-treatment period may be as long as or 2, 3, 4, 5, 6, 7, 8, 9 or 10 times as long as the treatment period.
- the treatment and nontreatment periods may be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more times.
- the treatment period is 1 week and the non-treatment period is 3 weeks, and these are repeated 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more times.
- the formulations provided herein may be administered once a day, twice a day, or thrice a day.
- the formulations provided herein may be administered every 3 hours, every 4 hours, every 6 hours, every 12 hours, or every 24 hours.
- cancer refers to a tumor resulting from abnormal or uncontrolled cellular growth.
- examples of cancers include but are not limited to breast cancers (e.g., ER+/HER2- breast cancer, ER+/HER2+ breast cancer, ER-/HER2+ breast cancer, triple negative breast cancer, etc.) , colon cancers, colorectal cancers, prostate cancers, ovarian cancers, pancreatic cancers, lung cancers, gastric cancers, esophageal cancers, glioma cancers, and hematologic malignancies. In some instances, the cancer is glioblastoma.
- neoplastic disorders include but are not limited to hematopoietic disorders, such as the myeloproliferative disorders, essential thrombocytosis, thrombocythemia, angiogenic myeloid metaplasia, polycythemia vera, myelofibrosis, myelofibrosis with myeloid metaplasia, chronic idiopathic myelofibrosis, the cytopenias, and pre-malignant myelodysplastic syndromes.
- myeloproliferative disorders such as the myeloproliferative disorders, essential thrombocytosis, thrombocythemia, angiogenic myeloid metaplasia, polycythemia vera, myelofibrosis, myelofibrosis with myeloid metaplasia, chronic idiopathic myelofibrosis, the cytopenias, and pre-malignant myelodysplastic syndromes.
- the indication to be treated is pancreatic cancer, breast cancer, prostate cancer, skin cancer (e.g., melanoma, basal cell carcinoma), B cell lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
- the indication to be treated is pancreatic cancer.
- the indication to be treated is breast cancer.
- the cancer to be treated may be a primary cancer (without indication of metastasis) or a metastatic stage cancer.
- hematologic malignancy refers to cancer of the bone marrow and lymphatic tissue -body's blood-forming and immune system.
- hematological malignancies include but are not limited to myelodysplasia, lymphomas, leukemias, lymphomas (non-Hodgkin's lymphoma), Hodgkin's disease (also known as Hodgkin's lymphoma), and myeloma, such as acute lymphocytic leukemia (ALL), adult T-cell ALL, acute myeloid leukemia (AML), AML with trilineage myelodysplasia, acute promyelocytic leukemia, acute undifferentiated leukemia, anaplastic large-cell lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic neutrophilic leukemia, juvenile myelomonocyctic leukemia, mixed lineage leukemia, myeloproliferative disorders, myelody
- Neurodegenerative disorder refers to a disorder in which progressive loss of neurons occurs either in the peripheral nervous system or in the central nervous system.
- Examples of neurodegenerative disorders include but are not limited to chronic neurodegenerative diseases such as diabetic peripheral neuropathy, Alzheimer's disease,
- age-related dementia and other dementias include tauopathies, and conditions with memory loss including vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma, chronic traumatic encephalopathy, and diffuse brain damage, dementia pugilistica, and frontal lobe dementia.
- vascular dementia diffuse white matter disease (Binswanger's disease)
- dementia of endocrine or metabolic origin dementia of head trauma, chronic traumatic encephalopathy, and diffuse brain damage
- dementia pugilistica dementia pugilistica
- frontal lobe dementia dementia pugilistica
- neurodegenerative disorders resulting from cerebral ischemia or infarction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type (including but not limited to epidural, subdural, subarachnoid, and intracerebral), and intracranial and intravertebral lesions (including but not limited to contusion, penetration, shear, compression, and laceration).
- embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type (including but not limited to epidural, subdural, subarachnoid, and intracerebral), and intracranial and intravertebral lesions (including but not limited to contusion, penetration, shear, compression, and laceration).
- neurodegenerative disorder also encompasses acute neurodegenerative disorders such as those involving stroke, traumatic brain injury, chronic traumatic encephalopathy, schizophrenia, peripheral nerve damage, hypoglycemia, spinal cord injury, epilepsy, anoxia, and hypoxia.
- the neurodegenerative disorder is selected from Alzheimer's disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis, complete androgen insensitivity syndrome (CAIS), spinal and bulbar muscular atrophy (SBMA or Kennedy's disease), sporadic frontotemporal dementia with parkinsonism (FTDP), familial FTDP-17 syndromes, age-related memory loss, senility, and age-related dementia.
- the neurodegenerative disorder is Alzheimer's disease, also characterized as an amyloidosis.
- amyloidosis disorders which share features, including, but not limited to, hereditary cerebral angiopathy, normeuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle- Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, Finnish amyloidosis, and Iowa amyloidosis.
- the Hsp90 inhibitors of this disclosure may be used in the treatment of inflammation (or inflammatory conditions).
- inflammation conditions include cardiovascular diseases and autoimmune diseases.
- Non-autoimmune inflammatory disorders are inflammatory disorders that are not autoimmune disorders. Examples include atherosclerosis, myocarditis, myocardial infarction, ischemic stroke, abscess, asthma, some inflammatory bowel diseases, chronic obstructive pulmonary disease (COPD), allergic rhinitis, non-autoimmune vasculitis (e.g.
- polyarteritis nodosa age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, atopic dermatitis, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, congestive heart failure, comeal ulceration, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, hemorrhage, viral (e.g., influenza) infections, chronic viral (e.g., Epstein-Barr, cytomegalovirus, herpes simplex virus) infection, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomy
- Alzheimer's disease ataxia telangiectasia, non-autoimmune vasculitis, non-autoimmune arthritis, bone diseases associated with increased bone resorption, ileitis, Barrett's syndrome, inflammatory lung disorders, adult respiratory distress syndrome, and chronic obstructive airway disease, inflammatory disorders of the eye including corneal dystrophy, trachoma, onchocerciasis, sympathetic ophthalmitis and endophthalmitis, chronic inflammatory disorders of the gums such as gingivitis, tuberculosis, leprosy, inflammatory diseases of the kidney including uremic complications, glomerulonephritis and nephrosis, inflammatory disorders of the skin including sclerodermatitis and eczema, inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral s
- cardiovascular diseases include atherosclerosis, elevated blood pressure, heart failure or a cardiovascular event such as acute coronary syndrome, myocardial infarction, myocardial ischemia, chronic stable angina pectoris, unstable angina pectoris, angioplasty, stroke, transient ischemic attack, claudication(s), or vascular occlusion(s).
- the Hsp90 inhibitors of this disclosure may be used in the treatment of autoimmune diseases.
- autoimmune diseases include but are not limited to multiple sclerosis, inflammatory bowel disease including Crohn's Disease and ulcerative colitis, rheumatoid arthritis, psoriasis, type I diabetes, uveitis, Celiac disease, pernicious anemia, Srojen's syndrome, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythamatosis, acute disseminated encephalomyelitis, Addison's disease, Ankylosing spondylitis, antiphospholipid antibody syndrome, Guillain-Barre syndrome, idiopathic thrombocytopenic purpura, Goodpasture's syndrome, Myasthenia gravis, Pemphigus, giant cell arteritis, aplastic anemia, autoimmune hepatitis, Kawaski's disease, mixed connective tissue disease, Ord throidit
- the Hsp90 inhibitors of this disclosure may be used in combination with one or more other therapeutic agents, referred to herein as secondary therapeutic agents.
- the Hsp90 inhibitors and secondary therapeutic agents may have an additive effect or a synergistic (i.e., greater than additive) effect on the targeted indication.
- secondary therapeutic agents include angiogenesis inhibitors, pro- apoptotic agents, cell cycle arrest agents, kinase inhibitors, AKT inhibitors, BTK inhibitors, Bcl2 inhibitors, SYK inhibitors, CD40 inhibitors, CD28 pathway inhibitors, MHC class II inhibitors, PI3K inhibitors, mTOR inhibitors, JAK inhibitors, IKK inhibitors, Raf inhibitors, SRC inhibitors, phosphodiesterase inhibitors, ERK-MAPK pathway inhibitors, and the like.
- AKT inhibitors include PF-04691502, Triciribine phosphate (NSC- 280594), A-674563, CCT128930, AT7867, PHT-427, GSK690693, MK-2206 dihydrochloride.
- BTK inhibitors examples include PCI-32765.
- Bcl2 inhibitors examples include ABT-737, Obatoclax (GX15-070), ABT-263.
- SYK inhibitors include R-406, R406, R935788 (Fostamatinib disodium).
- CD40 inhibitors examples include SGN-40 (anti-huCD40 mAb).
- inhibitors of the CD28 pathway include abatacept, belatacept, blinatumomab, muromonab-CD3, visilizumab.
- inhibitors of major histocompatibility complex include apolizumab.
- PI3K inhibitors examples include 2-(lH-indazol-4-yl)-6-(4- methanesulfonylpiperazin-l-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine, BKM120, NVP-BEZ235, PX-866, SF 1126, XL147.
- Example of mTOR inhibitors include deforolimus, everolimus, NVP-BEZ235, OST 027, tacrolimus, temsirolimus, Ku-0063794, WYE-354, PP242, OSI-027, GSK2126458, WAY-600, WYE- 125132.
- JAK inhibitors include Tofacitinib citrate (CP-690550), AT9283, AG- 490, INCBO 18424 (Ruxolitinib), AZD1480, LY2784544, NVP-BSK805, TGI 01209, TG- 101348.
- IkK inhibitors examples include SC-514, PF 184.
- inhibitors of Raf include sorafenib, vemurafenib, GDC-0879, PLX-4720, PLX4032 (Vemura/enib), NVP-BHG712, SB590885, AZ628, ZM 336372.
- inhibitors of SRC include AZM-475271, dasatinib, saracatinib.
- inhibitors of phosphodiesterases include aminophylline, anagrelide, arofylline, caffeine, cilomilast, dipyridamole, dyphylline, L 869298, L-826,141, milrinone, nitroglycerin, pentoxifylline, roflumilast, rolipram, tetomilast, theophylline, tolbutamide, amrinone, anagrelide, arofylline, caffeine, cilomilast, L 869298, L-826,141, milrinone, pentoxifylline, roflumilast, rolipram, tetomilast.
- Hsp90 inhibitors of this disclosure include AQ4N, becatecarin, BN 80927, CPI-0004Na, daunombicin, dexrazoxane, doxorubicin, elsamitrucin, epirubicin, etoposide, gatifloxacin, gemifloxacin, mitoxantrone, nalidixic acid, nemorubicin, norfloxacin, novobiocin, pixantrone, tafluposide, TAS-103, tirapazamine, valrubicin, XK469, BI2536.
- nucleoside analogs examples include (1) deoxyadenosine analogues such as didanosine (ddl) and vidarabine; (2) adenosine analogues such as BCX4430; (3) deoxycytidine analogues such as cytarabine, gemcitabine, emtricitabine (FTC), lamivudine (3TC), and zalcitabine (ddC); (4) guanosine and deoxyguanosine analogues such as abacavir, acyclovir, and entecavir; (5) thymidine and deoxythymidine analogues such as stavudine (d4T), telbivudine, zidovudine (azidothymidine, or AZT); and (6) deoxyuridine analogues such as idoxuridine and trifluridine.
- deoxyadenosine analogues such as didanosine (dd
- secondary therapeutic agents include taxanes such as paclitaxel, dicetaxel, cabazitaxel.
- Other secondary therapeutic agents include inhibitors of other heatshock proteins such as of Hsp70, Hsp60, and Hsp26.
- the Hsp90 inhibitors and the secondary therapeutic agents may be co-administered. Co-administered includes administering substantially simultaneously, concomitantly, sequentially or adjunctively.
- the Hsp90 inhibitors and the secondary therapeutic agents may be administered at different times. For example, the Hsp90 inhibitors may be administered before or after the secondary therapeutic agent including one or more hours before, one or more day before, or one or more week before the secondary therapeutic agents.
- One or more secondary therapeutic agents may be used. Each of the therapeutic agents may be administered at their predetermined optimal frequency and dose. In some instances, the Hsp90 inhibitors and the secondary therapeutic agents are administered in combination in a therapeutically effective amount.
- This Example describes production of Compound 2, a non-limiting example of an Sn- labeled Hsp90 inhibitor, using Pd 2 (dba) 3 as a catalyst.
- a schematic of the synthesis is shown in FIG. 1.
- Compound 2 was prepared in three steps from Compound 7 including one synthetic step and two purification steps.
- Compound 7 was coupled with hexamethylditin via a Stille reaction using Pd2(dba)3 as a catalyst to afford Compound 2, which was then purified via silica gel chromatography.
- Compound 2 was further purified with dichloromethane and toluene via silica gel chromatography followed by crystallization with dichloromethane and MTBE.
- the purified Compound 2 was then purified via crystallization with ethanol and heptane to afford Compound 2.
- the product was then assessed using HPLC.
- Step 1 Synthesis of 9-[2-( 2 ,2-Dimethyl-propylamino)-ethyl]-8-(6- trimethylstannanyl- benzo[l,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine ( Compound 2).
- FIG. 2A A schematic of Step 1 is shown in FIG. 2A.
- a 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen.
- Compound 7 (121 g), Pd 2 (dba) 3 (20.9 g), and toluene (2.4 L) were charged sequentially to the reactor.
- the reaction mixture was stirred for about 7 minutes until a suspension was formed. Nitrogen gas was bubbled through the reaction mixture for about 23 minutes. Hexamethylditin (302 g) was then charged to the reactor.
- the reaction mixture was heated to about 66 °C and stirred for about 41.5 hours at about 78 °C when a PCT by HPLC failed.
- the column was eluted to the upper surface of the silica gel and the eluent was collected in a clean container. Sea sand (996 g) was loaded onto the top of the column.
- the crude Compound 2 (382 g) and dichloromethane (0.6 L) were mixed thoroughly in a clean container until a solution was formed. The solution was carefully loaded onto the column, the container rinsed with dichloromethane (0.3 L) and the rinse charged to the column.
- the column was eluted with the collected eluent (1.8 L) and additional dichloromethane (3.6 L).
- Step 2 Purification of 9-[2-( 2 ,2-Dimethyl-propylamino)-ethyl]-8-(6- trimethylstannanyl- benzo[ 1,3 ]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine ( Purified Compound 2).
- FIG. 2B A schematic of Step 2 is shown in FIG. 2B.
- a 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen.
- Sn-PU- AD 83 g
- toluene 1.2 L
- the reaction mixture was heated to about 91 °C and the distillate was collected (105 mL).
- the reaction mixture was then stirred at about 107 °C for about 5 hours.
- the batch was cooled to about 45 °C, transferred to the rotavapor, and distilled under vacuum at 56 °C until distillation stopped, and the residue was weighed (86 g).
- the batch was heated to about 36°C and stirred for about 30 minutes at about 37 °C.
- the batch was filtered, the filter cake washed with dichloromethane (0.12 L) and the filtrate collected.
- the batch was then transferred to the rotavapor and distilled under vacuum at 34 °C until distillation stopped, and the residue was weighed (69 g).
- a 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen.
- Dichloromethane (0.8 L) was filtered through an in-line filter into a clean container.
- the distillation residue (69 g) and a portion of the filtered dichloromethane (0.08 L) were charged to the reactor, using dichloromethane to assist the transfer.
- the batch was then heated to about 39 °C.
- MTBE (0.83 L) was filtered through an in-line filter into a clean container.
- a portion of the filtered MTBE (0.21 L) was then charged to the reactor while maintaining a temperature of about 39 °C.
- the batch was stirred at about 38 °C for about 1 hour.
- the batch was cooled to about 6 °C and stirred for about 1 hour at about 6 °C.
- the batch was then filtered, the filter cake washed with polish filtered MTBE (0.12 L) and the filtrate collected.
- the filter cake was dried on a filter by pulling nitrogen for about 1 hour.
- the product was then transferred to drying trays and further dried under vacuum at about 40 °C for about 6.5 days to afford the purified Compound 2 (54.76
- Step 3 A schematic of Step 3 is shown in FIG. 2C. A summary of the purified Compound 2 produced in step 2 is presented in Table 3 below.
- Step 3 Purification of purified 9-[2-( 2 , 2-Dimethyl-propylamino)-ethyl]-8-(6- trimethylstannanyl-benzo[l,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine ( Compound 2).
- a 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen.
- Ethanol 1.1 L was filtered through an in-line filter into a clean container.
- Purified Compound 2 53.23 g and a portion of the filtered ethanol (0.85 L) were charged to the reactor.
- the batch was heated to about 61 °C and stirred at about 62 °C until a clear solution was obtained.
- Heptane (5.3 L) was then filtered through an in-line filter into a clean container.
- a portion of the filtered heptane (1.6 L) was charged to the reactor in small portions over about 1 hour at about 58 °C until a suspension was formed. The batch was then stirred at about 41 °C for about 1 hour. The batch was then transferred to the rotavapor and distilled under vacuum at 49 °C until the remaining volume was about 1.2 L. A portion of the filtered heptane (1.6 L) was charged to the rotavapor flask in small portions over about 18 minutes while maintaining a temperature of 49 °C. The batch was then distilled under vacuum at 45 °C until the remaining volume was about 1.2 L.
- a 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen.
- the distillation residue (1.2 L) and a portion of the filtered heptane (0.53 L) were charged to the reactor, using heptane to assist the transfer.
- the batch was cooled to about 3 °C and stirred for about 1 hour at about 4 °C.
- the batch was then filtered, the filter cake washed with polish filtered heptane (0.5 L) and the filtrate collected.
- the filter cake was dried on a filter by pulling nitrogen for about 1 hour.
- the product was then transferred to drying trays and further dried under vacuum at about 70 °C for about 22 hours to afford Compound 2 (52.40 g).
- Total Impurity (TI) sum of all average percent impurities greater than or equal to the reporting threshold (0 .05%).
- a s Area of the Compound 2 peak in the sample injection
- a st Average area of the Compound 2 peaks in the bracketing standard injections
- This Example describes production of a compound of Formula III: ents were conducted with Compound 2 as either a free base or as a hydrogen iodide salt (HI) and radioactivity of the product was assessed.
- ents were conducted with Compound 2 as either a free base or as a hydrogen iodide salt (HI) and radioactivity of the product was assessed.
- HI hydrogen iodide salt
- This Example describes production of a compound of Formula III: (Formula III) in which W is I 131 , using: 1) chloramine-T in which the ratio of the mass of chloramine-T to the mass of the compound of Formula III in the reaction was 3:5, and 2) Compound 2: (Compound 2) as a substrate. Experiments were conducted with Compound 2 as a free base and radioactivity of the product was assessed.
- This Example describes production of a compound of Formula III: (Formula III) in which W is I 131 , using 1) chloramine-T in which the ratio of the mass of chloramine-T to the mass of the compound of Formula III in the reaction was 3:5, and 2) Compound 2: (Compound 2) free base as a substrate, using the device shown in FIG. 3. Radioactivity of the product was assessed.
- R is the source vial. Inject pre-mixed Sn-PU-AD, chloramine-T and Buffer (not shown). The pre-mixed solution was prepared as indicated in Example 3, Experiment 4 above. 2-mL vial was used and injected a mixture of 25 ⁇ l Compound 2, chloramine-T, and Acetic acid, 10 ⁇ L NaI-131, and 100 ⁇ L 0.1 M PO 4 buffer. (A greater volume of diluted PO 4 buffer was used to ensure all mixture would transfer by a 0.3-mL syringe.)
- Table 12 shows the results that were obtained using the re-thawed solution that was refrigerated for six days. Excluding the amounts left in the vial and device, the conversion was 33.1%, with 62.2% in Waste and 4.7% in the Sep-Pak.
- Table 13 shows the results using Compound 2 stored in ethanol. The conversion was 98.6%. Therefore, this Experiment demonstrates that Compound 2 is stable in ethanol at 2-8 °C for about a week at minimum. Table 13. Results using the device in FIG.3 along with Compound 2 stored in ethanol.
- This example describes production of a compound of Formula III: (Formula III) in which W is I 124 , using: 1) chloramine-T in which the ratio of the mass of chloramine-T to the mass of the compound of Formula III in the reaction was 3:5, and 2) Compound 2: (Compound 2) free base as a substrate, using the device shown in FIG. 3. Experiments were conducted with Compound 2 as a free base and using the device shown in FIG. 3. Radioactivity of the product is assessed.
- reaction vial ® is source 1-124 vial.
- the following protocol is used:
- Clause 1 A method of producing a compound of Formula II: (Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting: a compound of Formula I: (Formula I) or a pharmaceutically acceptable salt thereof with a radioiodine salt in the presence of peracetic acid in a solution at a pH between 2-5, thereby forming a reaction mixture, wherein:
- W is a radioiodine
- X is — C3 ⁇ 4 — , — O — , or — S — ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
- each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
- Clause 2 The method of clause 1, wherein the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of Formula III or a pharmaceutically acceptable salt thereof, or Formula IV or a pharmaceutically acceptable salt thereof: (Formula III) or a pharmaceutically acceptable salt thereof; or
- Clause 4 The method of any one of clauses 1-3, wherein the compound of Formula I is provided as a free base or as a hydrogen iodide salt (HI).
- Clause 5 The method of any one of clauses 1-4, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
- Clause 6 The method of any one of clauses 1-5, wherein the compound of Formula I is provided as a free base.
- Clause 7. The method of any one of clauses 1-6, wherein the radioiodine or salt thereof is selected from I 123 , I 124 , or I 131 or a salt thereof.
- Clause 8 The method of any one of clauses 1-7, wherein the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
- GMP good manufacturing practices
- Clause 9 The method of any one of clauses 1-8, wherein the solution comprises about 0.1 to about 1 M phosphoric acid (H 3 PO 4 ) or sulfuric acid and water and the reaction occurs between about 15 to about 30 °C for about 0.5 to about 1.5 minutes, optionally about 1 minute.
- the solution comprises about 0.1 to about 1 M phosphoric acid (H 3 PO 4 ) or sulfuric acid and water and the reaction occurs between about 15 to about 30 °C for about 0.5 to about 1.5 minutes, optionally about 1 minute.
- Clause 10 The method of clause 9, wherein the solution comprises about 0.8 M phosphoric acid (H 3 PO 4 ) and water.
- Clause 11 The method of clause 10, wherein the reaction occurs between about 20 °C to about 30 °C for about 0.5 to about 1.5 minutes, optionally about 1 minute.
- Clause 12 The method of any one of clauses 1-11, wherein the method further comprises adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO 3 ) following the reaction.
- Clause 13 The method of any one of clauses 1-12, wherein the peracetic acid is about 3% to about 10% peracetic acid.
- Clause 14 The method of clause 13, wherein the peracetic acid is about 6% to about 7% peracetic acid, optionally about 6.3%, about 6.4% or about 6.5% peracetic acid.
- Clause 15 The method of any one of clauses 1-14, further comprising purifying the compound of Formula II or a pharmaceutically acceptable salt thereof from the reaction mixture.
- Clause 16 The method of any one of clauses 1-15, wherein the compound of Formula II or a pharmaceutically acceptable salt thereof is recovered at about 80%, about 85%, about 90%, or about 95% yield.
- Clause 17 The method of any one of clauses 1-16, wherein the specific activity of the compound of Formula II or a pharmaceutically acceptable salt thereof is at least 10 mCi/mg, at least 20 mCi/mg, at least 30 mCi/mg, or at least 40 mCi/mg.
- W is a radioiodine
- X is — CH 2 — , — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C 2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO 2— , — SO 2 N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO 2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
- Clause 19 The method of clause 18, wherein the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of (Formula III) or a pharmaceutically acceptable salt thereof; or a compound of
- Clause 20 The method of any one of clauses 18-19, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof comprises: (Compound 2) or a pharmaceutically acceptable salt thereof; or
- Clause 22 The method of any one of clauses 18-21, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
- Clause 23 The method of any one of clauses 18-22, wherein the reaction further comprises phosphate buffer at about pH 7.
- Clause 25 The method of any one of clauses 18-24, wherein the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof and is a good manufacturing practices (GMP) grade compound.
- GMP good manufacturing practices
- Clause 26 The method of any one of clauses 18-25, wherein the yield of the compound of Formula II or the pharmaceutically acceptable salt thereof is at least 80%.
- Clause 27 The method of any one of clauses 18-26, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is provided in ethanol.
- Clause 28 The method of any one of clauses 18-27, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a pre-mixed solution in acetic acid.
- Clause 29 The method of any one of clauses 18-28, further comprising passing the reaction mixture through a Sep-Pak and eluting the compound of Formula II with less than 3 mL of pure ethanol.
- Clause 30 The method of any one of clauses 18-29, wherein the radioiodine salt is provided in about 0.01M NaOH.
- Clause 31 The method of any one of clauses 18-30, wherein the amount of radioiodine salt is between about 3 and about 3.5 mCi.
- a method of producing a compound of Formula I: (Formula I) or a pharmaceutically acceptable salt thereof comprising reacting in a reaction mixture: a compound of Formula V: (Formula V) or a pharmaceutically acceptable salt thereof with hexamethylditin (Sn 2 Me 6 ) and tris(dibenzylideneacetone)dipalladium(0) (Pd 2 (dba) 3 ) in a solution, thereby producing a compound of Formula I or a pharmaceutically acceptable salt thereof.
- Clause 33 The method of clause 32, the reaction occurs between about 60 °C and about 80 °C.
- Clause 34 The method of any one of clauses clause 32-33, further comprising purifying the compound of Formula I.
- the method of clause 34, wherein purifying the purifying the compound of Formula I comprises mixing the compound of Formula I with dichloromethane (DCM) and stirring the mixture to form a substantially clear solution.
- DCM dichloromethane
- Clause 38 The method of any one of clauses 36-37, further comprising filtering the organic layer, washing the reaction vessel with DCM, and concentrating the filtrate and the wash.
- Clause 39 The method of clause 38, wherein the concentrating occurs at no more than 50 °C to distill the compound of Formula I.
- Clause 40 The method of clause 39, wherein the compound of Formula I is further dried under vacuum at no more than 70 °C.
- Clause 41 The method of any one of clauses 32-40, wherein the compound of Formula V or the pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
- GMP good manufacturing practices
- Clause 42 The method of any one of clauses 32-41, wherein the method further comprises adding ethanol (EtOH) -Heptane to the compound of Formula I.
- Clause 43 The method of any one of clauses 32-42, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof comprises :
- Clause 44 The method of any one of clauses 32-43, wherein the compound of Formula V or the pharmaceutically acceptable salt thereof comprises:
- a kit comprising:
- X is — CH 2— , — O— , or — S— ;
- R 1 is hydrogen or halogen
- L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO 2— , — SO 2 N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO 2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
- Clause 47 The kit of any one of clauses 45-46, further comprising a radioiodine salt.
- kit 49 The kit of any one of clauses 45-48, wherein the kit further comprises (iv) about 0.1 to about 1 M phosphoric acid (H 3 PO 4 ).
- kit 50 The kit of clause 49, wherein the kit further comprises (iv) about 0.8 M phosphoric acid (H 3 PO 4 ).
- Clause 52 The kit of any one of clauses 45-51, wherein the peracetic acid is about 3% to about 10% peracetic acid.
- Clause 53 The kit of clause 52, wherein the peracetic acid is about 6% to about 7% peracetic acid, optionally about 6.3%, about 6.4% or about 6.5% peracetic acid.
- Clause 54 The kit of any one of clauses 45-53, further comprising a syringe, Sep-Pak, and/or ethanol.
- a kit comprising:
- X is — CH 2— , — O— , or — S— ;
- R 1 is hydrogen or halogen;
- L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
- each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R 2 is hydrogen or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R 3 is independently halogen, — NO 2 , — CN, — OR, — SR, — N(R) 2 , — C(
- Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered
- R 3a is R 3 or hydrogen
- R 4 is C 1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C 1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur Clause 57.
- the kit of clause 56 further comprising phosphate buffer at about pH 7.
- Clause 58 The kit of clause 56 or 57, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a single container.
- Clause 59 The kit of clause 58, wherein the container comprising the compound of
- Formula I or the pharmaceutically acceptable salt thereof and chloramine-T further comprises acetic acid.
- Clause 60 The kit of clause 56 or 57, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in separate containers.
- Clause 62 The kit of any one of clauses 56-61, further comprising: i) ethanol; ii) water; ill) a reaction container; iv) a waste container; v) a product container; vi) a Sep-Pak; vii) one or more syringes; and/or viii) one or more stopcocks.
- Clause 63 The kit of any one of clauses 56-62, wherein the kit further comprises a radioiodine salt.
- inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
- inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
- a reference to "A and/or B", when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- the phrase "at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
- At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one,
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Provided herein, in some embodiments, are methods of producing radiolabeled Hsp90 inhibitors and precursors thereof, including tin (Sn)-labeled precursors.
Description
SN-LABELING AND RADIOLABELING OF EPICHAPEROME INHIBITORS
RELATED APPLICATIONS
This application claims the benefit under 35 U.S.C. § 119 of United States Provisional Application Serial Number 63/153,123, filed February 24, 2021, the entire contents of which are incorporated herein by reference.
BACKGROUND
The Hsp90 family of proteins has four recognized members in mammalian cells: Hsp90-alpha (a) and -beta (b), GRP94 and TRAP-1. Hsp90-alpha and -beta exist in the cytosol and the nucleus in association with many other proteins. The Hsp90 family collectively represents the most abundant cellular chaperones, and it has been proposed to function in several beneficial ways including for example as part of the cellular defense against stress such as exposure to heat or other environmental stress. However, it has also been postulated to facilitate the stability and function of mutated proteins such as for example mutated p53. Under extreme or chronic stress Hsp90 has also been found to form tight complexes, called epichaperomes, with other chaperones and regulatory proteins. Many diseased cells are dependent on epichaperome function thus epichaperomes have been identified as putative targets of therapeutic agents.
SUMMARY
Aspects of this disclosure provide new and improved methods for preparing radiolabeled inhibitors of Hsp90, Hsp90 isoforms and Hsp90 homologs. These radiolabeled inhibitors are referred to herein as radiolabeled Hsp90 inhibitors or radiolabeled epichaperome inhibitors. They are able to bind selectively to Hsp90 including Hsp90 isoforms and homologs when these proteins are complexed in an epichaperome.
Radiolabeled Hsp90 inhibitors have numerous clinical applications including in situ visualization of on-target and off-target inhibitor localization and Hsp90 inhibitor metabolism and pharmacokinetics. Such applications may be used to diagnose disease in addition to informing personalized treatment regimens for patients.
More specifically, this disclosure is premised, in part, on the unexpected finding that peracetic acid and a particular ratio of chloramine-T to Hsp90 inhibitor substrate can be used to produce radiolabeled Hsp90 inhibitors at a high purity and yield. This disclosure is also
premised, in part, on the unexpected finding that use of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as a catalyst to produce tin (Sn)-labeled precursors results in a more robust production method. In some instances, the use of this particular compound as a catalyst reduces reaction stalling and/or improves catalyst turnover. Existing methods for producing radiolabeled Hsp90 inhibitors and precursors thereof including Sn-labeled precursors, often result in reaction stalling and require additional charges of reagents. Aspects of the present disclosure in contrast provide improved methods of producing radiolabeled Hsp90 inhibitors and precursors thereof including Sn-labeled Hsp90 inhibitors having reduced stalling propensity. These claimed methods are therefore more robust and efficient than prior art methods. Reduced stalling propensity may manifest itself as a reduced requirement for catalyst charging or no requirement for catalyst charging at all.
Aspects of the present disclosure provide methods of producing a compound of Formula II:
(Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting: a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof with a radioiodine salt in the presence of peracetic acid in a solution at a pH between 2-5, thereby forming a reaction mixture, wherein:
W is a radioiodine;
X is — CH2— — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R) SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R, — CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of Formula III or a pharmaceutically acceptable salt thereof or of Formula IV, or a pharmaceutically acceptable salt thereof:
(Formula III) or a pharmaceutically acceptable salt thereof; or
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof is Compound 1 or a pharmaceutically acceptable salt thereof or Compound 2 or a pharmaceutically acceptable salt thereof:
(Compound 2) or a pharmaceutically acceptable salt thereof; or
In some embodiments, the compound of Formula I is provided as a free base. In some embodiments, the compound of Formula I is provided as a hydrogen iodide salt (HI).
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt. In some embodiments, the radioiodine or salt thereof is selected from I123, I124, or I131 or a salt thereof.
In some embodiments, the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
In some embodiments, the solution comprises about 0.1 to about 1 M (e.g., 0.1-1 M) phosphoric acid (H3PO4) or sulfuric acid and water and the reaction occurs between about 15 to about 30 °C (e.g., 15-30 °C) for about 0.5 to about 1.5 minutes (e.g., 0.5- 1.5 minutes). In some embodiments, the solution comprises about 0.8 M phosphoric acid (H3PO4) and water. In some embodiments, the reaction occurs between about 20 °C to about 30 °C for about 0.5 to about 1.5 minutes, including about 1 minute.
In some embodiments, the method further comprises adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO3) following the reaction.
In some embodiments, the peracetic acid is about 3% to about 10% peracetic acid. In some embodiments, the peracetic acid is about 6% to about 7% peracetic acid, including about 6.3%, about 6.4% and about 6.5% peracetic acid.
In some embodiments, the method further comprises purifying the compound of Formula II or a pharmaceutically acceptable salt thereof from the reaction mixture.
In some embodiments, the compound of Formula II or a pharmaceutically acceptable salt thereof is recovered at about 80%, about 85%, about 90%, or about 95% yield.
In some embodiments, the specific activity of the compound of Formula II or a pharmaceutically acceptable salt thereof is at least 10 mCi/mg, at least 20 mCi/mg, at least 30 mCi/mg, or at least 40 mCi/mg. Further aspects of the disclosure provide methods of producing a compound of
(b) chloramine-T; and
(c) a radioiodine salt, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I or the pharmaceutically acceptable salt thereof in the reaction is about 3 to about 5, thereby forming a reaction mixture, wherein:
W is a radioiodine;
X is — CH2— , — O— , or — S— ;
Y 1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms
selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of
(Formula III) or a pharmaceutically acceptable salt thereof; or a compound of
(Formula IV) or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof comprises:
(Compound 2) or a pharmaceutically acceptable salt thereof; or
(Compound 1) or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula I is provided as a free base.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
In some embodiments, the reaction further comprises phosphate buffer at about pH 7.
In some embodiments, the radioiodine or salt thereof is I123, I124, or I131 or a salt thereof.
In some embodiments, the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof and is a good manufacturing practices (GMP) grade compound.
In some embodiments, the yield of the compound of Formula II or the pharmaceutically acceptable salt thereof is at least 80%.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof is provided in ethanol.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a pre-mixed solution in acetic acid.
In some embodiments, the method further comprises passing the reaction mixture through a Sep-Pak and eluting the compound of Formula II with less than 3 mL of pure ethanol.
In some embodiments, the radioiodine salt is provided in about 0.01M NaOH. In some embodiments, the amount of radioiodine salt is between about 3 and about
3.5 mCi.
Further aspects of the present disclosure provide methods of producing a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof, comprising reacting in a reaction mixture: a compound of Formula V:
(Formula V) or a pharmaceutically acceptable salt thereof
with hexamethylditin (Sn2Me6) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in a solution, thereby producing a compound of Formula I or a pharmaceutically acceptable salt thereof.
In some embodiments, the reaction occurs between about 60 °C to about 80 °C.
In some embodiments, the method further comprises purifying the compound of Formula I.
In some embodiments, purifying the compound of Formula I comprises mixing the compound of Formula I with dichloromethane (DCM) and stirring the mixture to form a substantially clear solution.
In some embodiments, the method further comprises adding purified water to the substantially clear solution, stirring the solution for at least 5 minutes, and allowing the solution to separate into an organic layer and an aqueous layer.
In some embodiments, the method further comprises adding purified water, mixing the layers for at least 15 minutes, and allowing the layers to separate. In some embodiments, the method further comprises further adding purified water, mixing the layers for at least 15 minutes, and allowing the layers to separate.
In some embodiments, the method further comprises filtering the organic layer, washing the reaction vessel with DCM, and concentrating the filtrate and the wash.
In some embodiments, the concentrating occurs at no more than 50 °C to distill the compound of Formula I.
In some embodiments, the compound of Formula I is further dried under vacuum at no more than 70 °C.
In some embodiments, the compound of Formula V or the pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
In some embodiments, the method further comprises adding ethanol (EtOH)-Heptane to the compound of Formula I.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof comprises:
(Compound 2) or a pharmaceutically acceptable salt thereof; or
(Compound 1) or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of Formula V or the pharmaceutically acceptable salt thereof comprises:
Compound 6:
Further aspects of the present disclosure provide kits comprising: (i) a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof;
(ii) phosphoric acid (H3PO4); and
(iii) peracetic acid,
wherein:
X is — CH2— — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R, — CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
In some embodiments, the compound in (i) comprises:
(Compound 2) or a pharmaceutically acceptable salt thereof; or
In some embodiments, the kit further comprises a radioiodine salt. In some embodiments, the radioiodine salt is sodium radioiodine.
In some embodiments, the kit further comprises (iv) about 0.1 to about 1 M phosphoric acid (H3PO4).
In some embodiments, the kit further comprises (iv) about 0.8 M phosphoric acid (H3PO4). In some embodiments, the kit further comprises sodium metabisulfite in saturated sodium bicarbonate (NaHCO,).
In some embodiments, the peracetic acid is about 3% to about 10% peracetic acid.
In some embodiments, the peracetic acid is about 6% to about 7% peracetic acid, including about 6.3%, about 6.4% and about 6.5% peracetic acid. In some embodiments, the kit further comprises a syringe, Sep-Pak, and/or ethanol.
In some embodiments, the radioiodine salt is a salt of I123, I124, or I131.
Further aspects of the present disclosure provide kits comprising:
(i) a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof; and
(ii) chloramine-T, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I or the pharmaceutically acceptable salt thereof in the reaction is about 3 to about 5 and wherein:
X is — CH2— — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R, — CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered
partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
In some embodiments, the kit further comprises phosphate buffer at about pH 7.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a single container.
In some embodiments, the container comprising the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T further comprises acetic acid.
In some embodiments, the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in separate containers.
In some embodiments, the compound of Formula I or pharmaceutically acceptable salt thereof is provided in ethanol.
In some embodiments, the kit further comprises: i) ethanol; ii) water; iii) a reaction container; iv) a waste container; v) a product container; vi) a Sep-Pak; vii) one or more syringes; and/or viii) one or more stopcocks.
In some embodiments, the kit further comprises a radioiodine salt.
In some embodiments, the radioiodine salt is sodium radioiodine.
In some embodiments, the radioiodine salt is a salt of I123, I124, or I131.
BRIEF DESCRIPTION OF DRAWINGS
Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying Figures, which are schematic and are not intended to be drawn to scale.
It is also to be understood that various Figures and exemplifications of this disclosure refer to "a compound of Formula.. Compounds 1-7, or particular chemical structures. However, the disclosure intends this for illustrative purposes only and it is to be in no way limiting. Any of the compounds disclosed herein or a pharmaceutically acceptable salt, cocrystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug thereof can be used as provided herein.
FIG. 1 is a schematic showing a non-limiting example of Compound 2 production using Pd2(dba)3. The following abbreviations are used in this figure: DCM: dichloromethane, MTBE: methyl tert-butyl ether, NET: not less than, NMT: not more than, PCT: process control test, MeOH: methanol, and Et3N: triethylamine
FIGs. 2A-2C are schematics showing a non-limiting example of synthesis of Compound 2 using Pd2(dba)3. FIGs. 2A-2C show steps 1-3, respectively.
FIG. 3 shows a non-limiting example of a device configured for synthesis of a compound of a radiolabeled Hsp90 inhibitor (e.g., a compound of Formula II, such as a compound of Formula III, or of Formula IV, or a pharmaceutically acceptable salt thereof, as defined herein). The device comprises the following components: R: reaction container (e.g., vial); W: waste container (e.g., vial); P: product container (e.g., vial); SP: Sep-Pak, SI, S2, and S3: Syringes; and SCI, SC2, SC3: stopcocks.
DETAIFED DESCRIPTION
This disclosure provides new and suprisingly improved methods for tin (Sn)-labeling and radiolabeling of compounds such as certain agents bind selectively to Hsp90 (i.e.., Hsp90 and/or Hsp90 isoforms and/or Hsp90 homologs such as but not limited to GRP94 and TRAP1) as it is complexed in an epichaperome, and are thus able to interfere with the structure and ultimately function of the epichaperome. Existing methods of Sn-labeling certain Hsp90 inhibitors, including those that make use of Pd(PPh3)4 as a catalyst, have resulted in reaction stalling and have required additional charges of the catalyst, rendering
such methods inefficient and cumbersome. Methods described herein obviate certain limitations of existing methods of Sn-labeling of these compounds, by increasing the efficiency of the reaction and reducing reaction stalling. Aspects of the present disclosure provide methods of improving the yield of certain radiolabeled Hsp90 inhibitors. Radiolabeled Hsp90 inhibitors are useful in numerous clinical applications, including treatment of cancers, assessing the bioavailability of the inhibitor, disease diagnosis, and monitoring the efficacy of a treatment regimen. In some embodiments, the radiolabeled Hsp90 inhibitors disclosed herein may be used to determine the therapeutically effective amount of a non-radiolabeled Hsp90 inhibitor.
For the sake of brevity, the term Hsp90 will be used herein to collectively refer to Hsp90, its isoforms and its homologs such as but not limited to GRP94 and TRAP1. Thus, the Hsp90 inhibitors of this disclosure refer to a class of inhibitors that inhibit Hsp90 and/or Hsp90 isoforms and/or Hsp90 homologs including but not limited to GRP94 and TRAP1. In some embodiments, Hsp90 inhibitors interfere with the structure and ultimately function of an epichaperome.
As used herein, unless otherwise specified, the term "Hsp90 inhibitors" includes iodinated Hsp90 inhibitors, radiolabeled Hsp90 inhibitors and Sn-labeled Hsp90 inhibitors having a parent compound of Formula I, Formula II, or Formula V.
The Hsp90 inhibitor produced herein may interfere with the formation or stability of the epichaperome, thereby rendering target cells (such as cancer cells) more susceptible to cell death. The ability to target the epichaperome can also result in reduced general toxicity in subjects being treated. Accordingly, the inhibitors of this disclosure may also be referred to as epichaperome inhibitors.
The disclosure also provides methods of producing certain Hsp90 inhibitors comprising a radiolabel or producing precursor compounds (e.g., Sn-labeled Hsp90 inhibitor compounds) to be used in the production of a radiolabeled Hsp90 inhibitor.
Any of the compounds described herein, including those that are substrates and those that are products, may be a good manufacturing practices (GMP) grade compound.
Definitions
Compounds of this disclosure include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure,
the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and Formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
The term "about X," where X is a number or percentage, refers to a number or percentage that is between 99.5% and 100.5%, between 99% and 101%, between 98% and 102%, between 97% and 103%, between 96% and 104%, between 95% and 105%, between 92% and 108%, or between 90% and 110% of X, inclusive, of X.
The term "aliphatic" or "aliphatic group", as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle," "cycloaliphatic" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl) alkenyl .
The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quatemized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for
example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR (as in N- substituted pyrrolidinyl)).
The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.
The term "alkylene" refers to a bivalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., — (CH2)n — , wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
The term "halogen" means F, Cl, Br, or I.
The term "aryl" refers to a radical of a monocyclic or polycyclic ( e.g ., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 p electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("C6-14 aryl"). In some embodiments, an aryl group has 6 ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C10 aryl"; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C14 aryl"; e.g., anthracyl). Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an "unsubstituted aryl") or substituted (a "substituted aryl") with one or more substituents. In certain embodiments, the aryl group is an unsubstituted C6-14 aryl. In certain embodiments, the aryl group is a substituted C6-14 aryl.
The term "heteroaryl" refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 p electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-14 membered heteroaryl"). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system.
"Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, e.g., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In certain embodiments, the heteroaryl is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur. In certain embodiments, the heteroaryl is substituted or unsubstituted, 9- or 10-membered, bicyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.
In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some embodiments, the 5- 6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an "unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaryl.
Exemplary 5-membered heteroaryl groups containing 1 heteroatom include pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5- membered heteroaryl groups containing 3 heteroatoms include triazolyl, oxadiazolyl, and
thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 hetero atoms include tetrazolyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include triazinyl and tetrazinyl, respectively. Exemplary 7- membered heteroaryl groups containing 1 heteroatom include azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, and phenazinyl.
As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or +NR (as in N- substituted pyrrolidinyl).
A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic group," "heterocyclic moiety," and "heterocyclic radical," are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A
heterocyclyl group may be mono- or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
As described herein, compounds of the disclosure may, when specified, contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; — (CH2)0-4Rº; — (CH2)0-4OR°; — O(CH2)0-4Rº, — O— (CH2)0-4C(O)OR°; — (CH2)0-4CH(OR°)2; — (CH2)0-4SR°; — (CH2)0-4Ph, which may be substituted with R°; — (CH2)0-4O(CH2)0-1Ph which may be substituted with R°; — CH=CHPh, which may be substituted with R°; — (CH2)0-4O(CH2)0-1-pyridyl which may be substituted with R°; — N02; — CN; — N3; — (CH2)0-4N(R°)2; — (CH2)0-4N(R°)C(O)R°; — N(R°)C(S)R°;
— (CH2)0-4N(R°)C(O)NR° 2; — N(R°)C(S)NR° 2; — (CH2)0-4N(R°)C(O)OR°; — N(R°)N(R°)C(O)R°; — N(R°)N(R°)C(O)NR° 2; — N(R°)N(R°)C(O)OR°; — (CH2)0-4C(O)R°; — C(S)R°; — (CH2)O-4C(O)OR°; — (CH2)0-4C(O)SR°; — (CH2)0-4C(O)OSiR° 3; — (CH2)0- 4OC(O)R°; — OC(O)(CH2)0-4SR— , SC(S)SR°; — (CH2)0-4SC(O)R; — (CH2)0-4C(O)NR° 2; — C(S)NR° 2; — C(S)SR°; — SC(S)SRO, — (CH2)0-4OC(O)NR° 2; — C(O)N(OR)R°; — C(O)C(O)R°; C(O)CH2C(O)R°; — C(NOR°)R°; — (CH2)0-4SSR°; — (CH2)0-4S(O)2R°; — (CH2)0-4S (O)2OR° ; — (CH2)0-40S(O)2R°; — S(O)2NR° 2; — (CH2)0-4 S(O)R°; — N(R°)S(O)2NR° 2; — N(R°)S(O)2R°; — N(OR°)R°; — C(NH)NR° 2; — P(O)2R°; — P(O)R° 2; —
0P(O)R° 2; — OP(O)(OR°)2; SiR° 3; — (C1-4 straight or branched alkylene)0 — N(R°)2; or — (C1-4 straight or branched alkylene)C(O)O — N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, —CH2Ph, — O(CH2)o-iPh, — CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, aryl mono- or bicyclic ring, or heteroaryl mono- or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, — (CH2)O-2R·, -(haloR·), — (CH2)0-2OH, — (CH2)0-2OR, — (CH2)0-2CH(OR·)2; — O(haloR·), — CN, — N3, — (CH2)0-2C(O)R, — (CH2)0-2C(O)OH, — (CH2)0-2C(O)OR·, — (CH2)0-2SR·, — (CH2)0-2SH, — (CH2)0-2NH2, — (CH2)0-2NHR·, — (CH2)0-2NR· 2, — N02, — SiR· 3, —
OSiR· 3, — C(O)SR·, — (C1-4 straight or branched alkylene)C(O)OR·, or — SSR· wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from C1-4 aliphatic, — CH2Ph , — O(CH2)0-1Ph, or a 5- 6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.
Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, — O(C(R*2))2-3O— , or — S(C(R*2))2- 3S — , wherein each independent occurrence of R* is selected from hydrogen, Ci-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted" group include: — O(CR*2)2-3O — , wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on the aliphatic group of R* include halogen, — R*, -(haloR*), —OH, —OR·, —O(haloR·), — CN, — C(O)OH, — C(O)OR·, — NH2, — NHR·, —NR· 2, or — NO2, wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C1-4 aliphatic, — CH2Ph, — O(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include — R†, — NR† 2, — C(O)R†, — C(O)OR†, — C(O)C(O)R†, — C(O)CH2C(O)R†, — S(O)2R†, — S(O)2NR† 2, — C(S)NR† 2, — C(NH)NR† 2, or — N(R†)S(O)2R†; wherein each R† is independently hydrogen, C1-6 aliphatic which may be substituted as defined below, unsubstituted — OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, aryl mono- or bicyclic ring, or heteroaryl mono- or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on the aliphatic group of R† are independently halogen, — R*, - (haloR*), —OH, —OR*, —O(haloR*), — CN, — C(O)OH, — C(O)OR*, — NH2, —NHR*, — NR* 2, or — N02, wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci-4 aliphatic, — CH2Ph, — O(CH2)0- 1Ph, or a 5-6-membered saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1- 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
The term "pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the "free" compounds provided herein. Any of the Hsp90 inhibitors or precursor compounds disclosed herein may be provided as pharmaceutically acceptable salts. A pharmaceutically acceptable salt can be obtained from the reaction of the free base of an active compound provided herein with an inorganic acid, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or an organic acid, for example, sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, citric acid, fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic acid, lactic acid, tartaric acid (e.g., (+) -tartaric acid or (-)-tartaric acid or mixtures thereof), and the like. Additional non-limiting examples of suitable acids include acetic acid, acetylsalicylic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, bisulfic acid, boric acid,
butyric acid, camphoric acid, camphorsulfonic acid, carbonic acid, citric acid, cyclopentanepropionic acid, digluconic acid, dodecylsulfic acid, formic acid, glyceric acid, glycerophosphoric acid, glycine, glucoheptanoic acid, gluconic acid, glutamic acid, glutaric acid, glycolic acid, hemisulfic acid, heptanoic acid, hexanoic acid, hippuric acid, hydroiodic acid, hydroxyethanesulfonic acid, malic acid, malonic acid, mandelic acid, mucic acid, naphthylanesulfonic acid, naphthylic acid, nicotinic acid, nitrous acid, oxalic acid, pelargonic, propionic acid, saccharin, sorbic acid, thiocyanic acid, thioglycolic acid, thiosulfuric acid, tosylic acid, undecylenic acid, and naturally and synthetically derived amino acids.
Certain active compounds provided herein have acidic substituents and can exist as pharmaceutically acceptable salts with pharmaceutically acceptable bases. The present disclosure includes such salts. Examples of such salts include metal counterion salts, such as sodium, potassium, lithium, magnesium, calcium, iron, copper, zinc, silver, or aluminum salts, and organic amine salts, such as methylamine, dimethylamine, trimethylamine, diethylamine, triethylamine, n-propylamine, 2 -propylamine, or dimethylisopropylamine salts, and the like.
The term "pharmaceutically acceptable salt" includes mono-salts and compounds in which a plurality of salts is present, e.g. , di-salts and/or tri-salts. Pharmaceutically acceptable salts can be prepared by methods known to those in the art.
In certain embodiments, the neutral forms of the compounds are regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. In some embodiments, the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this disclosure. Such compounds are useful, for example, as analytical
tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.
The term "oxo," as used herein, means an oxygen that is double bonded to a carbon atom, thereby forming a carbonyl.
One of ordinary skill in the art will appreciate that the synthetic methods, as described herein, utilize a variety of protecting groups. By the term "protecting group," as used herein, it is meant that a particular functional moiety, e.g., O, S, or N, is masked or blocked, permitting, if desired, a reaction to be carried out selectively at another reactive site in a multifunctional compound. Suitable protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. In certain embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group is preferably selectively removable by readily available, preferably non-toxic reagents that do not attack the other functional groups; the protecting group forms a separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group will preferably have a minimum of additional functionality to avoid further sites of reaction. As detailed herein, oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized. Amino-protecting groups include methyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9- (2,7-dibromo)fluoroenylmethyl carbamate, 4-methoxyphenacyl carbamate (Phenoc), 2,2,2- trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 1 -methyl- 1 -(4- biphenylyl)ethyl carbamate (Bpoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N- dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), allyl carbamate (Alloc), 4-nitrocinnamyl carbamate (Noc), N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-nitobenzyl carbamate, p-chlorobenzyl carbamate, diphenylmethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, 2,4- dimethylthiophenyl carbamate (Bmpc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, phenyl(o- nitrophenyl)methyl carbamate, N'-p-toluenesulfonylaminocarbonyl derivative, N'- phenylaminothiocarbonyl derivative, t-amyl carbamate, p-cyanobenzyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, p-decyloxybenzyl carbamate, 2,2- dimethoxycarbonylvinyl carbamate, 2-furanylmethyl carbamate, isoborynl carbamate, isobutyl carbamate, 1 -methyl- 1-phenylethyl carbamate, 1 -methyl- l-(4-pyridyl)ethyl
carbamate, phenyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, N- benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitrophenoxyacetamide, acetoacetamide, 4-chlorobutanamide, 3 -methyl-3 -nitrobutanamide, o-nitrocinnamide, N- acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5- diphenyl-3-oxazolin-2-one, N-phthalimide, N-2,5-dimethylpyrrole, N-methylamine, N- allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N- benzylamine, N-triphenylmethylamine (Tr), N-2-picolylamino N'-oxide, N-1,1- dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N — (N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, N-p- nitrobenzylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N- cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-l-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o- nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,- trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6- trimethylbenzenesulfonamide (Mts), methanesulfonamide (Ms), b- trimethylsilylethanesulfonamide (SES), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide. Exemplary protecting groups are detailed herein, however, it will be appreciated that the present disclosure is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the method of the present disclosure. Additionally, a variety of protecting groups are described by Greene and Wuts ( Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999). In some embodiments, a compound described herein does not contain a protecting group. In some embodiments, a compound described herein does not contain a Boc protecting group.
The term "radiolabel", as used herein, refers to a moiety comprising a radioactive isotope of at least one element. Exemplary suitable radiolabels include but are not limited to those described herein. In some embodiments, a radiolabel is one used in positron emission
tomography (PET). In some embodiments, a radiolabel is one used in single-photon emission computed tomography (SPECT). In some embodiments, the radiolabel is radioiodine. In some embodiments, the radioiodine is selected from I123, I124, or I131.
The symbol
except when used as a bond to depict unknown or mixed stereochemistry, denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical Formula.
The term "good manufacturing practices (GMP) grade compound" refers to a compound produced according to practices that conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture of the compound for the intended use. As a non-limiting example, a good manufacturing practices (GMP) grade compound is suitable for use based on U.S. Food and Drug Administration guidelines.
Production of Sn-labeled Hsp90 inhibitors
Aspects of the present disclosure provide methods of producing Sn-labeled Hsp90 inhibitors. In some embodiments, the method comprises one or more steps depicted in FIGs. 2A-2C. In some embodiments, the method comprises all of the steps depicted in FIGs. 2A- 2C. As a non-limiting example, Step 1 shown in FIG. 2A allows for a one-step synthesis of a Sn-labeled Hsp90 inhibitor. Step 2 shown in FIG. 2B allows for purification of the synthesized Sn-labeled Hsp90 inhibitor. Purification of an Sn-labeled Hsp90 inhibitor may comprise silica gel chromatography and/or use of solvents for separation of target compound from impurities ( e.g ., dichloromethane and/or toluene). Purification of an Sn-labeled Hsp90 inhibitor may further comprise crystallization (e.g., with dichloromethane and methyl tert- butyl ether (MTBE)). Step 3 shown in FIG. 2B allows for further purification of a synthesized Sn-labeled Hsp90 inhibitor. For example, a synthesized Sn-labeled Hsp90 inhibitor purified via crystallization (e.g., with ethanol and/or heptane). As one of ordinary skill in the art would appreciate one or more purification steps shown in FIGs. 2A-2C may be omitted.
In certain embodiments the present disclosure provides a method of producing a compound of Formula I:
comprising reacting in a reaction mixture: a compound of Formula V:
(Formula V) with hexamethylditin (Sn2 MOe6) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in a solution, wherein each of R1, R2, R3, R4, L, X, Y1, Y2, Z1, Z2, and Z3 is as defined above and described in classes and subclasses herein.
Any substrates and/or products may be good manufacturing practices (GMP) grade compounds.
In some embodiments, X is — CH2 — . In some embodiments, X is — S — . In other embodiments, X is — O — .
In certain embodiments, Y1 is — CR3a — . In certain embodiments, Y1 is — N — .
In certain embodiments, Y2is — CR3a — . In certain embodiments, Y2is — N — .
In some embodiments, R3ais hydrogen.
In certain embodiments, Z1 is — CH — . In certain embodiments, Z1 is — N — . In certain embodiments, Z2 is — CH — . In certain embodiments, Z2 is — N — .
In certain embodiments, Z3 is — CH — . In certain embodiments, Z3 is — N — .
In some embodiments, R1 is hydrogen. In some embodiments, R1 is halogen. In some embodiments, R1 is fluro.
In some embodiments, -L-R2 comprises a methylene that is replaced with — NH — to form a secondary amine.
In some embodiments, L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L. In some embodiments, -L-R2 does not contain a Boc-protected secondary amine. In some embodiments, -L-R2 does not contain a secondary amine that is protected with an acid-labile protecting group. In some embodiments, -L-R2 does not contain a protected secondary amine.
In some embodiments, L is a straight or branched, optionally substituted C2- 14 aliphatic group wherein one, two, or three carbons are optionally and independently
replaced by -Cy-, —NR—, — N(R)C(O)— , — C(O)N(R)— , — C(O)N(O)— , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S— , —SO—, or — SO2— ,
In some embodiments, L is a straight or branched, C2-14 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C2-12 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C2-10 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments,
L is a straight or branched, C2-8 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C2-6 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C2- 4 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C6-14 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine. In some embodiments, L is a straight or branched, C6-12 aliphatic group wherein a methylene of the aliphatic group is replaced with — NH — to form a secondary amine.
In some embodiments, L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy- or — C(O) — . In some embodiments, L is a straight or branched, C2-8 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy- or — C(O) — . In certain embodiments, L is a straight or branched, C2-8 aliphatic group wherein one carbon of L is replaced by -Cy- and wherein -Cy- is a 6-membered saturated ring having one heteroatom selected from nitrogen.
In some embodiments, -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, -Cy- is an optionally substituted 3-8 membered bivalent, saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, -Cy- is an optionally substituted 5-6 membered bivalent, saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, -Cy- is bivalent piperidinyl.
In some embodiments, R2is hydrogen. In other embodiments, R2is optionally substituted C1-6 aliphatic. In some embodiments, R2is optionally substituted C 1-4 aliphatic. In some embodiments, R2is C1-4 alkyl.
In some embodiments, R2 is 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. In some embodiments, R2is 5- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur. In some embodiments, R2is piperidinyl. In some embodiments, R2is aziridinyl.
In some embodiments, R2 is 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R2 is cyclopropyl.
In some embodiments, -L-R2 forms a primary amino-alkyl group. In some embodiments, -L-R2 forms a secondary alkyl-amino-alkyl group. In some embodiments, -L-R2 is selected from the following:
In some embodiments, each R3 is independently halogen, — CN, — OR, — SR, — NCR)!, or optionally substituted C1-6 aliphatic. In some embodiments, each R3 is — OR. In some embodiments, one or both of Y1 and Y2 is =CR3a — , as valency permits and there are two occurrences of R3. In some embodiments, one or both of Y1 and Y2 is =CR3a — , as valency permits and there is one occurrence of R3. In some embodiments, both Y1 and Y2 are
=N — , as valency permits and there are two occurrences of R3. In some embodiments, both Y1 and Y2 are =N — , as valency permits and there is one occurrence of R3.
In some embodiments, there is at least one substituent on the ring bearing a trialkyltin group, and one of such substituents is located at the 5' position, wherein the ring numbering is as depicted below:
In some embodiments, there are two substituents on the ring bearing the trialkyltin group, located at the 4' and 5' positions. In some embodiments, these two substituents are taken together with their intervening atoms to form Ring A.
In certain embodiments wherein R3 is — OR, R is C1-6 aliphatic. In certain embodiments wherein R3 is — OR, R is methyl.
In some embodiments, two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl. In certain embodiments, Ring A is a 5-membered partially unsaturated monocyclic heterocyclyl having 2 heteroatoms selected from oxygen. In certain embodiments, Ring A is a 5-membered partially unsaturated monocyclic heterocyclyl having 1 heteroatom selected from oxygen. In certain embodiments, Ring A is a 6-membered partially unsaturated monocyclic heterocyclyl having 2 heteroatoms selected from oxygen. In some embodiments, Ring A is phenyl.
In some embodiments, two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl. In some embodiments, Ring A is an optionally substituted 5- to 6- membered partially unsaturated carbocyclyl.
In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is butyl.
In certain embodiments, a compound of the present disclosure is other than:
wherein each of Ring A, R1, R2, R4, L, Y1, Y2, Z1, Z2, Z3, and X is as defined above and described in classes and subclasses herein, both singly and in combination.
In some embodiments, a compound provided herein is of Formula I-a:
I-a
wherein each of R1, R2, L, and X is as defined above and described in classes and subclasses herein, both singly and in combination. In certain embodiments, a compound is a compound of Formula I-a and:
X is — CH2— or — S— ;
R1 is hydrogen or halogen; and
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L.
In some embodiments, a compound provided herein is a compound of Formula I-b, I- c, I-d, I-e, I-f, I-g, I-h, or I-j:
wherein each of R1, R2, R4, L, X, Y1, Y2, Z1, Z2, Z3, and R is as defined above and described in classes and subclasses herein, both singly and in combination.
In some embodiments, a compound provided herein is a compound of Formula I-i:
I-i
wherein each of R1, R2, R4, L, and X is as defined above and described in classes and subclasses herein, both singly and in combination. In certain embodiments, a compound of Formula I is selected from those depicted in
Table 1.
In some embodiments, the method comprises reacting a compound of Formula V:
(Formula V) with hexamethylditin (Sn2 Me6) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in a solution between about 60 °C to about 80 °C ( e.g between about 60°C to about 65°C, between about 65°C to about 70°C, between about 70°C to about 75°C, or
between about 75°C to about 80°C, between about 65°C to about 75°C, between about 60°C to about 70°C, or between about 70°C to about 80°C). In some embodiments, the temperature is about 65°C and about 75°C, or about 70°C.
In some embodiments, use of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as a catalyst reduces reaction stalling by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% as compared to a control. In some embodiments, use of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as a catalyst reduces reaction stalling by at most 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% as compared to a control. In some embodiments, use of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as a catalyst reduces reaction stalling by about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% as compared to a control. In some embodiments, use of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as a catalyst reduces reaction stalling about 1% to about 10%, about 1% to about 50%, about 50% to about 100%, about 10% to about 20%, about 20% to about 30%, 30% to about 40%, 40% to about 50%, 50% to about 60%, 70% to about 80%, 80% to about 90%, 90% to about 100% as compared to a control. In some embodiments, a control is performed using the same reaction but with a different catalyst, e.g., Pd(PPh3)4 in place of Pd2(dba)3. In some embodiments, reaction stalling is measured by the time it takes to produce a certain amount (mass) of product (i.e., the product yield), and the reduction in reaction stalling may be measured by comparison with the reaction time when another catalyst is used, including for example Pd(PPh3)4. In some embodiments, reaction stalling time is measured from when the substrates are initially combined. In some embodiments, the amount of substrate and the amount of product are measured for a reaction, and reaction stalling occurs when the conversion of the substrate to the product does not change for a particular amount of time (e.g., for about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10, minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 50 minutes, or an hour). In some embodiments, additional catalyst is added to the reaction following the stalling of a reaction.
In some embodiments, a reaction is stopped when the product (e.g., the Sn-labeled form of the Hsp90 inhibitor) represents greater than 70% of the combined amount of the product and substrate (e.g., the Sn-labeled form and the iodine-labeled form of the Hsp90
inhibitor) present in the reaction mixture ( e.g ., between 70% to 80%, between 80% to 90%, or between 90% to 100% (e.g., about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%).
In some embodiments, use of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as a catalyst improves the product yield. Improved product yield may be measured by the increased amount (mass) of product produced when Pd2(dba)3 is used as a catalyst compared to when another catalyst (e.g., Pd(PPh3)4) is used. The yield may be improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% when using tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as compared to a control that uses another catalyst. The yield may be improved by at most 1%, 5%, 10%, 15%,
20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% when using tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as compared to a control that uses another catalyst. The yield may be improved by 1% to 50%, 50 to 100%, 100% to 200%, 200% to 300%, 300% to 400%, 400% to 500%, 500% to 600%, 600% to 700%, 700% to 800%, 800% to 900%, 900% to 1000% when using tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) as compared to a control that uses another catalyst.
In some embodiments, the control uses Pd(PPh3)4 as the catalyst.
In some embodiments, the method further comprises purifying an Sn-labeled Hsp90 inhibitor by mixing the Sn-labeled Hsp90 inhibitor with dichloromethane (DCM) and stirring the mixture to form a substantially clear solution. A substantially clear solution may be determined by eye. In some embodiments, the method comprises adding water to the substantially clear solution, stirring the solution for at least 5 minutes (e.g., at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 10 minutes, at least 15 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes, at least 45 minutes, at least 50 minutes, or at least 60 minutes, but typically no longer than 90 minutes (e.g., about 5 to about 90 minutes, about 6 to about 90 minutes, about 7 to about 90 minutes, about 8 to about 90 minutes, about 9 to about 90 minutes, about 10 to about 90 minutes, about 15 to about 90 minutes, about 20 to about 90 minutes, about 25 to about 90 minutes, about 30 to about 90 minutes, about 35 to about 90 minutes, about 40 to about 90 minutes, about 45 to about 90 minutes, about 50 to about 90 minutes, about 55 to about 90 minutes, about 60 to about 90 minutes), and allowing or causing the solution to separate into
an organic layer and an aqueous layer. In some embodiments, the water is purified water. In some embodiments, the method comprises performing these steps one or more times. For example, a cycle comprising the steps of adding water to the solution, stirring the solution for at least 5 minutes, and allowing or causing the solution to separate into an organic layer and an aqueous layer, may be performed at least 1 time, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times, but typically no more than 12 times. In some embodiments, the water is purified water. In some embodiments, the solution is stirred for the same length of time in all of the cycles performed. In some embodiments, the solution is stirred for different lengths of time when the cycle is repeated.
In some embodiments, a method comprises filtering the organic layer, washing the reaction vessel with DCM, and concentrating the filtrate and the wash. In some embodiments, the concentrating occurs at no more than 50 °C (e.g., no more than 45 °C, 40 °C, 35 °C, 30 °C, 25 °C, 20 °C, 15 °C, or 10 °C) to distill the product. In some embodiments, the concentrating occurs at no less than 25 °C (e.g., no less than 45 °C, 40 °C, 35 °C, 30 °C, or 25 °C)) to distill the product. In some embodiments, the product is dried under vacuum at no more than 70 °C (e.g., no more than 65 °C, 60 °C, 55 °C, 50 °C, 45 °C, 40 °C, 35 °C, 30 °C, 25 °C, 20 °C, 15 °C, or 10 °C). In some embodiments, the product is dried under vacuum at no less than 10 °C (e.g., no less than 65 °C, 60 °C, 55 °C, 50 °C, 45 °C, 40 °C, 35 °C, 30 °C, 25 °C, 20 °C, or 15 °C).
In some embodiments, a method comprises adding ethanol (EtOH)-Heptane to the product, which may be useful to precipitate the product.
In some embodiments, the product comprises a compound of Formula I.
Production of Radiolabeled Hsp90 inhibitors
Further aspects of the disclosure provide methods of producing radiolabeled Hsp90 inhibitors. The methods of producing a radiolabeled Hsp90 inhibitor disclosed herein comprise producing a compound of Formula II:
(Formula II),
reacting, as substrates, a radioiodine and a compound of Formula I:
(Formula I), wherein:
W is radioiodine; X is — CH2— , — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is other than a -Boc protecting group; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, , aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl;
each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, —OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
In some embodiments, the compound of Formula I is provided as a free base. In some embodiments, the compound of Formula I is provided as a hydrogen iodide salt (HI).
In some embodiments, the compound of Formula I is reacted with a radioiodine sodium salt. In some embodiments, the radioiodine in Formula I is selected from I123, I124, or I131. In some embodiments, the radioiodine salt is selected from a I123, I124, or I131 salt. In some embodiments, a radioiodine or a pharmaceutically acceptable salt thereof is not I127 or a pharmaceutically acceptable salt thereof.
In some embodiments, the amount of radioiodine salt is at least 0.1 mCi ( e.g ., at least 0.5 mCi, at least 1 mCi, at least 1.5 mCi, at least 2 mCi, at least 2.5 mCi, at least 3 mCi, at least 3.5 mCi, at least 4 mCi, at least 4.5 mCi, at least 5 mCi, at least 6 m mCi, at least 7 mCi, at least 8 mCi, at least 9 mCi, at least 10 mCi, at least 11 mCi, at least 12 mCi, at least 13 mCi, at least 14 mCi, or at least 15 mCi). In some embodiments, the amount of radioiodine salt is at most 15 mCi (e.g., at most 0.5 mCi, at most 1 mCi, at most 1.5 mCi, at most 2 mCi, at most 2.5 mCi, at most 3 mCi, at most 3.5 mCi, at most 4 mCi, at most 4.5 mCi, at most 5 mCi, at most 6 m mCi, at most 7 mCi, at most 8 mCi, at most 9 mCi, at most 10 mCi, at most 11 mCi, at most 12 mCi, at most 13 mCi, at most 14 mCi, or at most 15 mCi). In some embodiments, the amount of radioiodine salt is between 1 mCi and 5 mCi, between 5 mCi and 10 mCi, or between 10 mCi and 15 mCi. In some embodiments, the amount of radioiodine salt is about 10 mCi, about 11 mCi, about 12 mCi, about 13 mCi, about 14 mCi, or about 15 mCi. In some embodiments, the amount of radioiodine salt is between 3 and 3.5 mCi (e.g., about 3 mCi, about 3.1 mCi, about 3.2 mCi, about 3.3 mCi, about 3.4 mCi, about 3.5 mCi).
Aspects of the present disclosure provide methods of producing a radiolabeled Hsp90 inhibitor comprising reacting substrates in the presence of peracetic acid. In some embodiments, the method of producing a compound of Formula II:
comprises reacting a compound of Formula
(Formula
I) with a radioiodine salt in the presence of peracetic acid, in a solution at a pH between 2-5 (e.g., at a pH between 2-3, between 3-4, between 4-5, or between 3-5). In some embodiments, the solution is at a pH of about 2, about 3, about 4, or about 5.
In some embodiments, the peracetic acid is about 3% to about 10% (e.g., 4-10%, 5- 10%, 6-10%, 7-10%, 8-10%, 9-10%, 3-4%, 3-5%, 3-6%, 3-7%, 3-8%, 3-9%, 4-5%, 4-6%, 4- 7%, 4-8%, 4-9%, 5-6%, 5-7%, 5-8%, 5-9%, 6-7%, 6-8%, 6-9%, 7-8%, 7-9%, or 8-9%) peracetic acid. In some embodiments, the peracetic acid is about 6%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, or 7% peracetic acid. In some embodiments, the peracetic acid is 6-6.5% peracetic acid. In some embodiments, the peracetic acid is about 6.4% peracetic acid.
In some embodiments, the solution comprises phosphoric acid (H3PO4) or sulfuric acid. In some embodiments, the solution comprises about 0.1- about 1 M (e.g., about 0.1 to about 0.2 M, about 0.1 to about 0.3 M, about 0.1 to about 0.4 M, about 0.1 to about 0.5 M, about 0.1 to about 0.6 M, about 0.1 to about 0.7 M, about 0.1 to about 0.8 M, about 0.1 to about 0.9 M, about 0.2 to about 0.3 M, about 0.2 to about 0.4 M, about 0.2 to about 0.5 M, about 0.2 to about 0.6 M, about 0.2 to about 0.7 M, about 0.2 to about 0.8 M, about 0.2 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3 to about 0.5 M, about 0.3 to about 0.6 M, about 0.3 to about 0.7 M, about 0.3 to about 0.8 M, about 0.3 to about 0.9 M, about or 0.3 to about 1 M, about 0.4 to about 0.5 M, about 0.4 to about 0.6 M, about 0.4 to about 0.7 M, about 0.4 to about 0.8 M, about 0.4 to about 0.9 M, about 0.4 to about 1 M, about 0.5 to about 0.6 M, about 0.5 to about 0.7 M, about 0.5 to about 0.8 M, about 0.5 to about 0.9 M, about 0.5 to about 1 M, about 0.6 to about 0.7 M, about 0.6 to about 0.8 M, about 0.6 to about 0.9 M, about 0.6 to about 1 M, about 0.7 to about 0.8 M, about 0.7 to about 0.9 M, about 0.7 to about 1 M, about 0.8 to about 0.9 M, about 0.8 to about 1 M, about or 0.9 to about 1 M) phosphoric acid (H3PO4). In some embodiments, the solution comprises 0.1-lM (e.g., 0.1-0.2 M, 0.1-0.3 M, 0.1-0.4 M, 0.1-0.5 M, 0.1-0.6 M, 0.1-0.7 M,
0.1-0.8 M, 0.1-0.9 M, 0.2-0.3 M, 0.2-0.4 M, 0.2-0.5 M, 0.2-0.6 M, 0.2-0.7 M, 0.2-0.8 M, 0.2- 0.9 M, 0.2-1 M, 0.3-0.4 M, 0.3-0.5 M, 0.3-0.6 M, 0.3-0.7 M, 0.3-0.8 M, 0.3-0.9 M, or 0.3-1 M, 0.4-0.5 M, 0.4-0.6 M, 0.4-0.7 M, 0.4-0.8 M, 0.4-0.9 M, 0.4-1 M, 0.5-0.6 M, 0.5-0.7 M, 0.5-0.8 M, 0.5-0.9 M, 0.5-1 M, 0.6-0.7 M, 0.6-0.8 M, 0.6-0.9 M, 0.6- 1 M, 0.7-0.8 M, 0.7-0.9 M, 0.7-1 M, 0.8-0.9 M, 0.8-1 M, or 0.9-1 M) phosphoric acid (H3PO4).
In some embodiments, the solution comprises 0.8 M H3PO4. In some embodiments, the solution comprises about 0.1 to about 1 M ( e.g ., (e.g., about 0.1 to about 0.2 M, about 0.1 to about 0.3 M, about 0.1 to about 0.4 M, about 0.1 to about 0.5 M, about 0.1 to about 0.6 M, about 0.1 to about 0.7 M, about 0.1 to about 0.8 M, about 0.1 to about 0.9 M, about 0.2 to about 0.3 M, about 0.2 to about 0.4 M, about 0.2 to about 0.5 M, about 0.2 to about 0.6 M, about 0.2 to about 0.7 M, about 0.2 to about 0.8 M, about 0.2 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3 to about 0.5 M, about 0.3 to about 0.6 M, about 0.3 to about 0.7 M, about 0.3 to about 0.8 M, about 0.3 to about 0.9 M, about or 0.3 to about 1 M, about 0.4 to about 0.5 M, about 0.4 to about 0.6 M, about 0.4 to about 0.7 M, about 0.4 to about 0.8 M, about 0.4 to about 0.9 M, about 0.4 to about 1 M, about 0.5 to about 0.6 M, about 0.5 to about 0.7 M, about 0.5 to about 0.8 M, about 0.5 to about 0.9 M, about 0.5 to about 1 M, about 0.6 to about 0.7 M, about 0.6 to about 0.8 M, about 0.6 to about 0.9 M, about 0.6 to about 1 M, about 0.7 to about 0.8 M, about 0.7 to about 0.9 M, about 0.7 to about 1 M, about 0.8 to about 0.9 M, about 0.8 to about 1 M, about or 0.9 to about 1 M)) sulfuric acid. In some embodiments, the solution comprises 0.8 M H3PO4. In some embodiments, the solution comprises 0.1-1 M (e.g., 0.1-0.2 M, 0.1-0.3 M, 0.1-0.4 M, 0.1-0.5 M, 0.1-0.6 M, 0.1-0.7 M, 0.1-0.8 M, 0.1-0.9 M, 0.2-0.3 M, 0.2-0.4 M, 0.2-0.5 M, 0.2-0.6 M, 0.2-0.7 M, 0.2-0.8 M, 0.2-0.9 M, 0.2-1 M, 0.3-0.4 M, 0.3-0.5 M, 0.3-0.6 M, 0.3-0.7 M, 0.3- 0.8 M, 0.3-0.9 M, or 0.3-1 M, 0.4-0.5 M, 0.4-0.6 M, 0.4-0.7 M, 0.4-0.8 M, 0.4-0.9 M, 0.4-1 M, 0.5-0.6 M, 0.5-0.7 M, 0.5-0.8 M, 0.5-0.9 M, 0.5-1 M, 0.6-0.7 M, 0.6-0.8 M, 0.6-0.9 M, 0.6- 1 M, 0.7-0.8 M, 0.7-0.9 M, 0.7-1 M, 0.8-0.9 M, 0.8-1 M, or 0.9-1 M) sulfuric acid.
In some embodiments, the solution comprises water.
In some embodiments, the reaction in the presence of peracetic acid occurs at a temperature between about 15 to about 30 °C (e.g., between about 15 to about 20 °C, between about 20 °C to about 30 °C, between about 20 °C to about 25 °C, between about 25 °C to about 30 °C, between about 21 °C to about 30 °C, between about 22 °C to about 30 °C, between about 23 °C to about 30 °C, between about 24 °C to about 30 °C, between about 26 °C to about 30 °C, between about 27 °C to about 30 °C, between about 28 °C to about 30 °C, or between about 29 °C to about 30 °C). In some embodiments, the reaction in the presence
of peracetic acid occurs at a temperature between 15°C and 30 °C (e.g., between 15°C and 20 °C, between 20°C and 30 °C, between 20°C and 25 °C, between 25°C and 30 °C, between 21°C and 30 °C, between 22°C and 30 °C, between 23°C and 30 °C, between 24°C and 30 °C, between 26°C and 30 °C, between 27°C and 30 °C, between 28°C and 30 °C, or between 29°C and 30 °C).
In some embodiments, about the reaction occurs for about 0.5 to about 1.5 minutes (e.g., about 0.6 to about 1.5 minutes, about 0.7 to about 1.5 minutes, about 0.8 to about 1.5 minutes, about 0.9 to about 1.5 minutes, about 1 to about 1.5 minutes, about 1.1 to about 1.5 minutes, about 1.2 to about 1.5 minutes, about 1.3 to about 1.5 minutes, about 1.4 to about
1.5 minutes, about 0.5 to about 1 minute, about 0.5 to about 1.5 minutes, about or 1 to about
1.5 minutes). In some embodiments, the reaction occurs for 0.5-1.5 minutes (e.g., 0.6-1.5 minutes, 0.7-1.5 minutes, 0.8-1.5 minutes, 0.9-1.5 minutes, 1-1.5 minutes, 1.1-1.5 minutes, 1.2-1.5 minutes, 1.3-1.5 minutes, 1.4-1.5 minutes, 0.5-1 minute, or 1-1.5 minutes).
In some embodiments, the method further adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO,) following the reaction (e.g., following about 0.5 to about 1.5 minutes (e.g., about 0.6 to about 1.5 minutes, about 0.7 to about 1.5 minutes, about 0.8 to about 1.5 minutes, about 0.9 to about 1.5 minutes, about 1 to about 1.5 minutes, about 1.1 to about 1.5 minutes, about 1.2 to about 1.5 minutes, about 1.3 to about 1.5 minutes, about 1.4 to about 1.5 minutes, about 0.5 to about 1 minute, about or 1 to about 1.5 minutes) of incubating the substrates). In some embodiments, the method further comprises adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO1,) following the reaction (e.g., following 0.5 to 1.5 minutes (e.g., 0.6 to
1.5 minutes, 0.7 to 1.5 minutes, 0.8 to 1.5 minutes, 0.9 to 1.5 minutes, 1 to 1.5 minutes, 1.1 to 1.5 minutes, 1.2 to 1.5 minutes, 1.3 to 1.5 minutes, 1.4 to 1.5 minutes, 0.5 to 1 minute, or 1 to 1.5 minutes) of incubating the substrates).
Any of the methods of producing a radiolabeled Hsp90 inhibitor disclosed herein may further comprise purifying the compound of Formula II from the reaction mixture. In some embodiments, the compound of Formula II is recovered at about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% yield. In some embodiments, the compound of Formula II is recovered at a particular percentage (e.g., least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% yield). In some embodiments, the percentage yield is determined by measuring the mass of a product
( e.g ., a radiolabeled Hsp90 inhibitor) relative to the mass of the starting materials (e.g., a tin- labeled Hsp90 inhibitor).
In some embodiments, the specific activity of the compound of Formula II is at least 10 mCi/mg (e.g., at least 15 mCi/mg, at least 20 mCi/mg, at least 25 mCi/mg, at least 30 mCi/mg, at least 35 mCi/mg, or at least 40 mCi/mg). In some embodiments, the specific activity of the compound of Formula II is at most 50 mCi/mg (e.g., at most 15 mCi/mg, at most 20 mCi/mg, at most 25 mCi/mg, at most 30 mCi/mg, at most 35 mCi/mg, or at most 40 mCi/mg).
(b) chloramine-T; and
(c) a radioiodine salt, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I in the reaction is about 3 to about 5, thereby forming a reaction mixture. For example, 25 μg of a compound of Formula I may be used with 15 pg chloramine-T.
In some embodiments, the reaction further comprises a phosphate buffer, optionally at a pH of about 7.
In some embodiments, the compound of Formula II is recovered at about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% yield. In some embodiments, the compound of Formula II is recovered at least 5%, at least 10%, at least
15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% yield. In some embodiments, the compound of Formula II is recovered at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, or at most 95% yield. In some embodiments, the percentage yield is determined by measuring the mass of a product ( e.g ., a radiolabeled Hsp90 inhibitor) relative to the mass of the starting materials (e.g., a tin- labeled Hsp90 inhibitor). In some embodiments, the yield of Formula II using a method described herein is increased by at least 5% (e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 80%, at least 90%, at least 95%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1,000%) as compared to a control. In some embodiments, a control is performed using the same reaction but with a different ratio of the mass of chloramine-T to the mass of Formula I in the reaction (e.g., a ratio that is not 3:5).
In some embodiments, the compound of Formula I is provided in ethanol.
In some embodiments, the compound of Formula I and chloramine-T are provided in a pre-mixed solution. In some embodiments, the pre-mixed solution further comprises acetic acid. In some embodiments, the compound of Formula I and chloramine-T are not provided in a pre-mixed solution.
In some embodiments, the method further comprises passing the reaction mixture through a column (e.g., a Sep-Pak) and eluting the product with less than 3 mL (e.g., less than 2.9 m., less than 2.8 ml, less than 2.7 ml, less than 2.6 ml, less than 2.7 ml, less than 2.6 ml, less than 2.5 ml, less than 2.4 ml, less than 2.3 ml, less than 2.2 ml, less than 2.1 ml, less than 2 ml, less than 1.5 ml, less than 1 ml, or less than 0.5 ml) of pure ethanol. In some embodiments, the product comprises a compound of Formula II.
In some embodiments, the radioiodine salt is provided in about 0.01 M NaOH. In some embodiments, the radioiodine salt is provided in about 0.005 to about 0.05 M NaOH.
Additional Methods
Additional examples of compounds of Hsp90 inhibitors that may be used for Sn- labeling and/or radiolabeling are provided in US published application US 2009/0298857 Al, International Application Publication No. WO 2018/200534 Al, and in US Patent No.
7834181, the entire disclosures of which as they relate to such Hsp90 inhibitors and classes thereof are incorporated by reference herein.
Reference can also be made to PCT Publication No. WO2011/044394 (Application No. PCT/US2010/051872) and US Patent No. 9,994,573 for additional compounds that can be used as Hsp90 inhibitors and that are contemplated as part of this disclosure. The teachings of such reference are incorporated by reference herein.
Any of the methods described herein may comprise purifying a compound of interest. In some embodiments, purifying a compound comprises distillation, chromatography, crystallization, filtration, or any combination thereof. Chromatography may comprise a normal phase, reverse phase, or ion-exchange elution over a cartridge comprising suitable sorbent media. In some embodiments, chromatography comprises high performance liquid chromatography (HPLC). A chromatography method may use one or more solvents, e.g., one or more known solvents or one or more solvents determined by routine experimentation. Non-limiting examples of solvents that are suitable for use with HPLC include acetonitrile (MeCN), ethanol (EtOH), methanol (MeOH), and trifluoroacetic acid (TFA). Any of the solvents may be prepared in a solution, e.g., TFA in deionized, Milli-Q or HPLC grade water. In some embodiments, HPLC comprises two mobile phases (see, e.g., Example 1 below).
Any of the methods described herein may result in a product purity of at least 1%, at least 15%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%. Product purity may be measured using known methods including HPLC. Product purity may be measured as the mass of the compound of interest relative to the entire mass of the product produced. See, e.g., the methods described in Example 1 below.
Kits
Also encompassed by the disclosure are kits (e.g., pharmaceutical packs). The kits provided may comprise a pharmaceutical composition (i.e., pharmaceutical formulation) or compound described herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container). In some embodiments, provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of a pharmaceutical composition or compound described herein. In
some embodiments, the pharmaceutical composition or compound described herein provided in the first container and the second container are combined to form one unit dosage form.
In certain embodiments, the kits are useful for producing a Sn-labeled Hsp90 inhibitor and/or a radiolabeled Hsp90 inhibitor. In some embodiments, a kit further comprises instructions for producing a Sn-labeled Hsp90 inhibitor and/or radiolabeled Hsp90 inhibitor using a method described herein. In some embodiments, a kit further comprises instructions for use of a compound disclosed herein (e.g., a radiolabeled Hsp90 inhibitor disclosed herein).
In some embodiments, a kit comprises a compound of Formula V:
(Formula V) and hexamethylditin (Sn2 Me6) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3).
In some embodiments, a kit comprises a compound of Formula I as defined herein, phosphoric acid (H3PO4), and peracetic acid. In some embodiments, the kit further comprises a radioiodine salt. In some embodiments, the kit does not comprise a radioiodine salt. In some embodiments, the radioiodine salt is sodium radioiodine. In some embodiments, the kit comprises about 0.1 to about 1 M ( e.g ., (e.g., about 0.1 to about 0.2 M, about 0.1 to about 0.3 M, about 0.1 to about 0.4 M, about 0.1 to about 0.5 M, about 0.1 to about 0.6 M, about 0.1 to about 0.7 M, about 0.1 to about 0.8 M, about 0.1 to about 0.9 M, about 0.2 to about 0.3 M, about 0.2 to about 0.4 M, about 0.2 to about 0.5 M, about 0.2 to about 0.6 M, about 0.2 to about 0.7 M, about 0.2 to about 0.8 M, about 0.2 to about 0.9 M, about 0.2 to about 1 M, about 0.3 to about 0.4 M, about 0.3 to about 0.5 M, about 0.3 to about 0.6 M, about 0.3 to about 0.7 M, about 0.3 to about 0.8 M, about 0.3 to about 0.9 M, about or 0.3 to about 1 M, about 0.4 to about 0.5 M, about 0.4 to about 0.6 M, about 0.4 to about 0.7 M, about 0.4 to about 0.8 M, about 0.4 to about 0.9 M, about 0.4 to about 1 M, about 0.5 to about 0.6 M, about 0.5 to about 0.7 M, about 0.5 to about 0.8 M, about 0.5 to about 0.9 M, about 0.5 to about 1 M, about 0.6 to about 0.7 M, about 0.6 to about 0.8 M, about 0.6 to about 0.9 M, about 0.6 to about 1 M, about 0.7 to about 0.8 M, about 0.7 to about 0.9 M, about 0.7 to about 1 M, about 0.8 to about 0.9 M, about 0.8 to about 1 M, about or 0.9 to about 1 M))
sulfuric acid. In some embodiments, the solution comprises 0.8 M H3PO4. In some embodiments, the solution comprises 0.1-1 M ( e.g ., 0.1-0.2 M, 0.1-0.3 M, 0.1-0.4 M, 0.1-0.5 M, 0.1-0.6 M, 0.1-0.7 M, 0.1-0.8 M, 0.1-0.9 M, 0.2-0.3 M, 0.2-0.4 M, 0.2-0.5 M, 0.2-0.6 M, 0.2-0.7 M, 0.2-0.8 M, 0.2-0.9 M, 0.2-1 M, 0.3-0.4 M, 0.3-0.5 M, 0.3-0.6 M, 0.3-0.7 M, 0.3- 0.8 M, 0.3-0.9 M, or 0.3-1 M, 0.4-0.5 M, 0.4-0.6 M, 0.4-0.7 M, 0.4-0.8 M, 0.4-0.9 M, 0.4-1 M, 0.5-0.6 M, 0.5-0.7 M, 0.5-0.8 M, 0.5-0.9 M, 0.5-1 M, 0.6-0.7 M, 0.6-0.8 M, 0.6-0.9 M, 0.6- 1 M, 0.7-0.8 M, 0.7-0.9 M, 0.7-1 M, 0.8-0.9 M, 0.8-1 M, or 0.9-1 M) sulfuric acid. In some embodiments, the kit comprises 0.8 M phosphoric acid (H3PO4). In some embodiments, the kit further comprises sodium metabisulfite. In some embodiments, the sodium metabisulfite is in saturated sodium bicarbonate (NaHCO3).
In some embodiments, the peracetic acid is about 3% to about 10% (e.g., 4-10%, 5- 10%, 6-10%, 7-10%, 8-10%, 9-10%, 3-4%, 3-5%, 3-6%, 3-7%, 3-8%, 3-9%, 4-5%, 4-6%, 4- 7%, 4-8%, 4-9%, 5-6%, 5-7%, 5-8%, 5-9%, 6-7%, 6-8%, 6-9%, 7-8%, 7-9%, or 8-9%) peracetic acid. In some embodiments, the peracetic acid is about 6%, about 6.1%, about 6.2%, about 6.3%, about 6.4%, about 6.5%, about 6.6%, about 6.7%, about 6.8%, about 6.9%, or about 7% peracetic acid. In some embodiments, the peracetic acid is 6-6.5% peracetic acid. In some embodiments, the peracetic acid is about 6.4% peracetic acid.
In some embodiments, the kit further comprises a syringe, Sep-Pak, and/or ethanol.
In some embodiments, the radioiodine salt is a salt of I123, I124, or I131.
In some embodiments, a kit comprises a compound of Formula I as defined herein and chloramine-T, in which the ratio of the mass of chloramine-T to the mass of Formula I in the reaction is about 3 to about 5. In some embodiments, the kit further comprises phosphate buffer at about pH 7. The compound of Formula I and chloramine-T may be provided in the same container or in separate containers. In some embodiments, the compound of Formula I and chloramine-T are provided in the same container that also comprises acetic acid. In some embodiments, the compound of Formula I is provided in ethanol in a container that is different from the container comprising chloramine-T. In some embodiments, the kit further comprises: i) ethanol; ii) water; iii) a reaction container; iv) a waste container; v) a product container; vi) a Sep-Pak; vii) one or more syringes; and/or viii) one or more stopcocks. In some embodiments, the kit further comprises a radioiodine salt. In some embodiments, the radioiodine salt is sodium radioiodine. In some embodiments, the radioiodine salt is a salt of I123, I124, or I131.
Thus, in one aspect, provided are kits including a first container comprising a compound or pharmaceutical composition described herein. In certain embodiments, the kits are useful for treating a disease ( e.g ., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof. In certain embodiments, the kits are useful for preventing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof. In certain embodiments, the kits are useful for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a Hsp90 protein in a subject or cell.
In certain embodiments, a kit described herein further includes instructions for using the kit. A kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information included in the kits is prescribing information. In certain embodiments, the kits and instructions provide for treating a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof. In certain embodiments, the kits and instructions provide for preventing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof. In certain embodiments, the kits and instructions provide for reducing the risk of developing a disease (e.g., cancer, neurodegenerative disorder, inflammation or inflammatory condition, autoimmune disease) in a subject in need thereof. In certain embodiments, the kits and instructions provide for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a Hsp90 protein in a subject or cell. In some instances, the kits and instructions provide for assessment of epichaperome levels and/or to identify subjects that may be sensitive (and thus responsive) to treatment with an epichaperone inhibitor. For example, the kits and instructions may provide for determination of epichaperome levels and identification patients that would respond to treatment with epichaperome inhibitors (e.g., Hsp90 inhibitors) and can be used to follow and evaluate treatment effects by PET scans to assess the epichaperome level, or size of a tumor, or extent of neurodegenerative diseases. A kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
Subjects and Indications
The subjects to be administered a radiolabeled Hsp90 produced by a method provided herein include mammals such as humans and animals such as non-human primates, agricultural animals (e.g., cow, pig, sheep, goat, horse, rabbit, etc.), companion animals (e.g., dog, cat, etc.), and rodents (e.g., rat, mouse, etc.). Preferred subjects are human subjects. Subjects may be referred to herein as patients in some instances.
In some embodiments, the active compounds and formulations provided herein are intended for use in subjects in need of Hsp90 inhibition. Such subjects may have or may be at risk of developing a condition characterized by the presence of epichaperomes or the elevated (compared to normal cells) presence of Hsp90 or which may benefit from inhibition of Hsp90 activity. Such conditions may be characterized by the presence of misfolded proteins. Such conditions include without limitation cancer, neurodegenerative disorder, inflammation (or inflammatory conditions) such as but not limited to cardiovascular diseases (e.g., atherosclerosis), autoimmune diseases, and the like.
The compounds and formulations provided herein may be administered via any standard route of administration including but not limited to intraveous administration.
As a non-limiting example, a radiolabeled Hsp90 inhibitor may be used to treat cancer. In some instances, the radiolabeled Hsp90 inhibitor is administered locally to treat glioblastoma. In some instances, the radiolabeled Hsp90 inhibitor is 131I.
A therapeutically effective amount of one or more active compounds disclosed herein may be provided in a formulation. The term "therapeutically effective amount" refers to an amount of an active compound or a combination of two or more compounds that inhibits, totally or partially, the progression of the condition being treated or alleviates, at least partially, one or more symptoms of the condition. For example, the compounds may be an Hsp90 inhibitor and a second therapeutic agent, and in some embodiments the therapeutically effective amount is the amount of these two classes of agents when used together (including for example the amount of each class of agent). A therapeutically effective amount can also be an amount which is prophylactically effective when given, for example, to a subject at risk of developing the condition or a subject who has been successfully treated but may be at risk of a recurrence. The amount which is therapeutically effective depends on the patient's gender and size, the condition to be treated, the condition's severity, and the result sought.
For a given patient, a therapeutically effective amount can be determined by methods known to those in the art.
Dosage strength, as used herein, refers to the amount of active compound in a single dose formulation (e.g., a single capsule, intravenous dose, or a single tablet, etc.). Dosages may range from about 0.001 to about 1000 mg, including about 0.01 mg to about 1000 mg, including 0.01 mg to about 1000 mg, including about 1 mg to about 1000 mg of Hsp90 inhibitor. Exemplary dosage strengths include at least 0.001, at least 0.005, at least 0.01, at least 0.05, at least 0.1, at least 0.5, at least 1 mg, at least 2 mg, at least 3 mg, at least 4 mg, at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 175 mg, at least 200 mg, at least 300 mg, at least 400 mg, at least 500 mg or more of Hsp90 inhibitor. Exemplary dosage strengths include 0.001 mg, 0.005 mg, 0.01 mg, 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 300 mg, 400 mg, 500 mg, or more, of Hsp90 inhibitor, including all doses therebetween as is explicitly recited herein. In some instances, when a large dose is required, several of a smaller dosage form may be administered or a single larger dosage form may be administered.
The formulations may be administered daily, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every week, every 2 weeks, every 3 weeks, every 4 weeks, every month, every 2 months, every 3 months, every 4 months, every 6 months, or every year.
The formulations provided herein may be administered for a period of time (referred to as a treatment period) followed by a period of time in which the formulations are not administered to the subjects (referred to herein as a non-treatment period). The treatment period may be 1, 2, 3, 4, 5, 6 or 7 days and the non-treatment period may be 1, 2, 3, 4, 5, 6, or 7 or more days. Alternatively, the treatment period may be 1, 2, 3 or 4 weeks and the nontreatment period may be 1, 2, 3, 4 or more weeks. The non-treatment period may be as long as or 2, 3, 4, 5, 6, 7, 8, 9 or 10 times as long as the treatment period. The treatment and nontreatment periods may be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more times. In some embodiments, the treatment period is 1 week and the non-treatment period is 3 weeks, and these are repeated 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more times.
The formulations provided herein may be administered once a day, twice a day, or thrice a day. The formulations provided herein may be administered every 3 hours, every 4 hours, every 6 hours, every 12 hours, or every 24 hours.
Cancer
The term "cancer" or "neoplastic disorder" refers to a tumor resulting from abnormal or uncontrolled cellular growth. Examples of cancers include but are not limited to breast cancers (e.g., ER+/HER2- breast cancer, ER+/HER2+ breast cancer, ER-/HER2+ breast cancer, triple negative breast cancer, etc.) , colon cancers, colorectal cancers, prostate cancers, ovarian cancers, pancreatic cancers, lung cancers, gastric cancers, esophageal cancers, glioma cancers, and hematologic malignancies. In some instances, the cancer is glioblastoma. Examples of neoplastic disorders include but are not limited to hematopoietic disorders, such as the myeloproliferative disorders, essential thrombocytosis, thrombocythemia, angiogenic myeloid metaplasia, polycythemia vera, myelofibrosis, myelofibrosis with myeloid metaplasia, chronic idiopathic myelofibrosis, the cytopenias, and pre-malignant myelodysplastic syndromes. In some instances, the indication to be treated is pancreatic cancer, breast cancer, prostate cancer, skin cancer (e.g., melanoma, basal cell carcinoma), B cell lymphoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. In some instances, the indication to be treated is pancreatic cancer. In some instances, the indication to be treated is breast cancer. The cancer to be treated may be a primary cancer (without indication of metastasis) or a metastatic stage cancer.
The term "hematologic malignancy" refers to cancer of the bone marrow and lymphatic tissue -body's blood-forming and immune system. Examples of hematological malignancies include but are not limited to myelodysplasia, lymphomas, leukemias, lymphomas (non-Hodgkin's lymphoma), Hodgkin's disease (also known as Hodgkin's lymphoma), and myeloma, such as acute lymphocytic leukemia (ALL), adult T-cell ALL, acute myeloid leukemia (AML), AML with trilineage myelodysplasia, acute promyelocytic leukemia, acute undifferentiated leukemia, anaplastic large-cell lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic neutrophilic leukemia, juvenile myelomonocyctic leukemia, mixed lineage leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, and prolymphocytic leukemia.
Neurodegenerative disorder
The term "neurodegenerative disorder" refers to a disorder in which progressive loss of neurons occurs either in the peripheral nervous system or in the central nervous system. Examples of neurodegenerative disorders include but are not limited to chronic neurodegenerative diseases such as diabetic peripheral neuropathy, Alzheimer's disease,
Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis ("ALS"), degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, multiple sclerosis, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado- Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Wemicke- Korsakoff s related dementia (alcohol induced dementia), Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohifart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, and prion diseases (including Creutzfeldt- Jakob, Gerstmann- Straussler-Scheinker disease, Kuru and fatal familial insomnia).
Other conditions also included within the methods of the present disclosure include age-related dementia and other dementias, tauopathies, and conditions with memory loss including vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma, chronic traumatic encephalopathy, and diffuse brain damage, dementia pugilistica, and frontal lobe dementia. Also other neurodegenerative disorders resulting from cerebral ischemia or infarction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type (including but not limited to epidural, subdural, subarachnoid, and intracerebral), and intracranial and intravertebral lesions (including but not limited to contusion, penetration, shear, compression, and laceration).
Thus, the term "neurodegenerative disorder" also encompasses acute neurodegenerative disorders such as those involving stroke, traumatic brain injury, chronic traumatic encephalopathy, schizophrenia, peripheral nerve damage, hypoglycemia, spinal cord injury, epilepsy, anoxia, and hypoxia.
In certain embodiments, the neurodegenerative disorder is selected from Alzheimer's disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis, complete
androgen insensitivity syndrome (CAIS), spinal and bulbar muscular atrophy (SBMA or Kennedy's disease), sporadic frontotemporal dementia with parkinsonism (FTDP), familial FTDP-17 syndromes, age-related memory loss, senility, and age-related dementia. In another embodiment, the neurodegenerative disorder is Alzheimer's disease, also characterized as an amyloidosis. Thus, other embodiments of the disclosure relate to the treatment or prevention of other amyloidosis disorders which share features, including, but not limited to, hereditary cerebral angiopathy, normeuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle- Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, Finnish amyloidosis, and Iowa amyloidosis.
Inflammation (or Inflammatory conditions)
The Hsp90 inhibitors of this disclosure may be used in the treatment of inflammation (or inflammatory conditions). Examples of inflammatory conditions include cardiovascular diseases and autoimmune diseases.
Non-autoimmune inflammatory disorders are inflammatory disorders that are not autoimmune disorders. Examples include atherosclerosis, myocarditis, myocardial infarction, ischemic stroke, abscess, asthma, some inflammatory bowel diseases, chronic obstructive pulmonary disease (COPD), allergic rhinitis, non-autoimmune vasculitis (e.g. polyarteritis nodosa), age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, atopic dermatitis, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, congestive heart failure, comeal ulceration, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, hemorrhage, viral (e.g., influenza) infections, chronic viral (e.g., Epstein-Barr, cytomegalovirus, herpes simplex virus) infection, hyperoxic alveolar injury, infectious arthritis, intermittent hydrarthrosis, Lyme disease, meningitis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, stroke, non-autoimmune ulcerative colitis, bursitis, uveitis, osteoporosis,
Alzheimer's disease, ataxia telangiectasia, non-autoimmune vasculitis, non-autoimmune arthritis, bone diseases associated with increased bone resorption, ileitis, Barrett's syndrome,
inflammatory lung disorders, adult respiratory distress syndrome, and chronic obstructive airway disease, inflammatory disorders of the eye including corneal dystrophy, trachoma, onchocerciasis, sympathetic ophthalmitis and endophthalmitis, chronic inflammatory disorders of the gums such as gingivitis, tuberculosis, leprosy, inflammatory diseases of the kidney including uremic complications, glomerulonephritis and nephrosis, inflammatory disorders of the skin including sclerodermatitis and eczema, inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and viral or autoimmune encephalitis, immune-complex vasculitis, erythematodes, and inflammatory diseases of the heart such as cardiomyopathy, ischemic heart disease, hypercholesterolemia, as well as various other diseases with significant inflammatory components, including preeclampsia, chronic liver failure, septic shock, haemodynamic shock, sepsis syndrome, malaria, diseases involving angiogenesis, skin inflammatory diseases, radiation damage, hyperoxic alveolar injury, periodontal disease, non-insulin dependent diabetes mellitus, and brain and spinal cord trauma.
Cardiovascular diseases
The Hsp90 inhibitors of this disclosure may be used in the treatment of cardiovascular diseases. Examples of cardiovascular diseases (or conditions) include atherosclerosis, elevated blood pressure, heart failure or a cardiovascular event such as acute coronary syndrome, myocardial infarction, myocardial ischemia, chronic stable angina pectoris, unstable angina pectoris, angioplasty, stroke, transient ischemic attack, claudication(s), or vascular occlusion(s).
Autoimmune diseases
The Hsp90 inhibitors of this disclosure may be used in the treatment of autoimmune diseases. Examples of autoimmune diseases include but are not limited to multiple sclerosis, inflammatory bowel disease including Crohn's Disease and ulcerative colitis, rheumatoid arthritis, psoriasis, type I diabetes, uveitis, Celiac disease, pernicious anemia, Srojen's syndrome, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythamatosis, acute disseminated encephalomyelitis, Addison's disease, Ankylosing spondylitis, antiphospholipid antibody syndrome, Guillain-Barre syndrome, idiopathic thrombocytopenic purpura, Goodpasture's syndrome, Myasthenia gravis, Pemphigus, giant cell arteritis, aplastic anemia,
autoimmune hepatitis, Kawaski's disease, mixed connective tissue disease, Ord throiditis, polyarthritis, primary biliary sclerosis, Reiter's syndrome, Takaysu's arteritis, vitiligo, warm autoimmune hemolytic anemia, Wegener's granulomatosis, Chagas' disease, chronic obstructive pulmonary disease, and sarcoidosis.
Secondary therapeutic agents
The Hsp90 inhibitors of this disclosure may be used in combination with one or more other therapeutic agents, referred to herein as secondary therapeutic agents. The Hsp90 inhibitors and secondary therapeutic agents may have an additive effect or a synergistic (i.e., greater than additive) effect on the targeted indication.
Examples of secondary therapeutic agents include angiogenesis inhibitors, pro- apoptotic agents, cell cycle arrest agents, kinase inhibitors, AKT inhibitors, BTK inhibitors, Bcl2 inhibitors, SYK inhibitors, CD40 inhibitors, CD28 pathway inhibitors, MHC class II inhibitors, PI3K inhibitors, mTOR inhibitors, JAK inhibitors, IKK inhibitors, Raf inhibitors, SRC inhibitors, phosphodiesterase inhibitors, ERK-MAPK pathway inhibitors, and the like.
Examples of AKT inhibitors include PF-04691502, Triciribine phosphate (NSC- 280594), A-674563, CCT128930, AT7867, PHT-427, GSK690693, MK-2206 dihydrochloride.
Examples of BTK inhibitors include PCI-32765.
Examples of Bcl2 inhibitors include ABT-737, Obatoclax (GX15-070), ABT-263.
TW-37 Examples of SYK inhibitors include R-406, R406, R935788 (Fostamatinib disodium).
Examples of CD40 inhibitors include SGN-40 (anti-huCD40 mAb).
Examples of inhibitors of the CD28 pathway include abatacept, belatacept, blinatumomab, muromonab-CD3, visilizumab.
Examples of inhibitors of major histocompatibility complex, class II include apolizumab.
Examples of PI3K inhibitors include 2-(lH-indazol-4-yl)-6-(4- methanesulfonylpiperazin-l-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine, BKM120, NVP-BEZ235, PX-866, SF 1126, XL147.
Example of mTOR inhibitors include deforolimus, everolimus, NVP-BEZ235, OST 027, tacrolimus, temsirolimus, Ku-0063794, WYE-354, PP242, OSI-027, GSK2126458, WAY-600, WYE- 125132.
Examples of JAK inhibitors include Tofacitinib citrate (CP-690550), AT9283, AG- 490, INCBO 18424 (Ruxolitinib), AZD1480, LY2784544, NVP-BSK805, TGI 01209, TG- 101348.
Examples of IkK inhibitors include SC-514, PF 184.
Examples of inhibitors of Raf include sorafenib, vemurafenib, GDC-0879, PLX-4720, PLX4032 (Vemura/enib), NVP-BHG712, SB590885, AZ628, ZM 336372.
Examples of inhibitors of SRC include AZM-475271, dasatinib, saracatinib.
Examples of inhibitors of phosphodiesterases include aminophylline, anagrelide, arofylline, caffeine, cilomilast, dipyridamole, dyphylline, L 869298, L-826,141, milrinone, nitroglycerin, pentoxifylline, roflumilast, rolipram, tetomilast, theophylline, tolbutamide, amrinone, anagrelide, arofylline, caffeine, cilomilast, L 869298, L-826,141, milrinone, pentoxifylline, roflumilast, rolipram, tetomilast.
Other secondary therapeutic agents that can be used in combination with the Hsp90 inhibitors of this disclosure include AQ4N, becatecarin, BN 80927, CPI-0004Na, daunombicin, dexrazoxane, doxorubicin, elsamitrucin, epirubicin, etoposide, gatifloxacin, gemifloxacin, mitoxantrone, nalidixic acid, nemorubicin, norfloxacin, novobiocin, pixantrone, tafluposide, TAS-103, tirapazamine, valrubicin, XK469, BI2536.
Still other secondary therapeutic agents are nucleoside analogs. Examples include (1) deoxyadenosine analogues such as didanosine (ddl) and vidarabine; (2) adenosine analogues such as BCX4430; (3) deoxycytidine analogues such as cytarabine, gemcitabine, emtricitabine (FTC), lamivudine (3TC), and zalcitabine (ddC); (4) guanosine and deoxyguanosine analogues such as abacavir, acyclovir, and entecavir; (5) thymidine and deoxythymidine analogues such as stavudine (d4T), telbivudine, zidovudine (azidothymidine, or AZT); and (6) deoxyuridine analogues such as idoxuridine and trifluridine.
Other secondary therapeutic agents include taxanes such as paclitaxel, dicetaxel, cabazitaxel. Other secondary therapeutic agents include inhibitors of other heatshock proteins such as of Hsp70, Hsp60, and Hsp26.
Still other secondary therapeutic agents that can be used in combination with the Hsp90 inhibitors of this disclosure are disclosed in published PCT Application No. WO2012/149493, the entire disclosure of which as it relates to such secondary therapeutic agents and classes thereof is incorporated by reference herein.
The Hsp90 inhibitors and the secondary therapeutic agents may be co-administered. Co-administered includes administering substantially simultaneously, concomitantly, sequentially or adjunctively. The Hsp90 inhibitors and the secondary therapeutic agents may
be administered at different times. For example, the Hsp90 inhibitors may be administered before or after the secondary therapeutic agent including one or more hours before, one or more day before, or one or more week before the secondary therapeutic agents. One or more secondary therapeutic agents may be used. Each of the therapeutic agents may be administered at their predetermined optimal frequency and dose. In some instances, the Hsp90 inhibitors and the secondary therapeutic agents are administered in combination in a therapeutically effective amount.
EXAMPLES
Example 1.
This Example describes production of Compound 2, a non-limiting example of an Sn- labeled Hsp90 inhibitor, using Pd2(dba)3 as a catalyst. A schematic of the synthesis is shown in FIG. 1. Compound 2 was prepared in three steps from Compound 7 including one synthetic step and two purification steps. Compound 7 was coupled with hexamethylditin via a Stille reaction using Pd2(dba)3 as a catalyst to afford Compound 2, which was then purified via silica gel chromatography. Compound 2 was further purified with dichloromethane and toluene via silica gel chromatography followed by crystallization with dichloromethane and MTBE. The purified Compound 2 was then purified via crystallization with ethanol and heptane to afford Compound 2. The product was then assessed using HPLC.
Materials and Methods
Step 1. Synthesis of 9-[2-(2,2-Dimethyl-propylamino)-ethyl]-8-(6- trimethylstannanyl- benzo[l,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine ( Compound 2).
A schematic of Step 1 is shown in FIG. 2A. A 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen. Compound 7 (121 g), Pd2(dba)3 (20.9 g), and toluene (2.4 L) were charged sequentially to the reactor. The reaction mixture was stirred for about 7 minutes until a suspension was formed. Nitrogen gas was bubbled through the reaction mixture for about 23 minutes. Hexamethylditin (302 g) was then charged to the reactor. The reaction mixture was heated to about 66 °C and stirred for about 41.5 hours at about 78 °C when a PCT by HPLC failed. Additional Pd2(dba)3 (20.9 g) was charged to the reactor and the reaction mixture was stirred at about 76 °C for an additional 19 hours until a PCT by HPLC passed. The reaction mixture was then cooled to about 44 °C and filtered through
celite (596 g). The filter cake was washed with toluene (0.6 L) and the filtrate was collected. The filtrate was then transferred to the rotavapor and distilled under vacuum at 60 °C until distillation stopped, and the residue was weighed (382 g). A clean, dry column with nitrogen inlet was then assembled. Dichloromethane (6.0 L) and silica gel (1922 g) were charged onto the column and thoroughly mixed. The column was eluted to the upper surface of the silica gel and the eluent was collected in a clean container. Sea sand (996 g) was loaded onto the top of the column. The crude Compound 2 (382 g) and dichloromethane (0.6 L) were mixed thoroughly in a clean container until a solution was formed. The solution was carefully loaded onto the column, the container rinsed with dichloromethane (0.3 L) and the rinse charged to the column. The column was eluted with the collected eluent (1.8 L) and additional dichloromethane (3.6 L). The column was then eluted with 300:10:0.05 (v/v/v) DCM : MeOH : Et3N, prepared separately from dichloromethane (18 L), methanol (0.60 L), and triethylamine (0.030 L). The fractions were checked by TLC. The desired fractions were collected, transferred to the rotavapor, and distilled under vacuum at 44 °C until distillation stopped to afford Compound 2 (86 g).
A summary of the Compound 2 produced in step 1 is presented in Table 2 below. Table 2. Synthesis of Compound 2
Step 2. Purification of 9-[2-(2,2-Dimethyl-propylamino)-ethyl]-8-(6- trimethylstannanyl- benzo[ 1,3 ]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine ( Purified Compound 2).
A schematic of Step 2 is shown in FIG. 2B. A 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen. Sn-PU- AD (83 g), dichloromethane (0.12 L), and toluene (1.2 L) were charged to the reactor. The reaction mixture was heated to about 91 °C and the distillate was collected (105 mL). The reaction mixture was then stirred at about 107 °C for about 5 hours. The batch was cooled to about 45 °C, transferred to the rotavapor, and distilled under vacuum at 56 °C until distillation stopped, and the residue was weighed (86 g). A clean, dry column with nitrogen inlet was then assembled. Dichloromethane (7.0 L) and
silica gel (1744 g) were charged onto the column and thoroughly mixed. The column was eluted to the upper surface of the silica gel. Sea sand (999 g) was loaded onto the top of the column. Eluting solvent, 300:10:0.5 (v/v/v) DCM: MeOH: Et3N, was prepared separately from dichloromethane (17 L), methanol (0.55 L), and triethylamine (0.028 L). The crude Compound 2 (86 g) and eluting solvent (0.5 L) were mixed thoroughly in a clean container until a solution was formed. The solution was carefully loaded onto the column, the container rinsed with eluting solvent (0.3 L) and the rinse charged to the column. The column was then eluted with the remainder of the eluting solvent (16.5 L), the fractions checked by TLC. The desired fractions were collected, transferred to the rotavapor, and distilled under vacuum at 38 °C until distillation stopped, and the residue was weighed (70 g). A 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen. The distillation residue (70 g) and dichloromethane (0.25 L) were charged to the reactor, using dichloromethane to assist the transfer. The batch was heated to about 36°C and stirred for about 30 minutes at about 37 °C. The batch was filtered, the filter cake washed with dichloromethane (0.12 L) and the filtrate collected. The batch was then transferred to the rotavapor and distilled under vacuum at 34 °C until distillation stopped, and the residue was weighed (69 g). A 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen. Dichloromethane (0.8 L) was filtered through an in-line filter into a clean container. The distillation residue (69 g) and a portion of the filtered dichloromethane (0.08 L) were charged to the reactor, using dichloromethane to assist the transfer. The batch was then heated to about 39 °C. MTBE (0.83 L) was filtered through an in-line filter into a clean container. A portion of the filtered MTBE (0.21 L) was then charged to the reactor while maintaining a temperature of about 39 °C. The batch was stirred at about 38 °C for about 1 hour. The batch was cooled to about 6 °C and stirred for about 1 hour at about 6 °C. The batch was then filtered, the filter cake washed with polish filtered MTBE (0.12 L) and the filtrate collected. The filter cake was dried on a filter by pulling nitrogen for about 1 hour. The product was then transferred to drying trays and further dried under vacuum at about 40 °C for about 6.5 days to afford the purified Compound 2 (54.76 g).
A schematic of Step 3 is shown in FIG. 2C. A summary of the purified Compound 2 produced in step 2 is presented in Table 3 below.
Step 3. Purification of purified 9-[2-(2, 2-Dimethyl-propylamino)-ethyl]-8-(6- trimethylstannanyl-benzo[l,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine ( Compound 2).
A 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen. Ethanol (1.1 L) was filtered through an in-line filter into a clean container. Purified Compound 2 (53.23 g) and a portion of the filtered ethanol (0.85 L) were charged to the reactor. The batch was heated to about 61 °C and stirred at about 62 °C until a clear solution was obtained. Heptane (5.3 L) was then filtered through an in-line filter into a clean container. A portion of the filtered heptane (1.6 L) was charged to the reactor in small portions over about 1 hour at about 58 °C until a suspension was formed. The batch was then stirred at about 41 °C for about 1 hour. The batch was then transferred to the rotavapor and distilled under vacuum at 49 °C until the remaining volume was about 1.2 L. A portion of the filtered heptane (1.6 L) was charged to the rotavapor flask in small portions over about 18 minutes while maintaining a temperature of 49 °C. The batch was then distilled under vacuum at 45 °C until the remaining volume was about 1.2 L. A 12 L glass reactor was assembled with a magnetic stirrer, condenser, thermocouple, addition funnel, and a nitrogen inlet and the apparatus was purged with nitrogen. The distillation residue (1.2 L) and a portion of the filtered heptane (0.53 L) were charged to the reactor, using heptane to assist the transfer. The batch was cooled to about 3 °C and stirred for about 1 hour at about 4 °C. The batch was then filtered, the filter cake washed with polish filtered heptane (0.5 L) and the filtrate collected. The filter cake was dried on a filter by pulling nitrogen for about 1 hour. The product was then transferred to drying trays and further dried under vacuum at about 70 °C for about 22 hours to afford Compound 2 (52.40 g).
A summary of the Compound 2 produced in step 3 is presented in Table 4 below.
Table 4. Purification of purified Compound 2
Analytical methods included HPLC analysis using the following preparation of solutions:
1. Mobile Phase A (0.1% TFA in DI Water): Example preparation: add 1.0 mL of TFA into 1000 mL of degassed DI Water. Mix well.
2. Mobile Phase B (0.1% in MeCN): Example preparation: added 1.0 mL of TFA into 1000 mL of degassed MeCN. Mix well.
3. Diluent: Pure Methanol (MeOH).
The following calculations were used:
For Area% Purity:
Total Impurity (TI) = sum of all average percent impurities greater than or equal to the reporting threshold (0 .05%).
Report the average for each individual impurity >. 0.05% to the nearest 0.01%. Report total impurities (TI) to the nearest 0.01%.
Compound 2 purity = 100.0 - TI
Report the Compound 2 purity to the nearest 0.1%
Where:
As = Area of the Compound 2 peak in the sample injection
Ast = Average area of the Compound 2 peaks in the bracketing standard injections
Cs = Sample concentration (mg/mL; based on sample corrected for moisture and residual solvents)
Cst, = Standard concentration (mg/mL)
P = Standard purity
Results
In prior studies, when Pd(PPh3)4 was used as a catalyst with Compound 6 to produce Compound 1 in a Stannylation reaction, the reaction stalled and additional charges of Pd(PPh3)4 were needed to mitigate the impact of the stalling (data not shown).
In contrast, as shown in Tables 5-6 below, reactions using Pd2(dba)3 as a catalyst resulted in production of Compound 2 with high chemical purity. For example, the chemical purity of the product in each batch was greater than 98%. Therefore, this Example shows that Pd2(dba)3 may be used as an efficient catalyst for production of Sn-labeled Hsp90 inhibitors. Such efficiency may be manifested by reduced stalling and/or reduced dependence on additional charges of the catalyst.
Table 5. Analysis results of a batch of Compound 2 produced using the methods described in this Example.
3 Water Content 4) 3
a: ND = Below the limit of detection (LOD). For HPLC, LOD is ~ 0.02%; For GC, LOD is 100 ppm.
Table 6. Analysis results of another batch of Compound 2 produced using the methods described in this Example.
a: ND = Below the limit of detection (LOO). For HPLC, LOD is -0.02%; For GC, LOD is 100 ppm.
Example 2.
This Example describes production of a compound of Formula III:
ents were conducted with Compound 2 as either a free base or as a hydrogen iodide salt (HI) and radioactivity of the product was assessed.
Materials and Methods
The following procedure was used in a 1 mCi reaction:
1. Charge Eppendorf with 25 μL Compound 2 as a free base or Compound 2· HI
2. Add 10 μL NaI-131
3. Add 100 μL water for injection
4. Add 25 μL 0.8 M H3PO4
5. Add 10 μL 6.4% peracetic acid
6. Incubate 1 min at room T
7. Add 50 μL sodium metabisulfite in saturated NaHC03
8. Invert 10-mL syringe containing 8 mL water. Inject reaction solution onto top of liquid.
9. Pass through Sep-Pak to waste
10. Elute with 3 mL ethanol to product
Results
The results described below were obtained using the methods described in this example. When using Compound 2 as a free base, 595 μCi product and 30 μCi waste were detected. 7 μCi remained in the Sep-Pak, while 62 μCi remained in the reaction vial and syringe. The method resulted in an 86% recovered yield with a specific activity of 24 mCi/mg.
When using Compound 2 as a hydrogen iodide salt, 573 μCi product and 34 μCi waste were detected. 3 μCi remained in the Sep-Pak and 63 μCi remained in the reaction vial and syringe. The method resulted in an 85% recovered yield with a specific activity of 23 mCi/mg.
Example 3.
This Example describes production of a compound of Formula III:
(Formula III) in which W is I131, using: 1) chloramine-T in which the ratio of the mass of chloramine-T to the mass of the compound of Formula III in the reaction was 3:5, and 2) Compound 2:
(Compound 2) as a substrate. Experiments were conducted with Compound 2 as a free base and radioactivity of the product was assessed.
Experiment 1
Materials and Methods
The following methods and materials were used in Experiment 1:
1. Combine 25 μL 1 mg/mL Compound 2 free base (in ethanol), 10 μL Nal- 131 (—3-3.5 mCi) in 0.01 M NaOH, 10 μL 1.5 mg/mL chloramine-T, and 10 μL 1 M phosphate buffer pH 7;
2. Incubate at ambient temperature for 5 minutes;
3. Push incubated reaction through Sep-Pak with 10 mL DI water to waste; and
4. Elute product with 3 mL ethanol.
Results
Table 7 shows the results when eluting the product in a single 3 mL fraction. Excluding the activity in the syringe and vial, which didn't get transferred to the Sep-Pak, conversion to product was 3270/3321 = 98.5%.
Materials and Methods
For experiment 2, the same methods and materials were used as in Experiment 1, except in step (4), three, 1-mL ethanol fractions were removed, rather than a single 3-mL fraction. Results
Table 8 shows the results when eluting with three, 1-mL ethanol fractions. Total product conversion was 3118/3173 = 98.3%. Of the product, 89.5% was in the first mL fraction, 9.4% in the second fraction, and 1.1% in the third fraction. The results suggest that the elution volume may be reduced to 2 mL or even 1.5 ml. Without being bound by a particular theory, less ethanol in the product may be desirable as the product may have to be diluted with less buffer when formulating an injectable product. The maximum allowable ethanol in injectable products is often 10%.
Experiment 3
Materials and Methods
For experiment 3, a pre-mixed solution of Compound 2 free base and chloramine-T in acetic acid were tested. A solution of 1 mg/mL Sn-PUAD and 0.6 mg/mL chloramine-T in acetic acid was prepared, so that 25 μL of the solution would contain the appropriate amounts of both reagents. 25 μL of the mixed solution, 10 μL of NaI-131, and 10 μL of P04 buffer were combined. Incubation ran ~ 7.5 minutes. The full 3 mL ethanol was used to elute the product. Results
Table 9 shows the results with pre-mixed Compound 2 free base and chloramine-T in acetic acid. Recovery was comparable to experiments using unmixed Compound 2 free base and chloramine-T. Recover was 3290/3380 = 97.3% in this experiment.
Experiment 4
Materials and Methods
For experiment 4, a refrigerated pre-mixed solution comprising Compound 2, chloramine-T and acetic acid was tested. The solution from Experiment 3 was incubated overnight and used the next day (about 17 hours later). The acetic in the solution froze during the refrigeration and was thawed prior to use. The methods described in Experiment 3 were used.
Results As shown in Table 10, overnight refrigeration of the pre-mixed solution comprising
Compound 2, chloramine-T and acetic acid did not significantly affect the recovered yield, suggesting a pre-mixed solution comprising Compound 2 is stable when refrigerated overnight. Recovery was 3050/3104 = 98.3% Table 10. Results of Experiment 4
Example 4.
This Example describes production of a compound of Formula III:
(Formula III)
in which W is I131, using 1) chloramine-T in which the ratio of the mass of chloramine-T to the mass of the compound of Formula III in the reaction was 3:5, and 2) Compound 2:
(Compound 2) free base as a substrate, using the device shown in FIG. 3. Radioactivity of the product was assessed.
Materials and Methods
Experiment 1
The device in FIG. 3 was used and the following protocol was used in Experiment 1:
1. In FIG. 3, R is the source vial. Inject pre-mixed Sn-PU-AD, chloramine-T and Buffer (not shown). The pre-mixed solution was prepared as indicated in Example 3, Experiment 4 above. 2-mL vial was used and injected a mixture of 25 μl Compound 2, chloramine-T, and Acetic acid, 10 μL NaI-131, and 100 μL 0.1 M PO4 buffer. (A greater volume of diluted PO4 buffer was used to ensure all mixture would transfer by a 0.3-mL syringe.)
2. Fill S 1 with 10 mL H2O, 10 mL air, flush reaction mixture from R through SP (SCI in proper orientation); SC3 oriented to deliver to W.
3. Reverse SCI and SC3 orientations, orient SC2 to deliver 3 mL EtOH from S3 through SP and 0.2 pm filter to P.
4. Reverse SC2 orientation to deliver make-up water (i.e., water to bring the solution to a particular volume and/or concentration) or buffer from S2 through SP and filter to P. a. In this experiment, air in S2 was used to push all Product through without use of a filter
Results
Table 11 shows the results of this experiment. Notably, product conversion was 2850/2891 = 98.6%. Even including losses in the system, the total recovery was 2850/2974 = 95.8%. Therefore, Compound 2 was produced with a high yield using the device in FIG. 3 and the methods described in this example.
Experiment 2
Materials and Methods The device in FIG. 3 was used with re-thawed solution comprising Compound 2, chloramine-T, and acetic acid that was refrigerated for 6 days. The materials and methods are otherwise the same as indicated in Experiment 1 of this Example.
Results
Table 12 shows the results that were obtained using the re-thawed solution that was refrigerated for six days. Excluding the amounts left in the vial and device, the conversion was 33.1%, with 62.2% in Waste and 4.7% in the Sep-Pak.
Decomposition of Compound 2 did occur in the frozen acetic acid over the course of six days as compared to the results with one day of refrigeration (Experiment 1 of this Example). However, despite the decomposition, 33% recovery was achieved.
Table 12. Results using the device in FIG.3 along with refrigerated pre-mixed reagents.
Experiment 3
Materials and Methods
The device in FIG. 3 was used with the reagents: 25 μL 1 mg/mL Compound 2, 10 μL NaI-131, 10 μL 1.5 mg/mL chloramine-T, 10 μL 1 M PO4 buffer, 3 mL EtOH elution). Compound 2 was stored in ethanol and was refrigerated for 6 days. Results
Table 13 shows the results using Compound 2 stored in ethanol. The conversion was 98.6%. Therefore, this Experiment demonstrates that Compound 2 is stable in ethanol at 2-8 °C for about a week at minimum. Table 13. Results using the device in FIG.3 along with Compound 2 stored in ethanol.
Experiment 4
Materials and Methods The materials and methods were the same as in Experiment 3 of this Example, but 3 mL 50% ethanol (in water) was used for elution.
Results
As shown in Table 14, elution in 50% ethanol resulted in a recovery of 80.3%. These results suggest that elution in pure ethanol may result in a higher recovery rate than in diluted ethanol.
Example 5.
This example describes production of a compound of Formula III:
(Formula III) in which W is I124, using: 1) chloramine-T in which the ratio of the mass of chloramine-T to the mass of the compound of Formula III in the reaction was 3:5, and 2) Compound 2:
(Compound 2) free base as a substrate, using the device shown in FIG. 3. Experiments were conducted with Compound 2 as a free base and using the device shown in FIG. 3. Radioactivity of the product is assessed.
Materials and Methods
The device of FIG. 3 is used with all vials (and the Sep-Pak) shielded. Reaction vial ® is source 1-124 vial. The following protocol is used:
1. Inject pre-mixed Sn-PU-AD, Chloramine-T and Buffer (not shown).
2. With SI, push reaction mixture from RV to SP (SCI in proper orientation)
3. Remove SI, fill with 10 mL H2O, 10 mL air, reattach.
4. Flush RV and SP with contents of SI (H20 first, then air); SC3 oriented to deliver to W.
5. Reverse SCI and SC3 orientations, orient SC2 to deliver 3 mL EtOH, 5 mL air from S3 (through SP and 0.2u filter to P).
6. Reverse SC2 orientation to deliver makeup water or buffer through SP and filter to P. Radioactivity is assessed.
Aspects and Embodiments
Various aspects and embodiments provided by this disclosure are listed below. Clause 1. A method of producing a compound of Formula II:
(Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting: a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof with a radioiodine salt in the presence of peracetic acid in a solution at a pH between 2-5, thereby forming a reaction mixture, wherein:
W is a radioiodine; X is — C¾ — , — O — , or — S — ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms
selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
Clause 2. The method of clause 1, wherein the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of Formula III or a pharmaceutically acceptable salt thereof, or Formula IV or a pharmaceutically acceptable salt thereof:
(Formula III) or a pharmaceutically acceptable salt thereof; or
(Formula IV) or a pharmaceutically acceptable salt thereof.
Clause 3. The method of any one of clauses 1-2, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof comprises Compound 1 or a pharmaceutically acceptable salt thereof or Compound 2 or a pharmaceutically acceptable salt thereof:
(Compound 2) or a pharmaceutically acceptable salt
(Compound 1) or a pharmaceutically acceptable salt thereof.
Clause 4. The method of any one of clauses 1-3, wherein the compound of Formula I is provided as a free base or as a hydrogen iodide salt (HI).
Clause 5. The method of any one of clauses 1-4, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
Clause 6. The method of any one of clauses 1-5, wherein the compound of Formula I is provided as a free base.
Clause 7. The method of any one of clauses 1-6, wherein the radioiodine or salt thereof is selected from I123, I124, or I131 or a salt thereof.
Clause 8. The method of any one of clauses 1-7, wherein the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
Clause 9. The method of any one of clauses 1-8, wherein the solution comprises about 0.1 to about 1 M phosphoric acid (H3PO4) or sulfuric acid and water and the reaction occurs between about 15 to about 30 °C for about 0.5 to about 1.5 minutes, optionally about 1 minute.
Clause 10. The method of clause 9, wherein the solution comprises about 0.8 M phosphoric acid (H3PO4) and water.
Clause 11. The method of clause 10, wherein the reaction occurs between about 20 °C to about 30 °C for about 0.5 to about 1.5 minutes, optionally about 1 minute.
Clause 12. The method of any one of clauses 1-11, wherein the method further comprises adding, to the reaction mixture, sodium metabisulfite in saturated sodium bicarbonate (NaHCO3) following the reaction.
Clause 13. The method of any one of clauses 1-12, wherein the peracetic acid is about 3% to about 10% peracetic acid.
Clause 14. The method of clause 13, wherein the peracetic acid is about 6% to about 7% peracetic acid, optionally about 6.3%, about 6.4% or about 6.5% peracetic acid.
Clause 15. The method of any one of clauses 1-14, further comprising purifying the compound of Formula II or a pharmaceutically acceptable salt thereof from the reaction mixture.
Clause 16. The method of any one of clauses 1-15, wherein the compound of Formula II or a pharmaceutically acceptable salt thereof is recovered at about 80%, about 85%, about 90%, or about 95% yield. Clause 17. The method of any one of clauses 1-16, wherein the specific activity of the compound of Formula II or a pharmaceutically acceptable salt thereof is at least 10 mCi/mg, at least 20 mCi/mg, at least 30 mCi/mg, or at least 40 mCi/mg.
Clause 18. A method of producing a compound of Formula II:
(Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting:
(b) chloramine-T; and
(c) a radioiodine salt, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I or the pharmaceutically acceptable salt thereof in the reaction is about 3 to about 5, thereby forming a reaction mixture, wherein:
W is a radioiodine;
X is — CH2— , — O— , or — S— ;
Y 1 and Y2 are independently =CR3a — or =N — , as valency permits;
Zl, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R, — CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl;
each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
Clause 19. The method of clause 18, wherein the compound of Formula II or the pharmaceutically acceptable salt thereof is a compound of
(Formula III) or a pharmaceutically acceptable salt thereof; or a compound of
Clause 20. The method of any one of clauses 18-19, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof comprises:
(Compound 2) or a pharmaceutically acceptable salt thereof; or
(Compound 1) or a pharmaceutically acceptable salt thereof.
Clause 21. The method of any one of clauses 18-20, wherein the compound of Formula I is provided as a free base.
Clause 22. The method of any one of clauses 18-21, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is reacted with a radioiodine sodium salt.
Clause 23. The method of any one of clauses 18-22, wherein the reaction further comprises phosphate buffer at about pH 7.
Clause 24. The method of any one of clauses 18-23, the radioiodine or salt thereof is I123, I124, or I131 or a salt thereof.
Clause 25. The method of any one of clauses 18-24, wherein the compound of Formula II or a pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof and is a good manufacturing practices (GMP) grade compound.
Clause 26. The method of any one of clauses 18-25, wherein the yield of the compound of Formula II or the pharmaceutically acceptable salt thereof is at least 80%.
Clause 27. The method of any one of clauses 18-26, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is provided in ethanol.
Clause 28. The method of any one of clauses 18-27, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a pre-mixed solution in acetic acid.
Clause 29. The method of any one of clauses 18-28, further comprising passing the reaction mixture through a Sep-Pak and eluting the compound of Formula II with less than 3 mL of pure ethanol.
Clause 30. The method of any one of clauses 18-29, wherein the radioiodine salt is provided in about 0.01M NaOH.
Clause 31. The method of any one of clauses 18-30, wherein the amount of radioiodine salt is between about 3 and about 3.5 mCi.
Clause 32. A method of producing a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof, comprising reacting in a reaction mixture: a compound of Formula V:
(Formula V) or a pharmaceutically acceptable salt thereof with hexamethylditin (Sn2 Me6) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in a solution, thereby producing a compound of Formula I or a pharmaceutically acceptable salt thereof.
Clause 33. The method of clause 32, the reaction occurs between about 60 °C and about 80 °C.
Clause 34. The method of any one of clauses clause 32-33, further comprising purifying the compound of Formula I. Clause 35. The method of clause 34, wherein purifying the purifying the compound of Formula I comprises mixing the compound of Formula I with dichloromethane (DCM) and stirring the mixture to form a substantially clear solution.
Clause 36. The method of clause 35, further comprising adding purified water to the substantially clear solution, stirring the solution for at least 5 minutes, and allowing the solution to separate into an organic layer and an aqueous layer. Clause 37. The method of clause 36, further comprising adding purified water, mixing the layers for at least 15 minutes, and allowing the layers to separate, optionally further adding purified water, mixing the layers for at least 15 minutes, and allowing the layers to separate.
Clause 38. The method of any one of clauses 36-37, further comprising filtering the organic layer, washing the reaction vessel with DCM, and concentrating the filtrate and the wash.
Clause 39. The method of clause 38, wherein the concentrating occurs at no more than 50 °C to distill the compound of Formula I.
Clause 40. The method of clause 39, wherein the compound of Formula I is further dried under vacuum at no more than 70 °C.
Clause 41. The method of any one of clauses 32-40, wherein the compound of Formula V or the pharmaceutically acceptable salt thereof and/or the compound of Formula I or the pharmaceutically acceptable salt thereof is a good manufacturing practices (GMP) grade compound.
Clause 42. The method of any one of clauses 32-41, wherein the method further comprises adding ethanol (EtOH) -Heptane to the compound of Formula I.
Clause 43. The method of any one of clauses 32-42, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof comprises :
Clause 44. The method of any one of clauses 32-43, wherein the compound of Formula V or the pharmaceutically acceptable salt thereof comprises:
Compound 6:
or a pharmaceutically acceptable salt thereof; or
Compound 7 :
pharmaceutically acceptable salt thereof.
Clause 45. A kit comprising:
(ii) phosphoric acid (H3PO4); and
(iii) peracetic acid, wherein:
X is — CH2— , — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L;
each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen,
or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
Clause 46. The kit of clause 45, wherein the compound in (i) comprises:
(Compound 2) or a pharmaceutically acceptable salt thereof; or
Clause 47. The kit of any one of clauses 45-46, further comprising a radioiodine salt.
Clause 48. The kit of clause 47, wherein the radioiodine salt is sodium radioiodine.
Clause 49. The kit of any one of clauses 45-48, wherein the kit further comprises (iv) about 0.1 to about 1 M phosphoric acid (H3PO4).
Clause 50. The kit of clause 49, wherein the kit further comprises (iv) about 0.8 M phosphoric acid (H3PO4).
Clause 51. The kit of any one of clauses 45-50, wherein the kit further comprises sodium metabisulfite in saturated sodium bicarbonate (NaHCO3)·
Clause 52. The kit of any one of clauses 45-51, wherein the peracetic acid is about 3% to about 10% peracetic acid. Clause 53. The kit of clause 52, wherein the peracetic acid is about 6% to about 7% peracetic acid, optionally about 6.3%, about 6.4% or about 6.5% peracetic acid.
Clause 54. The kit of any one of clauses 45-53, further comprising a syringe, Sep-Pak, and/or ethanol.
Clause 55. The kit of any one of clauses 47-54, wherein the radioiodine salt is a salt of I123, I124, or I131.
Clause 56. A kit comprising:
(ii) chloramine-T, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I or the pharmaceutically acceptable salt thereof in the reaction is about 3 to about 5 and wherein:
X is — CH2— , — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7-
membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur Clause 57. The kit of clause 56, further comprising phosphate buffer at about pH 7.
Clause 58. The kit of clause 56 or 57, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in a single container. Clause 59. The kit of clause 58, wherein the container comprising the compound of
Formula I or the pharmaceutically acceptable salt thereof and chloramine-T further comprises acetic acid.
Clause 60. The kit of clause 56 or 57, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof and chloramine-T are provided in separate containers.
Clause 61. The kit of clause 60, wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is provided in ethanol.
Clause 62. The kit of any one of clauses 56-61, further comprising: i) ethanol; ii) water; ill) a reaction container; iv) a waste container; v) a product container; vi) a Sep-Pak; vii) one or more syringes; and/or viii) one or more stopcocks.
Clause 63. The kit of any one of clauses 56-62, wherein the kit further comprises a radioiodine salt.
Clause 64. The kit of clause 63, wherein the radioiodine salt is sodium radioiodine.
Clause 65. The kit of clause 63-64, wherein the radioiodine or salt thereof is I123, I124, or
I131 or a salt thereof.
OTHER EMBODIMENTS AND EQUIVALENTS
While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.
All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.
The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one."
The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of' or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e. "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.
As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or
unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one,
B (and optionally including other elements); etc.
It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of' and "consisting essentially of' shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
Claims
1. A method of producing a compound of Formula II:
(Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting: a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof with a radioiodine salt in the presence of peracetic acid in a solution at a pH between 2-5, thereby forming a reaction mixture, wherein:
W is a radioiodine;
X is — CH2— , — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur,
thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
2. A method of producing a compound of Formula II:
(Formula II) or a pharmaceutically acceptable salt thereof, comprising reacting:
(b) chloramine-T; and
(c) a radioiodine salt, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I or the pharmaceutically acceptable salt thereof in the reaction is about 3 to about 5, thereby forming a reaction mixture, wherein:
W is a radioiodine;
X is — CH2— , — O— , or — S— ; Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Zl, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , —
C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms
selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, thereby producing a compound of Formula II or a pharmaceutically acceptable salt thereof.
3. A method of producing a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof, comprising reacting in a reaction mixture: a compound of Formula V:
(Formula V) or a pharmaceutically acceptable salt thereof with hexamethylditin (Sn2 Me6) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in a solution, thereby producing a compound of Formula I or a pharmaceutically acceptable salt thereof.
4. A kit comprising:
(i) a compound of Formula I:
(Formula I) or a pharmaceutically acceptable salt thereof;
(ii) phosphoric acid (H3PO4); and
(iii) peracetic acid, wherein:
X is —cm— — — , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from
oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R,
— CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, —OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl;
R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
5. A kit comprising:
(i) a compound of Formula
(Formula I) or a pharmaceutically acceptable salt thereof; and
(ii) chloramine-T, wherein the ratio of the mass of chloramine-T to the mass of the compound of Formula I or the pharmaceutically acceptable salt thereof in the reaction is about 3 to about 5 and wherein:
X is —CH2— — O— , or — S— ;
Y1 and Y2 are independently =CR3a — or =N — , as valency permits;
Z1, Z2, and Z3 are independently — CH= or — N=, as valency permits;
R1 is hydrogen or halogen;
L is a straight or branched, C2-14 aliphatic group wherein one or more carbons are optionally and independently replaced by -Cy-, — N(R)C(O) — , — C(O)N(R) — , — C(O)N(O) — , — N(R)SO2— , — SO2N(R)— , — O— , — C(O)— , — OC(O)— , — C(O)O— , — S — , — SO — , or — SO2 — , or wherein one or more carbons are independently replaced by — NR — , wherein R is not a -Boc protecting group in L; each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, aryl ring, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, aryl bicyclic ring, or heteroaryl bicyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen or an optionally substituted group selected from the group consisting of C1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10- membered saturated or partially unsaturated bicyclic carbocyclyl, 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, 7- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 8- to 10-membered bicyclic aryl; each R3 is independently halogen, — NO2, — CN, — OR, — SR, — N(R)2, — C(O)R, — CO2R, — C(O)C(O)R, — C(O)CH2C(O)R, — S(O)R, — S(O)2R, — C(O)N(R)2, — SO2N(R)2, — OC(O)R, — N(R)C(O)R, — N(R)N(R)2, or optionally substituted C1-6aliphatic or pyrrolyl; or two R3 groups are taken together with their intervening atoms to form Ring A, wherein Ring A is an optionally substituted 3- to 7-membered partially unsaturated
carbocyclyl, optionally substituted phenyl, an optionally substituted 5- to 6-membered partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or an optionally substituted 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or 6-membered aryl; R3a is R3 or hydrogen;
R4is C1-4 alkyl; each R is independently hydrogen or an optionally substituted group selected from C1- 6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, or 5- to 6-membered heteroaryl having 1-4 heteroatoms selected from oxygen, nitrogen, or sulfur.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163153123P | 2021-02-24 | 2021-02-24 | |
US63/153,123 | 2021-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022182731A1 true WO2022182731A1 (en) | 2022-09-01 |
Family
ID=83048437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/017482 WO2022182731A1 (en) | 2021-02-24 | 2022-02-23 | Sn-labeling and radiolabeling of epichaperome inhibitors |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202302591A (en) |
WO (1) | WO2022182731A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080253965A1 (en) * | 2005-02-01 | 2008-10-16 | Sloan-Kettering Institute For Cancer Research | Small-Molecule Hsp90 Inhibitors |
US20160015837A1 (en) * | 2013-03-15 | 2016-01-21 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
US20170029426A1 (en) * | 2013-12-23 | 2017-02-02 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
-
2022
- 2022-02-23 WO PCT/US2022/017482 patent/WO2022182731A1/en active Application Filing
- 2022-02-23 TW TW111106487A patent/TW202302591A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080253965A1 (en) * | 2005-02-01 | 2008-10-16 | Sloan-Kettering Institute For Cancer Research | Small-Molecule Hsp90 Inhibitors |
US20160015837A1 (en) * | 2013-03-15 | 2016-01-21 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
US20170029426A1 (en) * | 2013-12-23 | 2017-02-02 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
Non-Patent Citations (2)
Title |
---|
KOEHLER LENA, KATHERINE GAGNON, STEVE MCQUARRIE, FRANK WUEST : "lodine-124: A Promising Positron Emitter for Organic PET Chemistry", MOLECULES, vol. 15, 1 April 2010 (2010-04-01), pages 2686 - 2718, XP055965662 * |
WOOK SANG, JEONG KIMJ, PAR HOON, SEUNG ", YANGJ DAE, GOO MIN, CHANG HURJ, CHOI WOON, YU KOOK HYUN: "Glioma Imaging Using Radioiodine Labelled Hypericin Synthesis and in vitro/vivo Evaluation of Iodine-123/124 Labelled Hypericin Derivatives", BULL. KOREAN CHEM. SOC, vol. 29, no. 10, 20 October 2008 (2008-10-20), pages 2023 - 2025, XP055965677 * |
Also Published As
Publication number | Publication date |
---|---|
TW202302591A (en) | 2023-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6673969B2 (en) | Bruton-type tyrosine kinase inhibitors | |
US9273028B2 (en) | Heterocyclic tyrosine kinase inhibitors | |
EP3068784B1 (en) | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors | |
EP3166608B1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
JP7046940B2 (en) | Aminopyrazolopyrimidine compound used as a neurotrophic factor tyrosine kinase receptor inhibitor | |
IL262345A (en) | Inhibitors of activin receptor-like kinase | |
WO2011029043A1 (en) | Heteroaryl btk inhibitors | |
CN113666923A (en) | Alkoxy alkyl substituted heterocyclic inhibitor and preparation method and application thereof | |
EP4092024A1 (en) | Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology | |
EP2935271B1 (en) | Novel substituted imidazoles as casein kinase 1 / inhibitors | |
CN112125911B (en) | CDK9 inhibitor and preparation method and application thereof | |
CA3117849A1 (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
CN112824410A (en) | Aza-heptacyclic inhibitor and preparation method and application thereof | |
CN117177960A (en) | Heterocyclic compounds as TYK2 pseudo kinase domain inhibitors, synthesis method and application | |
AU2019339994B2 (en) | Furo[3,4-b]pyrrole-containing BTK inhibitor | |
WO2022182731A1 (en) | Sn-labeling and radiolabeling of epichaperome inhibitors | |
CN117050086A (en) | Pyrimidinone pyrazolo compound containing fused ring group, preparation method and application thereof | |
CN112812145B (en) | Benzimidazole derivative BI293 and preparation method and application thereof | |
CN112920241B (en) | Benzimidazole derivative BI308 and preparation method and application thereof | |
AU2022376773A1 (en) | Pyridyl-containing compound | |
CN117186074A (en) | Pyridazine-3-carboxamide compounds as TYK2 inhibitors | |
EP3421473A1 (en) | Method for preparing pyrrolopyrimidine compound and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22760319 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22760319 Country of ref document: EP Kind code of ref document: A1 |